Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the Omicron (B.1.1.529) variant surge in UK.

Supplementary appendix
Contents
METHODS: ..... 3
RESULTS: ..... 4
Regression analysis SARS-CoV2 cases, hospitalizations and deaths in UK. ..... 4
SARS-CoV2 cases, SARS-CoV2 Hospitalizations (in England) and SARS-CoV2 deaths (England and Wales) among age groups ..... 5
Vaccine effectiveness among over 50 years NIMS population in UK ..... 6
Vaccine effectiveness of the third dose population prior to December 20, 2021 ..... 8
Public health restrictions, lockdowns and reopening in the United Kingdom (UK): ..... 9
Figures and Tables ..... 10
Figure S1: Regression analysis of SARS-CoV2 cases, Hospitalizations and deaths ..... 11
Figures S2a-c: SARS-CoV2 cases, hospitalizations and deaths per 100,000 population from August 16, 2021-May 27, 2022 ..... 13
Table S1a-c: SARS-CoV2 cases and hospitalization in England, SARS-CoV2 deaths in England and Wales among age groups. ..... 16
Table S2: Pre-existing condition among deaths during the Omicron variant surge in England ..... 20
Table S3a: NIMS database with vaccination status of all age groups, over 18 and 50 years of age ..... 22
Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IMD score of the over 18 years of age ..... 26
Table S4: Population of United Kingdom based on mid 2020 census estimate ..... 28
Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths ..... 29
Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status ..... 32
Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission in NIMS-database based on vaccination status ..... 36
Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death in NIMS- database based on vaccination ..... 40
Table S7a: Vaccine effectiveness of over 18 years of age NIMS population ..... 44
Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health England ..... 46
Table S7c: Vaccine effectiveness of over 50 years of age NIMS population ..... 47
Table S8a-f: Proportion test of SARS-CoV2 cases, hospitalizations and deaths among NIMS vaccinated population of over 18 and over 50 years of age ..... 50
REFERENCES: ..... 63

## METHODS:

Following is the additional details to methods that are described in details in the manuscript.

Regression analysis: Analysis of the SARS-CoV2 cases (specimen date), SARS-
CoV2 hospitalizations and SARS-CoV2 deaths (date of death on the death certificate) in UK was performed as described in the Methods section of the manuscript during the Alpha, Delta and Omicron variant surge until May 1, 2022. The weekly deaths were adjusted for two weeks back to coincide with the timing of infection. During the Omicron variant surge, due to the rapid rise and decline of cases, the hospitalizations were adjusted back to one week to coincide with peaks of cases and hospitalizations.

Missing data: The UKHSA did not publish the outcomes for the SARS-CoV2 cases, hospital admissions and deaths among vaccinated population for the rolling four weeks period; November 23 to December 20, 2021 (week 48-51) and the hospital admissions among vaccinated groups for the rolling four weeks for the period January 31, 2022 to February 27, 2022 (week 5-8). However, the rolling four weeks outcomes for the prior and later weeks were available, thereby limiting the impact of missing data only to those missing week(s). The UKHSA stopped reporting the data of SARS-CoV2 cases, hospitalizations and deaths among NIMS population in the weekly vaccine surveillance reports and hence we are unable to report vaccine effectiveness or the proportionality test results from March 28-May 1, 2022 period.

## Pillar 1 and 2 cases among various age groups in England for weeks 13-17 in

 2022 (March 28-May 1, 2022): The National Flue and COVID-19 surveillance reports were published rolling two weekly pillar 1 (public health laboratories and hospitals) and pillar 2 (community testing) CARS-CoV2 cases among age groups from September 28, 2020 to March 27, 2022. Since March 28, 2022 only weekly pillar 1 and 2 SARS-CoV2 cases per 100,000 were published in the weekly National Flue and COVID-19 surveillance reports. We computed weekly SARS-CoV2 cases (pillar 1 and 2) among various age groups in England for the period March 28-May 1, 2022 (week 13-17) using mid-year 2020 census estimate of England and case rates (pillar 1 and 2) per 100,000 population for each age group.
## RESULTS:

Regression analysis SARS-CoV2 cases, hospitalizations and deaths in UK (Figure S1): The liner regression analysis of SARS-CoV2 cases (specimen date), SARS-CoV2 hospital admissions and SARS-CoV2 deaths (data death certificate) was performed during the Alpha variant, the Delta variant surge and Omicron variant surge until May 1, 2022. During the Alpha variant surge, the increased SARS-CoV2 cases predicted increased SARS-CoV2 hospitalizations (adjusted R2=0.85; slope $=0.172 ; p<0.001$ ) and increased SARS-CoV2 deaths (adjusted R2=0.98; slope $=0.026$; $p<0.001$ ). The increased SARS-CoV2 cases also predicted increased SARS-CoV2 hospitalizations
and deaths during the Delta variant surge (hospitalizations; adjusted $\mathrm{R} 2=0.68$; slope 0.019; $p<0.001$ ) and deaths; adjusted $R 2=0.68$; slope 0.0032 ; $p<0.001$ ) and Omicron variant surge (hospitalization; adjusted $R 2=0.22$; slope $=0.005 ; p=0.023$ and deaths; adjusted $\mathrm{R} 2=0.72$; slope $=0.00075$; $\mathrm{p}<0.001$ ).

## SARS-CoV2 cases, SARS-CoV2 Hospitalizations (in England) and SARS-CoV2 deaths (England and Wales) among age groups (Figures 2a-c; Tables S1a-c):

Analysis of SARS-CoV2 cases (Figure 2a and Table S1a) in England among various age group showed significantly increased percent of SARS-CoV2 cases among <30 years (0-19 years, 20-29 years) in transition from Alpha variant surge to the initial part of Delta variant surge. During the latter part of the Delta variant surge the over 50 years of age (particularly over 70 years of age) have significantly increased cases with decreased cases among 20-29 years of age. The analysis of various age groups SARS-CoV2 hospitalizations (Figure 2 b and Table S1b) showed significantly increased hospitalizations among under 55 years of age (particularly among 0-34 years of age) during the initial part of Delta variant surge; and during the latter part of Delta variant surge hospitalizations among over 55 years of age (particularly over 65 years) and during latter part of Omicron variant surge (February 28-May 1, 2022) hospitalizations among over 75 years of age significantly increased with significantly decreased hospitalization among other age groups. Analysis of deaths among various age groups in England and Wales (Figure 2c and Table S1c) showed a significantly increased Deaths among under 70 years of age (particularly among under 50 years) during Delta
variant surge until August 1, 2021 and significantly increased deaths noted among over 70 years of age and significantly decreased deaths among $<70$ years of age during the latter part of Delta variant surge (August 2-December 5, 2021). Similarly, during the latter part of the Omicron variant surge (February 28-May 1, 2022) significantly increased deaths were noted among over 75 years of age and significantly decreased deaths among under 75 years of age. The significantly increased SARS-CoV2 cases during the latter part of Alpha variant surge and initial part of Delta variant surge among $<50$ years of age groups was associated with significantly increased deaths during the same period.

## Vaccine effectiveness among over 50 years NIMS population in UK (Table S7b-c and Figure 4)

The Public Health England reported the outcomes among delta variant cases (confirmed and provisional) in the UK technical briefings until September 12, 2022. The UK vaccine surveillance reports started publishing from August 16, 2021 until March 27, 2022. As shown on Table S3, about $66.7 \%$ of the over 50 years of age NIMS population was vaccinated with two doses of primary vaccination by May 23, 2021 during the beginning of the Delta variant surge. The vaccine effectiveness of $\geq 50$ years of age NIMS population vaccinated with two doses was $53.1 \% ~(95 \% \mathrm{Cl} 48.4 \%-57.2 \%)$ for the period ending June 20, 2021. Since June 21, 2021 period as shown on the Table S7b, the vaccine effectiveness declined to $18.0 \%-23.2 \%$ among $\geq 50$ years of age vaccinated with two doses and was in negative territory with incidence rate (IR) of cases
higher among vaccinated with two doses than unvaccinated since August 16, 2021 period. The vaccine effectiveness of the $\geq 50$ years of age vaccinated with two doses was also in the negative territory since August 16, 2021 among four weekly running cases that were reported in the weekly vaccine surveillance reports with IR of cases among those vaccinated with two doses higher than unvaccinated. Since the rolling four weekly cases from December 20, 2021 to June 16, 2021; the vaccinated with the third dose among $\geq 50$ years of age was also in the negative. The proportions test also showed that the proportion of SARS-CoV2 cases were higher among the vaccinated population than unvaccinated since August 16, 2021 among the Delta variant cases (vaccinated with two doses; $X^{2}=2.9683, \mathrm{df}=1, \mathrm{p}=0.042$ and all vaccinated $X^{2}=$ 4.4235, df $=1, p$-value $=0.01772$ ) and NIMS population of $\geq 50$ years of age (two doses cases; $X^{2}=708.94, \mathrm{df}=1, \mathrm{p}<0.001$; all vaccinated cases; $X^{2}=688.86, \mathrm{df}=1, \mathrm{p}<0.001$ ). Since the reporting period of December 20, 2021, the over 50 years of age vaccinated with third dose have significantly higher proportion of cases ( $X^{2}=7987, \mathrm{df}=1, \mathrm{p}<0.001$ ) than unvaccinated and since Jan 31, 2022 the third dose population have significantly higher proportion of cases than the two doses ( $X^{2}=309.3, \mathrm{df}=1, \mathrm{p}<0.001$ ). The proportion test on the hospitalization among $\geq 50$ years of age, showed vaccinated with two doses ( $X^{2}=678.34, \mathrm{df}=1, \mathrm{p}<0.001$ ) have significantly higher proportion of hospitalizations than unvaccinated since December 6 . The third dose population of $\geq 50$ years of age ( $X^{2}=5.523, \mathrm{df}=1, \mathrm{p}=0.009384$ ) and all vaccinated population ( $X^{2}=$ $10.468, \mathrm{df}=1, \mathrm{p}<0.001$ ) have significantly higher proportion of hospitalizations than unvaccinated since February 28, 2022. Similarly, the proportion test on the SARSCoV2 Deaths within 28 days of the positive test among those vaccinated with two doses
were higher than unvaccinated $\left(X^{2}=39.061, \mathrm{df}=1, \mathrm{p}<0.001\right)$ since November 8, 2021 and the third dose do not have significantly higher proportion of deaths than unvaccinated as of March 27, 2022.

Analysis of the SARS-CoV2 deaths in England and Wales showed that the 97.95\% of the deaths during the latter part of the Omicron variant surge occurred among $\geq 50$ years of age ( $80.07 \%$ ) of deaths $\geq 75$ years of age. The pre-existing conditions were present in $95.6 \%$ of deaths among all ages and $96.2 \%$ of deaths $\geq 60$ years of age during the Omicron variant surge in England. The deaths among elderly vaccinated population has to be considered in the context of advanced age among with pre-existing conditions.

## Vaccine effectiveness of the third dose population prior to December 20, 2021:

Since the third dose vaccination approval in September 2021, about 77.3\% of the $\geq 50$ years of age NIMS population were vaccinated with the third dose by December 19, 2021. The UKHSA did not report third dose outcomes until December 20, 2021 in their weekly reports. In our study, we analyzed the 999,064 pillar 2 cases among over 18 years old reported from an UKHSA publication with 336,046 cases among the third dose (booster); 484,742 among the two doses and 137,478 cases among unvaccinated ${ }^{1}$. Using the third dose weekly vaccinated population between December 26, 2021; January 2, 2022 and January 9,2022, the best vaccine effectiveness for the third dose was $13.8 \% ; 18.4 \%$ and $22.2 \%$, respectively. During the same period (November 27, 2021-January 12, 2022) the England reported 52,369 SARS-CoV2 hospitalizations and 4,101 COVD-19 deaths among over 18 years of age ${ }^{2,3}$.

Public health restrictions, lockdowns and reopening in the United Kingdom (UK): The UK instituted the first lockdown during the beginning of the pandemic on March 23, 2020. The second lockdown (October 30, 2020) and the third lockdown (December 22, 2020) were instituted during the second wave and the surge in cases during the Alpha variant surge.

The phased easing of restriction in UK started with reopening of the schools and colleges effective March 8, 2021 (week 10). The step 2 of the reopening became effective since April 12, 2021 and step 3 of the reopening since May 17, 2021 and by May 2021 the outdoor social contact were to be removed, two households or six people were allowed to meet indoors, and indoor hospitality services were provided and hotels were opened ${ }^{4-7}$. The UK government announced that most restrictions including face masks mandates, social distancing measures and capacity limitations in venues were lifted in England by July 19, 2021 and these were replaced by recommendations ${ }^{6,7}$.

## Figures and Tables

## Figure S1: Regression analysis of SARS-CoV2 cases, Hospitalizations and deaths



Figure S1: Regression analysis of SARS-CoV2 cases, Hospitalizations and deaths (death certificate) during the Alpha variant, Delta variant and Omicron variant surges.

Figures S2a-c: SARS-CoV2 cases, hospitalizations and deaths per 100,000 population from August 16, 2021-May 27, 2022


Figure S2a: SARS-CoV2 cases per 100,000 population among over 50 years of age group from August 16, 2021 to March 27, 2022.


Figure S2b: SARS-CoV2 hospitalizations per 100,000 population among over 50 years of age group from August 16, 2021 to March 27, 2022.


Figure S2c: SARS-CoV2 deaths per 100,000 population among over 50 years of age group from August 16, 2021 to March 27, 2022.

## Table S1a-c: SARS-CoV2 cases and hospitalization in England, SARS-CoV2 deaths in England and Wales among age groups

|  | Pre-Alpha | Alpha variant surge |  | Delta variant surge |  | Omicron variant surge |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Time period | Sept 28, 2020- <br> Dec 6, 2020 | $\begin{aligned} & \text { Dec 7,2020-Feb } \\ & 28,2021 \\ & \hline \end{aligned}$ | Mar 1, 2021-May $23,2021$ | $\begin{aligned} & \text { May 24, 2021-Aug 1, } \\ & 2021 \end{aligned}$ | Aug 2, 2021-Dec 5, $2021$ | Dec 6, 2021-Feb 27, $2022$ | $\begin{aligned} & \text { Feb 28, 2022-May } \\ & 1,2022 \\ & \hline \end{aligned}$ |
| COVID-19 cases; All ages ( $\mathrm{n}=$ ) | 1,055,142 | 2,074,606 | 235,582 | 1,243,075 | 3,721,600 | 5,459,340 | 2,460,597 |
| 0-19 yrs ( $\mathrm{n}=\%$ ) | 190,310 (18.0\%) | 289,018 (13.9\%) | 65,475 (27.8\%) | 368,060 (29.6\%) | 1,395,180 (37.5\%) | 1,380,507 (25.3\%) | 345,279 (14.0\%) |
| 20-29 yrs ( $\mathrm{n}=\%$ ) | 201,561 (19.1\%) | 380,818 (18.4\%) | 39,470 (16.8\%) | 353,755 (28.5\%) | 418,792 (11.3\%) | 913,345 (16.7\%) | 300,745 (12.2\%) |
| 30-49 yrs ( $\mathrm{n}=\%$ ) | 332,709 (31.5\%) | 728,813 (35.1\%) | 81,706 (34.7\%) | 355,519 (28.6\%) | 1,091,029 (29.3\%) | 1,873,509 (34.3\%) | 823,063 (22.4\%) |
| 50-69 yrs ( $\mathrm{n}=\%$ ) | 238,349 (22.6\%) | 487,939 (23.5\%) | 38,921 (16.5\%) | 138,527 (11.1\%) | 655,025 (17.6\%) | 994,954 (18.2\%) | 687,604 (27.9\%) |
| $\geq 50$ yrs ( $\mathrm{n}=\%$ ) | 330,562 (31.3\%) | 675,957 (32.6\%) | 48,931 (20.8\%) | 165,741 (13.3\%) | 816,599 (21.9\%) | 1,291,979 (23.7\%) | 991,510 (40.3\%) |
| $\geq 70$ yrs ( $\mathrm{n}=\%$ ) | 92,213 (8.7\%) | 188,018 (9.1\%) | 10,010 (4.2\%) | 27,214 (2.2\%) | 161,574 (4.3\%) | 297,025 (5.4\%) | 303,905 (12.4\%) |
| $\geq 80$ yrs ( $\mathrm{n}=\%$ ) | 46,640 (4.4\%) | 101,056 (4.9\%) | 4,845 (2.1\%) | 8,910 (0.7\%) | 48,156 (1.3\%) | 110,302 (2.0\%) | 115,288 (4.7\%) |
| Statistical analysis |  | $(\Delta)$ from prior period | ( $\Delta$ ) from prior period | $(\Delta)$ from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period |
| 0-19 yrs [RR (95\%CI); p value] |  | $\begin{aligned} & 0.77 \text { (0.77-0.78); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 2.00 \text { (1.98-2.01); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.07 \text { (1.06-1.07); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.27 \text { (1.26-1.27); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.67 \text { (0.67-0.68); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.55(0.55-0.56) ; \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 20-29 yrs [RR (95\%CI); p value] |  | $\begin{aligned} & \hline 0.96 \text { (0.96-0.97); } \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 0.91(0.90-0.92) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.70(1.68-1.71) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & \hline 0.40(0.39-0.40) ; \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 1.48 \text { (1.48-1.49); } \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 0.73(0.72-0.73) ; \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 30-49 yrs [RR (95\%CI); p value] |  | $\begin{aligned} & 1.11 \text { (1.11-1.12); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.99 \text { (0.98-0.99); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.82(0.82-0.83) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.03(1.02-1.03) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.17 \text { (1.168-1.172); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.97 \text { (0.97-0.98); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 50-69 yrs [RR (95\%CI); p value] |  | $\begin{aligned} & 1.04 \text { (1.04-1.05); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.70 \text { (0.69-0.71); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.67 \text { (0.66-0.68); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.58 \text { (1.57-1.59); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.03 \text { (1.03-1.04); } \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 1.53 \text { (1.52-1.54); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| $\geq 50$ years [RR (95\%CI); p value] |  | $\begin{aligned} & 1.04 \text { (1.03-1.04); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.64 \text { (0.63-0.64); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.64 \text { (0.63-0.65); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.65 \text { (1.63-1.65); } \\ & \text { p<0.001 } \end{aligned}$ | $\begin{aligned} & 1.07 \text { (1.07-1.08); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.70 \text { (1.70-1.71); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| $\geq 70$ yrs [RR (95\%CI); p value] |  | $\begin{aligned} & 1.04 \text { (1.03-1.04); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.47 \text { (0.46-0.48); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.52(0.50-0.53) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.98 \text { (1.95-2.01); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.25(1.24-1.26) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 2.27 \text { (2.26-2.28); } \\ & p<0.001 \end{aligned}$ |
| $\geq 80 \mathrm{yrs}$ [RR (95\%CI); p value] |  | $\begin{aligned} & 1.10 \text { (1.09-1.11); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & \hline 0.42(0.41-0.43) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.35(0.37-0.36) ; \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 1.81 \text { (1.76-1.85); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.56 \text { (1.54-1.58); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 2.32(2.30-2.34) ; \\ & p<0.001 \end{aligned}$ |

Table S1a: SARS-CoV2 cases in England among age groups in between September 28, 2020 to May 1, 2022.

|  | Pre-Alpha | Alpha variant surge |  | Delta variant surge |  | Omicron variant surge |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Time period | Oct 12, 2020-Dec $6,2020$ | $\begin{aligned} & \text { Dec 7, 2020-Feb } \\ & 28,2021 \end{aligned}$ | Mar 1, 2021- <br> May 23, 2021 | May 24-Aug 1, $2021$ | $\begin{aligned} & \text { Aug 2-Dec 5, } \\ & 2021 \end{aligned}$ | $\begin{aligned} & \text { Dec 6,2021-Feb } \\ & \text { 27,2022 } \end{aligned}$ | $\begin{aligned} & \text { Feb 28-May 1, } \\ & 2022 \end{aligned}$ |
| COVID-19 <br> Hospitalizations; All ages ( $\mathrm{n}=$ ) | 65,419 | 179,599 | 17,295 | 24,880 | 87,823 | 106,834 | 95,278 |
| 0-17 yrs ( $\mathrm{n}=\%$ ) | 952 (1.5\%) | 2,496 (1.4\%) | 599 (3.5\%) | 1,602 (6.4\%) | 4,779 (5.4\%) | 7,396 (6.9\%) | 4,971 (5.2\%) |
| 18-34 yrs ( $\mathrm{n}=\%$ ) | 3,440 (5.3\%) | 9,942 (5.5\%) | 1,924 (11.1\%) | 5,784 (23.2\%) | 9,994 (11.4\%) | 13,775 (12.9\%) | 7,933 (8.3\%) |
| 35-54 yrs (n=\%) | 8,970 (13.7\%) | 29,483 (16.4\%) | 3,759 (21.7\%) | 6,831 (27.5\%) | $\begin{aligned} & 18,847 \\ & (21.5 \%) \end{aligned}$ | 16,710 (15.6\%) | $\begin{aligned} & 10,362 \\ & (10.9 \%) \\ & \hline \end{aligned}$ |
| 55-64 yrs ( $\mathrm{n}=\%$ ) | 8,669 (13.3\%) | 28,208 (15.7\%) | 2,697 (15.6\%) | 3,028 (12.2\%) | $\begin{aligned} & 12,189 \\ & (13.9 \%) \end{aligned}$ | 11,580 (10.8\%) | 9,210 (9.7\%) |
| 65-74 yrs ( $\mathrm{n}=\%$ ) | 12,107 (18.5\%) | 32,426 (18.1\%) | 2,540 (14.7\%) | 2,770 (11.1\%) | $\begin{aligned} & 14,944 \\ & (17.0 \%) \end{aligned}$ | 15,466 (14.5\%) | $\begin{aligned} & 14,794 \\ & (15.5 \%) \\ & \hline \end{aligned}$ |
| $\geq 75$ yrs ( $\mathrm{n}=\%$ ) | 30,586 (46.8\%) | 76,831 (42.8\%) | 5,761 (33.3\%) | 4,806 (19.3\%) | $\begin{aligned} & \hline 27,047 \\ & (30.8 \%) \\ & \hline \end{aligned}$ | 41,875 (39.2\%) | $\begin{aligned} & \hline 47,970 \\ & (50.3 \%) \\ & \hline \end{aligned}$ |
| Statistical analysis |  | $(\Delta)$ from prior period | $(\Delta)$ from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period | $(\Delta)$ from prior period | $(\Delta)$ from prior period |
| 0-17 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.96 \text { (0.88-1.02); } \\ & \mathrm{p}<0.223 \end{aligned}$ | $\begin{aligned} & 2.49(2.28-2.72) ; \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 1.86(1.70-2.03) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.85 \text { (0.80-0.89); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.27(1.22-1.31) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.75(0.72-0.78) ; \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 18-34 yrs [RR ( $95 \% \mathrm{Cl}$ ); p value] |  | $\begin{aligned} & 1.05 \text { (1.01-1.09); } \\ & p=0.007 \end{aligned}$ | $\begin{aligned} & 2.01 \text { (1.91-2.10); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 2.09(1.99-2.19) ; \\ & \mathrm{D}<0.001 \end{aligned}$ | $\begin{aligned} & 0.49(0.47-0.50) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.13 \text { (1.10-1.16); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.65(0.62-0.66) ; \\ & p<0.001 \end{aligned}$ |
| 35-54 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 1.20 \text { (1.17-1.22); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.32(1.28-1.36) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.26 \text { (1.22-1.31); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.78 \text { (0.76-0.80); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.73 \text { (0.71-0.74); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.70 \text { (0.67-0.71); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 55-64 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 1.19 \text { (1.16-1.21); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.99 \text { (0.95-1.03); } \\ & p=0.699 \end{aligned}$ | $\begin{aligned} & 0.78 \text { (0.74-0.82); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.14 \text { (1.10-1.18); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.78 \text { (0.76-0.80); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.89(0.86-0.91) ; \\ & p<0.001 \end{aligned}$ |
| 65-74 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.98 \text { (0.95-0.99); } \\ & p=0.010 \end{aligned}$ | $\begin{aligned} & 0.81 \text { (0.78-0.84); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.76 \text { (0.72-0.80); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.53 \text { (1.47-1.59); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.85 \text { (0.83-0.87); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.07 \text { (1.05-1.09); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| $\geq 75$ yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.92 \text { (0.90-0.92); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.78 \text { (0.76-0.80); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.58(0.56-0.60) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.59(1.55-1.64) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.27 \text { (1.25-1.29); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.28 \text { (1.27-1.30); } \\ & \mathrm{p}<0.001 \end{aligned}$ |

Table S1b: SARS-CoV2 hospitalizations in England among age groups in between September 28, 2020 to May 1, 2022.

|  | First wave | Pre-alfa | Alpha variant surge |  | Delta variant surge |  | Omicron variant surge |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Study period | $\begin{aligned} & \text { Feb 24-Aug } \\ & 16,2020 \end{aligned}$ | Aug 17-Dec $\text { 6, } 2020$ | $\begin{aligned} & \text { Dec 7,2020-Feb } \\ & 28,2021 \end{aligned}$ | Mar 1, 2021- <br> May 23, 2021 | May 24, 2021- <br> Aug 1, 2021 | Aug 2, 2021- <br> Dec 5, 2021 | Dec 6, 2021- <br> Feb 27, 2022 | Feb 28, 2022- <br> May 1, 2022 |
| COVID-19 <br> deaths, all ages $(n=)$ | 52,410 | 19,082 | 63,118 | 7,281 | 1,719 | 13,980 | 12,063 | 7,787 |
| 0-19 yrs ( $\mathrm{n}=\%$ ) | 15 (0.03\%) | 2 (0.01\%) | 16 (0.03\%) | 4 (0.05\%) | 6 (0.35\%) | 33 (0.24\%) | 27 (0.22\%) | 12 (0.15\%) |
| 20-29 yrs ( $\mathrm{n}=\%$ ) | 76 (0.15\%) | 21 (0.11\%) | 74 (0.12\%) | 16 (0.22\%) | 14 (0.81\%) | 51 (0.36\%) | 35 (0.29\%) | 14 (0.18\%) |
| 30-49 yrs ( $\mathrm{n}=\%$ ) | $\begin{aligned} & 886 \\ & \text { (1.69\%) } \end{aligned}$ | 266 (1.39\%) | 1,153 (1.83\%) | 241 (3.31\%) | 114 (6.63\%) | 611 (4.37\%) | 399 (3.31\%) | 118 (1.52\%) |
| 50-69 yrs ( $\mathrm{n}=\%$ ) | $\begin{aligned} & 7,468 \\ & (14.25 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,600 } \\ & \text { (13.63\%) } \end{aligned}$ | $\begin{aligned} & 9,887 \\ & (15.66 \%) \end{aligned}$ | 1,785 (24.52\%) | 468 (27.23\%) | $\begin{aligned} & 3,302 \\ & (23.62 \%) \end{aligned}$ | $\begin{aligned} & 2,241 \\ & (18.58 \%) \end{aligned}$ | 793 (10.18\%) |
| 70-74 yrs ( $\mathrm{n}=\%$ ) | $\begin{aligned} & 4,817 \\ & \text { (9.19\%) } \end{aligned}$ | $\begin{aligned} & 1,956 \\ & (10.25 \%) \end{aligned}$ | 6,077 (9.63\%) | 708 (9.72\%) | 166 (9.66\%) | $\begin{aligned} & 1,619 \\ & (11.58 \%) \end{aligned}$ | $\begin{aligned} & 1,933 \\ & \text { (16.02\%) } \end{aligned}$ | 599 (7.69\%) |
| $\geq 50 \mathrm{yrs}$ ( $\mathrm{n}=\%$ ) | $\begin{aligned} & 51345 \\ & \text { (97.97\%) } \end{aligned}$ | $\begin{aligned} & 18,765 \\ & \text { (98.34\%) } \end{aligned}$ | $\begin{aligned} & \hline 61,771 \\ & (97.87 \%) \\ & \hline \end{aligned}$ | 6,987 (95.96\%) | $\begin{aligned} & 1,570 \\ & \text { (91.33\%) } \end{aligned}$ | $\begin{aligned} & 13,215 \\ & \text { (94.53\%) } \end{aligned}$ | $\begin{aligned} & \hline 11,546 \\ & \text { (95.71\%) } \end{aligned}$ | $\begin{aligned} & \hline 7,627 \\ & \text { (97.95\%) } \end{aligned}$ |
| $\geq 75$ yrs ( $\mathrm{n}=\%$ ) | $\begin{aligned} & 39060 \\ & \text { (74.53\%) } \end{aligned}$ | $\begin{aligned} & 14,209 \\ & (74.46 \%) \end{aligned}$ | $\begin{aligned} & 45,807 \\ & \text { (72.57\%) } \end{aligned}$ | 4,494 (61.72\%) | 936 (54.45\%) | $\begin{aligned} & 8,294 \\ & \text { (59.33\%) } \end{aligned}$ | $\begin{aligned} & 8,189 \\ & (67.89 \%) \end{aligned}$ | $\begin{aligned} & 6,235 \\ & \text { (80.07\%) } \end{aligned}$ |
| Statistical analysis |  | ( $\Delta$ ) from prior period | $(\Delta)$ from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period | ( $\Delta$ ) from prior period |
| 0-19 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.36 \text { (0.08- } \\ & 1.60) ; p=0.182 \end{aligned}$ | $\begin{aligned} & 2.42(0.55-10.51) ; \\ & p=0.238 \end{aligned}$ | $\begin{aligned} & \text { 2.17 (0.72-6.48); } \\ & p=0.166 \end{aligned}$ | $\begin{aligned} & 6.35(1.79- \\ & 22.49) ; p=0.004 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.68 \text { (0.28- } \\ & 1.61) ; p=0.377 \end{aligned}$ | $\begin{aligned} & 0.95(0.57- \\ & 1.58) ; p=0.837 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.69(0.35-1.36) ; \\ & p=0.281 \end{aligned}$ |
| 20-29 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & \hline 0.75 \text { (0.46- } \\ & 1.23) ; p=0.263 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1.07(0.66-1.73) ; \\ & \mathrm{p}=0.797 \end{aligned}$ | $\begin{aligned} & 1.87(1.09-3.22) ; \\ & p=0.022 \end{aligned}$ | $\begin{aligned} & 3.71 \text { (1.81-7.57); } \\ & \mathrm{p}=0.0003 \end{aligned}$ | $\begin{aligned} & 0.45(0.24- \\ & 0.80) ; p=0.007 \end{aligned}$ | $\begin{aligned} & 0.80(0.51- \\ & 1.22) ; p=0.296 \end{aligned}$ | $\begin{aligned} & 0.62(0.33-1.15) ; \\ & p=0.130 \end{aligned}$ |
| 30-49 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.82(0.72- \\ & 0.944) ; \\ & p=0.005 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1.31 \text { (1.15-1.49); } \\ & \mathrm{p}=0.001 \end{aligned}$ | $\begin{aligned} & 1.81 \text { (1.58-2.08); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 2.00 \text { (1.61-2.49); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.66 \text { (0.54- } \\ & 0.80) ; ~ p<0.001 \end{aligned}$ | $\begin{aligned} & 0.76 \text { ( } 0.66- \\ & 0.86 \text { ); } p<0.001 \end{aligned}$ | $\begin{aligned} & 0.46 \text { (0.37-0.56); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| 50-69 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.96 \text { (0.92- } \\ & 0.99) ; p=0.034 \end{aligned}$ | $\begin{aligned} & \hline 1.15(1.10-1.12) ; \\ & p<0.001 \end{aligned}$ | $\begin{aligned} & 1.57 \text { (1.49-1.64); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.11(1.02-1.21) ; \\ & \mathrm{p}=0.018 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.87(0.79- \\ & 0.94) ; p=0.001 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.79 \text { (0.75- } \\ & 0.82) ; p<0.001 \end{aligned}$ | $\begin{aligned} & 0.41 \text { (0.38-0.45); } \\ & p<0.001 \end{aligned}$ |
| 70-74 yrs [RR (95\% CI); p value] |  | $\begin{aligned} & \hline 1.11 \text { (1.06- } \\ & \text { 1.17); } \mathrm{p}<0.001 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.94(0.89-0.98) ; \\ & \mathrm{p}=0.011 \end{aligned}$ | $\begin{aligned} & 1.01 \text { (0.93-1.09); } \\ & p=0.792 \end{aligned}$ | $\begin{aligned} & 0.99(0.84-1.17) ; \\ & p=0.932 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1.20(1.03- \\ & 1.39) ; p=0.019 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1.38 \text { (1.30- } \\ & 1.47) ; p<0.001 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.48 \text { (0.44-0.52); } \\ & \mathrm{p}<0.001 \end{aligned}$ |
| $\geq 50$ yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 1.00(1.00- \\ & 1.01) ; p=0.001 \end{aligned}$ | $\begin{aligned} & 0.995 \text { (0.993- } \\ & 0.997) ; p<0.001 \end{aligned}$ | $\begin{aligned} & 0.98 \text { (0.97-0.99); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.95 \text { (0.93-0.97); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.04 \text { (1.01- } \\ & 1.05) ; p<0.001 \end{aligned}$ | $\begin{aligned} & 1.01 \text { (1.01- } \\ & 1.02) ; \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.02(1.02-0.03) ; \\ & \mathrm{p}<0.001 \end{aligned}$ |
| $\geq 75$ yrs [RR (95\% CI); p value] |  | $\begin{aligned} & 0.99 \text { (0.98- } \\ & 1.01) ; p=0.860 \end{aligned}$ | $\begin{aligned} & 0.97 \text { (0.96-0.98); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.85 \text { (0.83-0.87); } \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 0.88(0.84-0.92) ; \\ & \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.09(1.04- \\ & 1.14) ; p=0.001 \end{aligned}$ | $\begin{aligned} & 1.14 \text { (1.12- } \\ & \text { 1.17); } \mathrm{p}<0.001 \end{aligned}$ | $\begin{aligned} & 1.18 \text { ((1.16- } \\ & 1.20) ; p<0.001 \end{aligned}$ |

Table S1c: SARS-CoV2 deaths in England and Wales among age groups in between September 28, 2020 to May 1, 2022.

Table S2: Pre-existing condition among deaths during the Omicron variant surge in England

| Pre-existing conditions during the Omicron variant surge (December 6, 2021-May 1, 2022) |  |  |  |
| :---: | :---: | :---: | :---: |
| Age group (yrs) | Total SARS-COV2 deaths | Pre-existing condition |  |
|  |  | Present | Absent |
| All ages | 17,142 | 16,387 (95.6\%) | 755 (4.4\%) |
| 0-19 | 39 | 27 (69.2\%) | 12 (30.8\%) |
| 20-39 | 198 | 164 (82.8\%) | 34 (17.2\%) |
| 40-59 | 1,206 | 1,093 (90.6\%) | 113 (9.4\%) |
| 60-79 | 5,803 | 5,537 (95.4\%) | 266 (4.6\%) |
| 80+ | 9,895 | 9,566 (96.7\%) | 329 (3.3\%) |
| 60+ | 15,698 | 15,103 (96.2\%) | 595 (3.8\%) |
| Pre existing conditions during the entire pandemic |  |  |  |
| Date introduced | Pre-existing condition | Count of all deaths since condition introduced | Deaths with preexisting condition (n=\%) |
| 31-Mar-20 | Diabetes | 115,463 | 29,572 (25.6\%) |
| 31-Mar-20 | Chronic Kidney Disease | 115,463 | 19,548 (16.9\%) |
| 31-Mar-20 | Chronic Pulmonary Disease | 115,463 | 18,455 (16.0\%) |
| 31-Mar-20 | Dementia | 115,463 | 17,011 (14.7\%) |
| 1-May-20 | Ischaemic Heart Disease | 96,645 | 12,468 (12.9\%) |
| 31-Mar-20 | Asthma | 115,463 | 8,690 (7.5\%) |
| 31-Mar-20 | Rheumatological Disorder | 115,463 | 3,904 (3.4\%) |
| 31-Mar-20 | Chronic Neurological Disorder | 115,463 | 2,934 (2.5\%) |
| 24-Mar-20 | Received treatment for a Mental Health condition | 117,059 | 2,653 (2.3\%) |


| 24-Mar-20 | Learning Disability and or Autism | 117,059 | $1,397(1.2 \%)$ |
| :--- | :--- | :--- | :--- |
| 31-Mar-20 | Other | 115,463 | $84,544(73.2 \%)$ |

Table S2: Pre-existing condition among deaths during the Omicron variant surge in England

Table S3a: NIMS database with vaccination status of all age groups, over 18 and 50 years of age

| week endin g | All ages vaccination status; $\mathbf{n = p o p u l a t i o n}$ (\%) |  |  |  | $\geq 18$ yrs. of age vaccination status; $\mathrm{n}=$ population (\%) |  |  |  | $\geq \mathbf{5 0}$ yrs. of age vaccination status; $\mathrm{n}=$ population (\%) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{array}{\|l} 2 \text { doses } \\ \text { (no } 3^{\text {rd }} \text { ) } \end{array}$ | Third dose | 1 dose only | Unvaccinate <br> d | $\begin{aligned} & 2 \text { doses } \\ & \text { (no } 3^{\text {rd }} \text { ) } \\ & \hline \end{aligned}$ | Third dose | 1 dose only | Unvaccinate <br> d | $\begin{aligned} & 2 \text { doses } \\ & \text { (no 3 }{ }^{\text {rd }} \text { ) } \\ & \hline \end{aligned}$ | Third dose | 1 dose only | Unvaccinate d |
| $\begin{array}{r} \hline \text { 3-Jan- } \\ \hline \end{array}$ | $\begin{aligned} & \hline 29,783 \\ & (0.05 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 1,108,851 \\ & (1.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 61,961,296 \\ & (98.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 29,775 \\ & (0.1 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 1,108,534 \\ & (2.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 49,085,900 \\ & (97.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,145 \\ & (0.1 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 873,796 \\ & (3.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 21,607,893 \\ & (96.0 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 10-\text { Jan- } \\ 21 \end{array}$ | $\begin{aligned} & 402,102 \\ & (0.6 \%) \end{aligned}$ |  | $\begin{aligned} & 1,661,407 \\ & (2.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 61,036,379 \\ & (96.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 402,058 \\ & (0.8 \%) \end{aligned}$ |  | $\begin{aligned} & 1,660,718 \\ & (3.3 \%) \end{aligned}$ | $\begin{aligned} & \text { 48,161,391 } \\ & (95.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 354,641 \\ & (1.6 \%) \end{aligned}$ |  | $\begin{aligned} & 1,207,864 \\ & (5.4 \%) \end{aligned}$ | $\begin{aligned} & \text { 20,937,311 } \\ & (93.1 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 17-Jan- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 442,698 \\ & (0.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 3,174,888 \\ & (5.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 59,482,270 \\ & (94.3 \%) \end{aligned}$ | $\begin{aligned} & 442,647 \\ & (0.9 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 3,173,666 \\ & (6.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 46,607,822 \\ & (92.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 384,361 \\ & (1.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 2,349,075 \\ & (10.4 \%) \end{aligned}$ | $\begin{aligned} & 19,766,359 \\ & (87.9 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 24-J a n- \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 450,064 \\ & (0.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 5,359,396 \\ & (8.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 57,290,372 \\ & (90.8 \%) \end{aligned}$ | $\begin{aligned} & 450,010 \\ & (0.9 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 5,357,481 \\ & (10.7 \%) \end{aligned}$ | $\begin{aligned} & 44,416,620 \\ & (88.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 388,937 \\ & (1.7 \%) \end{aligned}$ |  | $\begin{aligned} & \text { 4,123,495 } \\ & (18.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 17,987,350 \\ & (79.9 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 31-Jan- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 460,029 \\ & (0.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \text { 7,513,401 } \\ & (11.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 55,126,358 \\ & (87.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 459,963 \\ & (0.9 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 7,510,529 \\ & (15.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 42,253,575 \\ & (84.1 \%) \end{aligned}$ | $\begin{aligned} & 394,382 \\ & (1.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 5,924,604 \\ & (26.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 16,180,765 \\ & (71.9 \%) \end{aligned}$ |
| $\begin{array}{r} \text { 7-Feb- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 470,877 \\ & (0.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 9,874,536 \\ & (15.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 52,754,344 \\ & (83.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 470,811 \\ & (0.9 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 9,870,576 \\ & (19.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 39,882,649 \\ & (79.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 400,108 \\ & (1.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 7,960,696 \\ & (35.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 14,138,919 \\ & (62.8 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 14-\mathrm{Feb}- \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 490,579 \\ & (0.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 12,141,76 \\ & 3(19.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 50,467,364 \\ & (80.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 490,500 \\ & (1.0 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 12,136,09 \\ & 5(24.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 37,597,390 \\ & (74.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 411,497 \\ & (1.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 9,906,334 \\ & (44.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 12,181,858 \\ & (54.1 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 21-\mathrm{Feb}- \\ 21 \end{array}$ | $\begin{aligned} & 515,699 \\ & (0.8 \%) \end{aligned}$ |  | $\begin{aligned} & 14,167,95 \\ & 2(22.5 \%) \end{aligned}$ | $\begin{aligned} & 48,416,011 \\ & (76.7 \%) \end{aligned}$ | $\begin{aligned} & 515,602 \\ & (1.0 \%) \end{aligned}$ |  | $\begin{aligned} & 14,157,86 \\ & 9(28.2 \%) \end{aligned}$ | $\begin{aligned} & 35,550,470 \\ & (70.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 425,363 \\ & (1.9 \%) \end{aligned}$ |  | $\begin{aligned} & 11,453,744 \\ & (50.9 \%) \end{aligned}$ | $\begin{aligned} & 10,620,547 \\ & (47.2 \%) \end{aligned}$ |
| $\begin{array}{r} 28 \text {-Feb- } \\ 21 \end{array}$ | $\begin{aligned} & 606,844 \\ & (1.0 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 16,326,97 \\ & 6(25.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 46,165,791 \\ & (73.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 606,671 \\ & (1.2 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 16,307,12 \\ & 8(32.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 33,310,091 \\ & (66.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 477,899 \\ & (2.1 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 12,897,769 \\ & (57.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,123,957 \\ & (40.6 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 7 \text {-Mar- } \\ \hline \end{array}$ | $\begin{aligned} & 804,235 \\ & (1.3 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 17,915,49 \\ & 9(28.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 44,379,802 \\ & (70.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 803,960 \\ & (1.6 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 17,892,58 \\ & 9(35.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 31,527,266 \\ & (62.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 619,281 \\ & (2.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 13,951,393 \\ & (62.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 7,928,897 \\ & (35.2 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 14- \\ \text { Mar-21 } \\ \hline \end{array}$ | $\begin{aligned} & 1,117,297 \\ & (1.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 19,298,91 \\ & 2(30.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 42,683,207 \\ & (67.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,116,884 \\ & (2.2 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 19,272,70 \\ & 1(38.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 29,834,110 \\ & (59.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 837,736 \\ & (3.7 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 14,951,636 \\ & (66.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6,710,129 \\ & (29.8 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 21- \\ \text { Mar-21 } \end{array}$ | $\begin{aligned} & 1,612,580 \\ & (2.6 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 21,881,71 \\ & 9(34.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 39,604,914 \\ & (62.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,611,856 \\ & (3.2 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 21,852,25 \\ & 8(43.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 26,759,378 \\ & (53.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,168,952 \\ & (5.2 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 16,952,088 \\ & (75.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 4,378,368 \\ & (19.5 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 28- \\ \text { Mar-21 } \\ \hline \end{array}$ | $\begin{aligned} & \hline 2,799,963 \\ & (4.4 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 22,724,93 \\ & 2(36.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 37,574,058 \\ & (59.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,798,602 \\ & (5.6 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 22,689,61 \\ & 1(45.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 24,735,019 \\ & (49.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,061,993 \\ & (9.2 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 17,281,497 \\ & (76.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,155,746 \\ & (14.0 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \text { 4-Apr- } \\ 21 \end{array}$ | $\begin{array}{\|l} \hline 4,323,280 \\ (6.9 \%) \\ \hline \end{array}$ |  | $\begin{aligned} & \hline 22,014,10 \\ & 3(34.9 \%) \end{aligned}$ | $\begin{aligned} & \hline 36,761,369 \\ & (58.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 4,321,262 \\ & (8.6 \%) \end{aligned}$ |  | $\begin{aligned} & \hline 21,975,77 \\ & 7(43.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 23,925,992 \\ & (47.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,275,787 \\ & (14.6 \%) \end{aligned}$ |  | $\begin{aligned} & \hline 16,413,863 \\ & (73.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,809,437 \\ & (12.5 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 11-Apr- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 6,297,786 \\ & (10.0 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 20,384,85 \\ & 0(32.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 36,415,884 \\ & (57.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6,294,836 \\ & (12.5 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 20,344,81 \\ & 6(40.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 23,583,147 \\ & (47.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 4,894,124 \\ & (21.8 \%) \\ & \hline \end{aligned}$ |  | $\begin{aligned} & \hline 14,902,291 \\ & (66.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,702,514 \\ & (12.0 \%) \\ & \hline \end{aligned}$ |


| $\begin{array}{r} \text { 18-Apr- } \\ 21 \end{array}$ | $\begin{aligned} & 8,436,940 \\ & (13.4 \%) \end{aligned}$ | $\begin{aligned} & 18,769,54 \\ & 4(29.7 \%) \end{aligned}$ | $\begin{aligned} & 35,891,780 \\ & (56.9 \%) \end{aligned}$ | $\begin{aligned} & 8,432,628 \\ & (16.8 \%) \end{aligned}$ | $\begin{aligned} & 18,728,62 \\ & 8(37.3 \%) \end{aligned}$ | $\begin{aligned} & 23,061,287 \\ & (45.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 6,685,917 } \\ & (29.7 \%) \end{aligned}$ | $\begin{aligned} & \text { 13,190,927 } \\ & (58.6 \%) \end{aligned}$ | $\begin{aligned} & 2,621,896 \\ & (11.7 \%) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{r} \hline 25-A p r- \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 10,680,33 \\ & 7(16.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 17,186,76 \\ & 4(27.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 35,230,749 \\ & (55.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,674,31 \\ & 2(21.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 17,145,97 \\ & 9(34.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 22,401,838 \\ & (44.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 8,595,553 \\ & (38.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 11,356,042 \\ & (50.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,546,853 \\ & (11.3 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 2-May- } \\ 21 \end{array}$ | $\begin{aligned} & 12,822,57 \\ & 7(20.3 \%) \end{aligned}$ | $\begin{aligned} & 15,718,25 \\ & 2(24.9 \%) \end{aligned}$ | $\begin{aligned} & \text { 34,556,605 } \\ & (54.8 \%) \end{aligned}$ | $\begin{aligned} & 12,814,31 \\ & 2(25.5 \%) \end{aligned}$ | $\begin{aligned} & 15,678,22 \\ & 8(31.2 \%) \end{aligned}$ | $\begin{aligned} & \text { 21,729,174 } \\ & (43.3 \%) \end{aligned}$ | $\begin{aligned} & 10,380,47 \\ & 9(46.1 \%) \end{aligned}$ | $\begin{aligned} & 9,621,020 \\ & (42.8 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,496,624 } \\ & (11.1 \%) \end{aligned}$ |
| $\begin{array}{r} \text { 9-May- } \\ 21 \end{array}$ | $\begin{aligned} & 14,872,85 \\ & 2(23.6 \%) \end{aligned}$ | $\begin{aligned} & 14,359,97 \\ & 0(22.8 \%) \end{aligned}$ | $\begin{aligned} & 33,864,269 \\ & (53.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 14,859,44 \\ & 6(29.6 \%) \end{aligned}$ | $\begin{aligned} & 14,323,50 \\ & 4(28.5 \%) \end{aligned}$ | $\begin{aligned} & 21,038,422 \\ & (41.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 11,930,95 \\ & 2(53.0 \%) \end{aligned}$ | $\begin{aligned} & 8,108,973 \\ & (36.0 \%) \end{aligned}$ | $\begin{aligned} & 2,457,945 \\ & (10.9 \%) \\ & \hline \end{aligned}$ |
| $16-$ May- 21 | $\begin{aligned} & 17,003,35 \\ & 2(26.9 \%) \end{aligned}$ | $\begin{aligned} & 13,255,20 \\ & 7(21.0 \%) \end{aligned}$ | $\begin{aligned} & 32,838,081 \\ & (52.0 \%) \end{aligned}$ | $\begin{aligned} & 16,979,88 \\ & 6(33.8 \%) \end{aligned}$ | $\begin{aligned} & 13,223,27 \\ & 3(26.3 \%) \end{aligned}$ | $\begin{aligned} & 20,017,762 \\ & (39.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 13,397,39 \\ & 3(59.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 6,692,260 } \\ & (29.7 \%) \end{aligned}$ | $\begin{aligned} & 2,407,916 \\ & (10.7 \%) \end{aligned}$ |
| $23-$ May- 21 | $\begin{aligned} & 19,266,07 \\ & 1(30.5 \%) \end{aligned}$ | $\begin{aligned} & 12,201,72 \\ & 8(19.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 31,628,350 \\ & (50.1 \%) \end{aligned}$ | $\begin{aligned} & 19,238,43 \\ & 5(38.3 \%) \end{aligned}$ | $\begin{aligned} & 12,169,33 \\ & 9(24.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,812,657 \\ & (37.5 \%) \end{aligned}$ | $\begin{aligned} & 15,002,86 \\ & 3 \text { (66.7\%) } \end{aligned}$ | $\begin{aligned} & \text { 5,141,253 } \\ & \text { (22.9\%) } \end{aligned}$ | $\begin{aligned} & 2,353,113 \\ & (10.5 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 30- \\ \text { May- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 21,501,13 \\ & 3 \text { (34.1\%) } \end{aligned}$ | $\begin{aligned} & 11,106,52 \\ & 1 \text { (17.6\%) } \end{aligned}$ | $\begin{aligned} & 30,487,981 \\ & (48.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 21,469,88 \\ & 3(42.7 \%) \end{aligned}$ | $\begin{aligned} & 11,074,83 \\ & 9(22.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 17,675,195 \\ & (35.2 \%) \end{aligned}$ | $\begin{aligned} & 16,624,52 \\ & 7(73.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,585,879 \\ & (15.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,286,459 \\ & (10.2 \%) \end{aligned}$ |
| $\begin{array}{r} 6 \text {-Jun- } \\ 21 \end{array}$ | $\begin{aligned} & 23,480,37 \\ & 7(37.2 \%) \end{aligned}$ | $\begin{aligned} & 9,997,612 \\ & (15.8 \%) \end{aligned}$ | $\begin{aligned} & 29,617,087 \\ & (46.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 23,446,39 \\ & 5(46.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,964,995 \\ & (19.8 \%) \end{aligned}$ | $\begin{aligned} & 16,807,969 \\ & (33.5 \%) \end{aligned}$ | $\begin{aligned} & 17,991,86 \\ & 4(80.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,251,444 \\ & (10.0 \%) \end{aligned}$ | $\begin{aligned} & 2,253,174 \\ & (10.0 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 13-Jun- } \\ 21 \end{array}$ | $\begin{aligned} & \hline 25,151,89 \\ & 1 \text { (39.9\%) } \end{aligned}$ | $\begin{aligned} & \hline 9,383,450 \\ & (14.9 \%) \end{aligned}$ | $\begin{aligned} & \text { 28,558,988 } \\ & (45.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 25,113,93 \\ & 5(50.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,350,595 \\ & (18.6 \%) \end{aligned}$ | $\begin{aligned} & 15,754,083 \\ & (31.4 \%) \end{aligned}$ | $\begin{aligned} & 18,951,55 \\ & 7(84.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 1,317,673 \\ & (5.9 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,226,792 } \\ & (9.9 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 20-\mathrm{Jun}- \\ 21 \end{array}$ | $\begin{aligned} & \hline 26,287,67 \\ & 9(41.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,504,211 \\ & (15.1 \%) \end{aligned}$ | $\begin{aligned} & \text { 27,301,589 } \\ & (43.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 26,246,20 \\ & 1 \text { (52.3\%) } \end{aligned}$ | $\begin{aligned} & \hline 9,469,778 \\ & (18.9 \%) \end{aligned}$ | $\begin{aligned} & 14,501,789 \\ & (28.9 \%) \end{aligned}$ | $\begin{aligned} & \hline 19,393,71 \\ & 9 \text { (86.2\%) } \end{aligned}$ | $\begin{aligned} & 900,099 \\ & (4.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,201,669 \\ & (9.8 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 27-\text { Jun- } \\ 21 \end{array}$ | $\begin{aligned} & \hline 27,168,99 \\ & 8(43.1 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,798,677 \\ & (15.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 26,124,962 \\ & (41.4 \%) \end{aligned}$ | $\begin{aligned} & 27,124,12 \\ & 1 \text { (54.0\%) } \end{aligned}$ | $\begin{aligned} & \text { 9,763,129 } \\ & \text { (19.4\%) } \end{aligned}$ | $\begin{aligned} & 13,329,676 \\ & (26.5 \%) \end{aligned}$ | $\begin{aligned} & 19,567,59 \\ & 3 \text { (87.0\%) } \end{aligned}$ | $\begin{aligned} & \hline 750,506 \\ & (3.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,176,842 \\ & (9.7 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 4-Jul- } \\ 21 \end{array}$ | $\begin{aligned} & \hline 28,061,61 \\ & 3(44.5 \%) \end{aligned}$ | $\begin{aligned} & 9,648,230 \\ & (15.3 \%) \end{aligned}$ | $\begin{aligned} & \text { 25,382,133 } \\ & (40.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 28,013,51 \\ & 8(55.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,611,624 \\ & (19.1 \%) \end{aligned}$ | $\begin{aligned} & 12,591,124 \\ & (25.1 \%) \end{aligned}$ | $\begin{aligned} & 19,666,12 \\ & 1 \text { (87.4\%) } \end{aligned}$ | $\begin{aligned} & \hline 671,838 \\ & (3.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,156,617 \\ & (9.6 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 11-Jul- } \\ 21 \end{array}$ | $\begin{aligned} & \hline 28,950,15 \\ & 0(45.9 \%) \end{aligned}$ | $\begin{aligned} & 9,242,451 \\ & (14.6 \%) \end{aligned}$ | $\begin{aligned} & \text { 24,898,854 } \\ & (39.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 28,898,87 \\ & 6(57.5 \%) \end{aligned}$ | $\begin{aligned} & 9,205,675 \\ & (18.3 \%) \end{aligned}$ | $\begin{aligned} & 12,111,194 \\ & (24.1 \%) \end{aligned}$ | $\begin{aligned} & 19,739,27 \\ & 9 \text { (87.8\%) } \end{aligned}$ | $\begin{aligned} & \text { 617,709 } \\ & (2.7 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,137,378 \\ & (9.5 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 18 \text {-Jul- } \\ 21 \end{array}$ | $\begin{aligned} & 29,966,24 \\ & 7(47.5 \%) \end{aligned}$ | $\begin{aligned} & 8,554,088 \\ & (13.6 \%) \end{aligned}$ | $\begin{aligned} & 24,570,647 \\ & (38.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 29,911,28 \\ & 7(59.6 \%) \end{aligned}$ | $\begin{aligned} & 8,517,418 \\ & (17.0 \%) \end{aligned}$ | $\begin{aligned} & 11,786,568 \\ & (23.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,798,53 \\ & 6(88.0 \%) \end{aligned}$ | $\begin{aligned} & 575,609 \\ & (2.6 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,120,034 } \\ & (9.4 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 25-\mathrm{Jul}- \\ 21 \end{array}$ | $\begin{aligned} & \hline 30,932,50 \\ & 4(49.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 7,821,016 \\ & (12.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 24,336,996 \\ & (38.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 30,874,69 \\ & 1 \text { (61.5\%) } \end{aligned}$ | $\begin{aligned} & \hline 7,783,137 \\ & (15.5 \%) \end{aligned}$ | $\begin{aligned} & 11,556,979 \\ & (23.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 19,843,30 \\ & 3(88.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 543,956 \\ & (2.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,106,761 \\ & (9.4 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \text { 1-Aug- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 31,852,32 \\ & 1 \text { (50.5\%) } \end{aligned}$ | $\begin{aligned} & 7,098,507 \\ & (11.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 24,139,246 \\ & (38.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 31,791,04 \\ & 8(63.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 7,058,043 \\ & (14.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 11,365,276 \\ & (22.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,883,63 \\ & 6(88.4 \%) \end{aligned}$ | $\begin{aligned} & 515,571 \\ & (2.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,094,646 } \\ & (9.3 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 8-\text { Aug- } \\ 21 \end{array}$ | $\begin{aligned} & 32,756,02 \\ & 4 \text { (51.9\%) } \end{aligned}$ | $\begin{aligned} & \text { 6,373,113 } \\ & (10.1 \%) \end{aligned}$ | $\begin{aligned} & 23,960,443 \\ & (38.0 \%) \end{aligned}$ | $\begin{aligned} & 32,691,19 \\ & 9(65.1 \%) \end{aligned}$ | $\begin{aligned} & \text { 6,320,771 } \\ & (12.6 \%) \end{aligned}$ | $\begin{aligned} & 11,201,905 \\ & (22.3 \%) \end{aligned}$ | $\begin{aligned} & 19,916,77 \\ & 8(88.5 \%) \end{aligned}$ | $\begin{aligned} & 493,433 \\ & (2.2 \%) \end{aligned}$ | $\begin{aligned} & 2,083,467 \\ & (9.3 \%) \end{aligned}$ |
| $\begin{array}{r} 15- \\ \text { Aug-21 } \end{array}$ | $\begin{aligned} & 33,727,54 \\ & 5 \text { (53.5\%) } \end{aligned}$ | $\begin{aligned} & \text { 5,611,293 } \\ & (8.9 \%) \end{aligned}$ | $\begin{aligned} & \text { 23,750,160 } \\ & (37.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 33,659,12 \\ & 0(67.0 \%) \end{aligned}$ | $\begin{aligned} & \text { 5,490,998 } \\ & (10.9 \%) \end{aligned}$ | $\begin{aligned} & 11,063,176 \\ & (22.0 \%) \end{aligned}$ | $\begin{aligned} & 19,944,74 \\ & 8(88.7 \%) \end{aligned}$ | $\begin{aligned} & 475,305 \\ & (2.1 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,073,405 } \\ & (9.2 \%) \end{aligned}$ |
| $\begin{array}{r} 22- \\ \text { Aug-21 } \end{array}$ | $\begin{aligned} & 34,687,26 \\ & 9(55.0 \%) \end{aligned}$ | $\begin{aligned} & 4,942,094 \\ & (7.8 \%) \end{aligned}$ | $\begin{aligned} & 23,459,028 \\ & (37.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 34,615,29 \\ & 2 \text { (68.9\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 4,655,978 \\ & (9.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,941,417 \\ & (21.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,969,18 \\ & 7(88.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 459,499 \\ & (2.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,064,546 \\ & (9.2 \%) \\ & \hline \end{aligned}$ |


| $\begin{array}{r} 29- \\ \text { Aug-21 } \end{array}$ | $\begin{aligned} & 35,479,76 \\ & 3(56.2 \%) \end{aligned}$ |  | $\begin{aligned} & 4,423,944 \\ & (7.0 \%) \end{aligned}$ | $\begin{aligned} & 23,184,181 \\ & (36.7 \%) \end{aligned}$ | $\begin{aligned} & 35,404,65 \\ & 8(70.5 \%) \end{aligned}$ |  | $\begin{aligned} & 3,972,304 \\ & (7.9 \%) \end{aligned}$ | $\begin{aligned} & 10,835,225 \\ & (21.6 \%) \end{aligned}$ | $\begin{aligned} & 19,992,04 \\ & 3(88.9 \%) \end{aligned}$ |  | $\begin{aligned} & 444,528 \\ & (2.0 \%) \end{aligned}$ | $\begin{aligned} & 2,056,504 \\ & (9.1 \%) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{r} \hline \text { 5-Sep- } \\ 21 \end{array}$ | $\begin{aligned} & \hline 36,118,11 \\ & 8(57.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 12,738 \\ & (0.02 \%) \end{aligned}$ | $\begin{aligned} & \hline 3,977,545 \\ & (6.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 22,991,593 \\ & (36.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 36,039,89 \\ & 5(71.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 12,713 \\ & (0.03 \%) \end{aligned}$ | $\begin{aligned} & \hline 3,428,983 \\ & (6.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 10,742,682 \\ & (21.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 20,008,54 \\ & 1 \text { (88.9\%) } \end{aligned}$ | $\begin{aligned} & \hline 7,045 \\ & (0.03 \%) \end{aligned}$ | $\begin{aligned} & \hline 434,345 \\ & (1.9 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,049,929 } \\ & (9.1 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 12-Sep- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 36,632,60 \\ & 6(58.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 14,276 \\ & (0.02 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,593,049 \\ & (5.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 22,860,063 \\ & (36.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 36,551,52 \\ & 9(72.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 14,248 \\ & (0.03 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,005,016 \\ & (6.0 \%) \end{aligned}$ | $\begin{aligned} & 10,653,480 \\ & (21.2 \%) \end{aligned}$ | $\begin{aligned} & 20,024,67 \\ & 2(89.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 7,995 \\ & (0.04 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 423,866 \\ & (1.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,043,327 \\ & (9.1 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \text { 19-Sep- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 36,984,09 \\ & 0(58.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 43,185 \\ & (0.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,326,622 \\ & (5.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 22,746,097 \\ & (36.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 36,899,86 \\ & 5(73.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 43,126 \\ & (0.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,709,140 \\ & (5.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,572,142 \\ & (21.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 20,018,49 \\ & 2(89.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 30,591 \\ & (0.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 414,203 \\ & (1.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,036,574 \\ & (9.1 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 26-Sep- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 36,865,26 \\ & 6(58.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 432,235 \\ & (0.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,178,256 \\ & (5.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 22,624,237 \\ & (35.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 36,777,08 \\ & 2(73.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 432,070 \\ & (0.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,518,065 \\ & (5.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,497,056 \\ & (20.9 \%) \end{aligned}$ | $\begin{aligned} & 19,709,29 \\ & 5(87.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 357,852 \\ & (1.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 402,771 \\ & (1.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,029,942 \\ & (9.0 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 3-Oct- } \\ \hline 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 36,136,12 \\ & 1 \text { (57.3\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,360,104 \\ & (2.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,162,512 \\ & (5.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 22,441,257 \\ & (35.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 36,043,13 \\ & 5(71.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,359,758 \\ & (2.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,387,178 \\ & (4.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,434,202 \\ & (20.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,940,07 \\ & 3 \text { (84.2\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,145,668 \\ & (5.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 389,978 \\ & (1.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,024,141 \\ & (9.0 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 10-O c t- \\ 21 \end{array}$ | $\begin{aligned} & 35,097,67 \\ & 9(55.6 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,575,568 } \\ & (4.1 \%) \end{aligned}$ | $\begin{aligned} & 3,202,469 \\ & (5.1 \%) \end{aligned}$ | $\begin{aligned} & 22,224,278 \\ & (35.2 \%) \end{aligned}$ | $\begin{aligned} & 34,992,71 \\ & 5(69.7 \%) \end{aligned}$ | $\begin{aligned} & 2,574,955 \\ & (5.1 \%) \end{aligned}$ | $\begin{aligned} & 2,287,832 \\ & (4.6 \%) \end{aligned}$ | $\begin{aligned} & 10,368,771 \\ & (20.6 \%) \end{aligned}$ | $\begin{aligned} & 17,922,16 \\ & 4 \text { (79.7\%) } \end{aligned}$ | $\begin{aligned} & 2,179,876 \\ & (9.7 \%) \end{aligned}$ | $\begin{aligned} & 380,041 \\ & (1.7 \%) \end{aligned}$ | $\begin{aligned} & 2,017,779 \\ & (9.0 \%) \end{aligned}$ |
| $\begin{array}{r} 17-\text { Oct- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 33,924,69 \\ & 1 \text { (53.8\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,913,065 \\ & (6.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,278,275 \\ & (5.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 21,983,963 \\ & (34.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 33,800,59 \\ & 6(67.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,912,076 \\ & (7.8 \%) \end{aligned}$ | $\begin{aligned} & 2,206,454 \\ & (4.4 \%) \end{aligned}$ | $\begin{aligned} & 10,305,147 \\ & (20.5 \%) \end{aligned}$ | $\begin{aligned} & 16,792,82 \\ & 0(74.6 \%) \end{aligned}$ | $\begin{aligned} & 3,323,957 \\ & (14.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 371,757 \\ & (1.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,011,326 } \\ & (8.9 \%) \end{aligned}$ |
| $\begin{array}{r} 24-O c t- \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 32,526,36 \\ & 3 \text { (51.5\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 5,461,045 \\ & (8.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,382,332 \\ & (5.4 \%) \end{aligned}$ | $\begin{aligned} & 21,730,254 \\ & (34.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 32,383,55 \\ & 1 \text { (64.5\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 5,459,513 \\ & (10.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,141,948 } \\ & (4.3 \%) \end{aligned}$ | $\begin{aligned} & 10,239,261 \\ & (20.4 \%) \end{aligned}$ | $\begin{aligned} & 15,452,29 \\ & 7(68.7 \%) \end{aligned}$ | $\begin{aligned} & 4,679,006 \\ & (20.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 364,458 \\ & (1.6 \%) \end{aligned}$ | $\begin{aligned} & 2,004,099 \\ & (8.9 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \text { 31-Oct- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 31,082,16 \\ & 0(49.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 7,035,752 \\ & (11.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,464,949 \\ & (5.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 21,517,133 \\ & (34.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 30,921,58 \\ & 7(61.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 7,033,556 \\ & (14.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,086,992 } \\ & (4.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,182,138 \\ & (20.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 14,066,96 \\ & 2(62.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 6,077,670 } \\ & \text { (27.0\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 358,133 \\ & (1.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,997,095 \\ & (8.9 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 7-\text { Nov- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 29,391,86 \\ & 0(46.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 8,847,251 \\ & (14.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,601,201 \\ & (5.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 21,259,682 \\ & (33.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 29,217,61 \\ & 3(58.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 8,844,063 \\ & (17.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,034,479 \\ & (4.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,128,118 \\ & (20.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 12,477,51 \\ & 5 \text { (55.5\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 7,680,221 \\ & (34.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 352,272 \\ & (1.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,989,852 \\ & (8.8 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 14- \\ \text { Nov-21 } \\ \hline \end{array}$ | $\begin{aligned} & \hline 27,527,38 \\ & 2(43.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,841,33 \\ & 7(17.2 \%) \end{aligned}$ | $\begin{aligned} & 3,684,054 \\ & (5.8 \%) \end{aligned}$ | $\begin{aligned} & \text { 21,047,221 } \\ & (33.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 27,339,40 \\ & 3(54.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,836,40 \\ & 3(21.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,977,027 \\ & (3.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 10,071,440 \\ & (20.1 \%) \end{aligned}$ | $\begin{aligned} & 10,769,33 \\ & 3(47.9 \%) \end{aligned}$ | $\begin{aligned} & 9,403,246 \\ & (41.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 345,025 \\ & (1.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,982,256 \\ & (8.8 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 21- \\ \text { Nov-21 } \end{array}$ | $\begin{aligned} & 25,605,74 \\ & 9(40.6 \%) \end{aligned}$ | $\begin{aligned} & 12,884,76 \\ & 4(20.4 \%) \end{aligned}$ | $\begin{aligned} & 3,723,869 \\ & (5.9 \%) \end{aligned}$ | $\begin{aligned} & 20,885,612 \\ & (33.1 \%) \end{aligned}$ | $\begin{aligned} & 25,402,40 \\ & 4(50.6 \%) \end{aligned}$ | $\begin{aligned} & 12,877,48 \\ & 8(25.6 \%) \end{aligned}$ | $\begin{aligned} & 1,927,847 \\ & (3.8 \%) \end{aligned}$ | $\begin{aligned} & 10,016,534 \\ & (19.9 \%) \end{aligned}$ | $\begin{aligned} & 9,072,178 \\ & (40.3 \%) \end{aligned}$ | $\begin{aligned} & 11,116,35 \\ & 2(49.4 \%) \end{aligned}$ | $\begin{aligned} & 337,097 \\ & (1.5 \%) \end{aligned}$ | $\begin{aligned} & 1,974,233 \\ & (8.8 \%) \end{aligned}$ |
| $\begin{array}{r} 28- \\ \text { Nov-21 } \end{array}$ | $\begin{aligned} & 23,621,27 \\ & 5(37.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 15,029,38 \\ & 4(23.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,695,318 \\ & (5.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 20,754,017 \\ & (32.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 23,366,74 \\ & 8(46.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 15,019,48 \\ & 8(29.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,876,521 \\ & (3.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,961,516 \\ & (19.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 7,387,515 \\ & (32.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 12,824,31 \\ & 1(57.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 321,984 \\ & (1.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,966,050 \\ & (8.7 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 5-\text { Dec- } \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & \hline 21,594,19 \\ & 1(34.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 17,253,86 \\ & 9(27.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,632,098 \\ & (5.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 20,619,836 \\ & (32.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 21,261,36 \\ & 3(42.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 17,240,89 \\ & 2(34.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,824,939 \\ & (3.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 9,897,079 \\ & (19.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 5,774,535 \\ & (25.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 14,461,14 \\ & 7(64.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 307,839 \\ & (1.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,956,339 \\ & (8.7 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 12- \\ \text { Dec-21 } \end{array}$ | $\begin{aligned} & 19,265,73 \\ & 1(30.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,773,94 \\ & 1(31.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,566,118 \\ & (5.7 \%) \end{aligned}$ | $\begin{aligned} & 20,494,204 \\ & (32.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,864,31 \\ & 5(37.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 19,757,26 \\ & 0(39.3 \%) \end{aligned}$ | $\begin{aligned} & 1,774,889 \\ & (3.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,827,809 \\ & (19.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 4,272,802 \\ & (19.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 15,982,96 \\ & 0(71.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 298,816 \\ & (1.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,945,282 \\ & (8.6 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 19- \\ \text { Dec-21 } \\ \hline \end{array}$ | $\begin{aligned} & 14,761,02 \\ & 2(23.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 24,518,70 \\ & 4(38.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,513,151 \\ & (5.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 20,307,117 \\ & (32.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 14,283,11 \\ & 1(28.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 24,492,87 \\ & 0(48.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,735,265 \\ & (3.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,713,027 \\ & (19.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,894,226 \\ & (12.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 17,384,40 \\ & 1(77.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 293,512 \\ & (1.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,927,721 \\ & (8.6 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 26- \\ \text { Dec-21 } \end{array}$ | $\begin{aligned} & \hline 12,144,70 \\ & 9(19.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 27,318,27 \\ & 7(43.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,467,929 \\ & (5.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 20,169,079 \\ & (32.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 11,601,91 \\ & 0(23.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 27,283,93 \\ & 2(54.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,712,801 \\ & (3.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 9,625,630 \\ & (19.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,301,915 \\ & (10.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 17,991,95 \\ & 7(80.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 290,631 \\ & (1.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,915,357 \\ & (8.5 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline \text { 2-Jan- } \\ \hline 22 \end{array}$ | $\begin{aligned} & \hline 10,944,96 \\ & 9(17.3 \%) \end{aligned}$ | $\begin{aligned} & 28,675,14 \\ & 0(45.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 3,432,361 \\ & (5.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 20,047,524 \\ & (31.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 10,325,49 \\ & 9(20.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 28,634,73 \\ & 4(57.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,706,797 \\ & (3.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,557,243 \\ & (19.0 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,051,827 \\ & (9.1 \%) \end{aligned}$ | $\begin{aligned} & \hline 18,250,87 \\ & 9(81.1 \%) \end{aligned}$ | $\begin{aligned} & \hline 290,032 \\ & (1.3 \%) \end{aligned}$ | $\begin{aligned} & 1,907,122 \\ & (8.5 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 9-J a n- \\ 22 \\ \hline \end{array}$ | $\begin{aligned} & \hline 9,977,945 \\ & (15.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 29,846,06 \\ & 7(47.3 \%) \end{aligned}$ | $\begin{aligned} & \text { 3,371,664 } \\ & \text { (5.3\%) } \end{aligned}$ | $\begin{aligned} & 19,904,318 \\ & (31.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,255,079 \\ & (18.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 29,798,03 \\ & 2(59.3 \%) \end{aligned}$ | $\begin{aligned} & 1,691,094 \\ & (3.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,480,068 \\ & (18.9 \%) \end{aligned}$ | $\begin{aligned} & \hline 1,844,119 \\ & (8.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 18,468,98 \\ & 6(82.1 \%) \end{aligned}$ | $\begin{aligned} & \hline 288,108 \\ & (1.3 \%) \end{aligned}$ | $\begin{aligned} & 1,898,647 \\ & (8.4 \%) \end{aligned}$ |


| $\begin{array}{r} \text { 16-Jan- } \\ 22 \\ \hline \end{array}$ | $\begin{aligned} & 9,546,563 \\ & (15.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 30,459,19 \\ & 9(48.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,307,547 \\ & (5.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,786,685 \\ & (31.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 8,725,007 \\ & (17.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 30,401,73 \\ & 9(60.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,684,402 \\ & (3.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,413,125 \\ & (18.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,739,053 \\ & (7.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,582,41 \\ & 9(82.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 286,899 \\ & (1.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,891,489 \\ & (8.4 \%) \\ & \hline \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{r} \hline 23-\mathrm{Jan}- \\ 22 \end{array}$ | $\begin{aligned} & \hline 9,390,117 \\ & (14.9 \%) \end{aligned}$ | $\begin{aligned} & \hline 30,805,72 \\ & 9(48.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 3,217,300 \\ & (5.1 \%) \end{aligned}$ | $\begin{aligned} & 19,686,848 \\ & (31.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 8,454,911 \\ & (16.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 30,734,48 \\ & 5(61.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,677,190 \\ & (3.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 9,357,687 \\ & (18.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 1,685,346 \\ & (7.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 18,642,85 \\ & 6 \text { (82.9\%) } \end{aligned}$ | $\begin{aligned} & \text { 285,949 } \\ & (1.3 \%) \end{aligned}$ | $\begin{aligned} & 1,885,709 \\ & (8.4 \%) \end{aligned}$ |
| $\begin{array}{r} \hline \text { 30-Jan- } \\ 22 \end{array}$ | $\begin{aligned} & 9,296,619 \\ & (14.7 \%) \end{aligned}$ | $\begin{aligned} & 31,087,43 \\ & 6(49.3 \%) \end{aligned}$ | $\begin{aligned} & 3,117,686 \\ & (4.9 \%) \end{aligned}$ | $\begin{aligned} & 19,598,253 \\ & (31.1 \%) \end{aligned}$ | $\begin{aligned} & 8,243,011 \\ & (16.4 \%) \end{aligned}$ | $\begin{aligned} & 31,004,98 \\ & 3 \text { (61.7\%) } \end{aligned}$ | $\begin{aligned} & 1,668,538 \\ & (3.3 \%) \end{aligned}$ | $\begin{aligned} & 9,307,741 \\ & (18.5 \%) \end{aligned}$ | $\begin{aligned} & 1,639,123 \\ & (7.3 \%) \end{aligned}$ | $\begin{aligned} & 18,695,45 \\ & 7 \text { (83.1\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 284,923 \\ & (1.3 \%) \end{aligned}$ | $\begin{aligned} & 1,880,357 \\ & (8.4 \%) \end{aligned}$ |
| $\begin{array}{r} 6 \text {-Feb- } \\ 22 \\ \hline \end{array}$ | $\begin{aligned} & 9,262,440 \\ & (14.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 31,274,87 \\ & 5(49.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 3,032,392 \\ & (4.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 19,530,287 \\ & (31.0 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 8,110,384 \\ & (16.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 31,184,76 \\ & 0(62.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,654,914 \\ & (3.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,274,215 \\ & (18.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,611,069 \\ & (7.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,728,23 \\ & 1(83.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 283,227 \\ & (1.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,877,333 \\ & (8.3 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} \hline 13 \text {-Feb- } \\ 22 \end{array}$ | $\begin{aligned} & 9,241,569 \\ & (14.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 31,442,36 \\ & 7(49.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,950,014 \\ & (4.7 \%) \end{aligned}$ | $\begin{aligned} & 19,466,044 \\ & (30.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 7,995,490 \\ & (15.9 \%) \end{aligned}$ | $\begin{aligned} & 31,345,39 \\ & 4 \text { (62.4\%) } \end{aligned}$ | $\begin{aligned} & \hline 1,634,487 \\ & (3.3 \%) \end{aligned}$ | $\begin{aligned} & 9,248,902 \\ & (18.4 \%) \end{aligned}$ | $\begin{aligned} & 1,589,530 \\ & (7.1 \%) \end{aligned}$ | $\begin{aligned} & 18,754,37 \\ & 8 \text { (83.4\%) } \end{aligned}$ | $\begin{aligned} & 280,876 \\ & (1.2 \%) \end{aligned}$ | $\begin{aligned} & 1,875,076 \\ & (8.3 \%) \end{aligned}$ |
| $\begin{array}{r} 20-\text { Feb- } \\ 22 \end{array}$ | $\begin{aligned} & 9,209,801 \\ & (14.6 \%) \end{aligned}$ | $\begin{aligned} & 31,581,86 \\ & 4(50.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,892,982 \\ & (4.6 \%) \end{aligned}$ | $\begin{aligned} & 19,415,347 \\ & (30.8 \%) \end{aligned}$ | $\begin{aligned} & 7,902,747 \\ & (15.7 \%) \end{aligned}$ | $\begin{aligned} & 31,476,58 \\ & 4(62.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,615,652 \\ & (3.2 \%) \end{aligned}$ | $\begin{aligned} & 9,229,290 \\ & (18.4 \%) \end{aligned}$ | $\begin{aligned} & 1,572,678 \\ & (7.0 \%) \end{aligned}$ | $\begin{aligned} & 18,775,25 \\ & 9(83.4 \%) \end{aligned}$ | $\begin{aligned} & 278,643 \\ & (1.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,873,280 \\ & (8.3 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 27-\text { Feb- } \\ 22 \end{array}$ | $\begin{aligned} & 9,175,261 \\ & (14.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 31,712,91 \\ & 2(50.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,842,449 \\ & (4.5 \%) \end{aligned}$ | $\begin{aligned} & 19,369,372 \\ & (30.7 \%) \end{aligned}$ | $\begin{aligned} & \hline 7,824,511 \\ & (15.6 \%) \end{aligned}$ | $\begin{aligned} & \hline 31,592,29 \\ & 9(62.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,598,003 \\ & (3.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,209,460 \\ & (18.3 \%) \end{aligned}$ | $\begin{aligned} & 1,556,155 \\ & (6.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 18,795,47 \\ & 5(83.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 276,809 \\ & (1.2 \%) \end{aligned}$ | $\begin{aligned} & 1,871,421 \\ & (8.3 \%) \end{aligned}$ |
| $\begin{array}{r} \hline 6-\mathrm{Mar}- \\ 22 \end{array}$ | $\begin{aligned} & \text { 9,156,404 } \\ & (14.5 \%) \end{aligned}$ | $\begin{aligned} & \hline 31,823,14 \\ & 2(50.4 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,787,551 } \\ & (4.4 \%) \end{aligned}$ | $\begin{aligned} & 19,332,897 \\ & (30.6 \%) \end{aligned}$ | $\begin{aligned} & 7,767,075 \\ & (15.5 \%) \end{aligned}$ | $\begin{aligned} & 31,683,45 \\ & 8 \text { (63.1\%) } \end{aligned}$ | $\begin{aligned} & 1,580,454 \\ & (3.1 \%) \end{aligned}$ | $\begin{aligned} & \text { 9,193,286 } \\ & \text { (18.3\%) } \end{aligned}$ | $\begin{aligned} & 1,543,289 \\ & (6.9 \%) \end{aligned}$ | $\begin{aligned} & 18,811,62 \\ & 0(83.6 \%) \end{aligned}$ | $\begin{aligned} & 274,926 \\ & (1.2 \%) \end{aligned}$ | $\begin{aligned} & 1,870,025 \\ & (8.3 \%) \end{aligned}$ |
| $\begin{array}{r} 13- \\ \text { Mar-22 } \end{array}$ | $\begin{aligned} & 9,141,789 \\ & (14.5 \%) \end{aligned}$ | $\begin{aligned} & 31,926,56 \\ & 4(50.6 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,731,039 } \\ & (4.3 \%) \end{aligned}$ | $\begin{aligned} & 19,300,602 \\ & (30.6 \%) \end{aligned}$ | $\begin{aligned} & 7,717,387 \\ & (15.4 \%) \end{aligned}$ | $\begin{aligned} & 31,766,82 \\ & 2 \text { (63.2\%) } \end{aligned}$ | $\begin{aligned} & 1,561,398 \\ & (3.1 \%) \end{aligned}$ | $\begin{aligned} & 9,178,666 \\ & (18.3 \%) \end{aligned}$ | $\begin{aligned} & 1,532,248 \\ & (6.8 \%) \end{aligned}$ | $\begin{aligned} & 18,825,91 \\ & 8(83.7 \%) \end{aligned}$ | $\begin{aligned} & 272,981 \\ & (1.2 \%) \end{aligned}$ | $\begin{aligned} & 1,868,713 \\ & (8.3 \%) \end{aligned}$ |
| $\begin{array}{r} 20- \\ \text { Mar-22 } \end{array}$ | $\begin{aligned} & 9,131,054 \\ & (14.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 32,024,76 \\ & 0(50.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,672,836 } \\ & (4.2 \%) \end{aligned}$ | $\begin{aligned} & 19,271,344 \\ & (30.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 7,672,917 \\ & (15.3 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 31,844,16 \\ & 5(63.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,541,996 \\ & (3.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 9,165,195 \\ & (18.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,522,702 \\ & (6.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 18,838,82 \\ & 4 \text { (83.7\%) } \end{aligned}$ | $\begin{aligned} & 270,793 \\ & (1.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,867,541 \\ & (8.3 \%) \\ & \hline \end{aligned}$ |
| $\begin{array}{r} 27- \\ \text { Mar-22 } \end{array}$ | $\begin{aligned} & 9,117,101 \\ & (14.4 \%) \end{aligned}$ | $\begin{aligned} & \hline 32,115,50 \\ & 0(50.9 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,622,602 \\ & (4.2 \%) \end{aligned}$ | $\begin{aligned} & 19,244,791 \\ & (30.5 \%) \end{aligned}$ | $\begin{aligned} & 7,629,664 \\ & (15.2 \%) \end{aligned}$ | $\begin{aligned} & \hline 31,915,63 \\ & 1(63.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,525,760 \\ & (3.0 \%) \end{aligned}$ | $\begin{aligned} & 9,153,218 \\ & (18.2 \%) \end{aligned}$ | $\begin{aligned} & 1,511,149 \\ & (6.7 \%) \end{aligned}$ | $\begin{aligned} & 18,853,41 \\ & 2 \text { (83.8\%) } \end{aligned}$ | $\begin{aligned} & \hline 269,098 \\ & (1.2 \%) \end{aligned}$ | $\begin{aligned} & 1,866,201 \\ & (8.3 \%) \end{aligned}$ |

Table S3a: NIMS database with vaccination status of all age groups, over 18 and 50 years of age. The weekly number of population in each vaccination group and percentage represented for each week based on the age. The total NIMS cohort of all age groups ( $\mathrm{n}=63,099,994$ ); over 18 years of age ( $n=50,224,273$ ) and over 50 years of age ( $n=22,499,860$ ) as of March 27, 2022.

## Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IMD score of the over 18 years of age

| 18+ years of age <br> Ethnicity status | Denominator | Vaccination status |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1 dose only | 2 doses only | Third dose | Unvaccinated |
| White - British | 30,755,212 | 654,705 (2.1\%) | 3,847,492 (12.5\%) | 23,506,318 (76.4\%) | 2,746,697 (8.9\%) |
| White - Irish | 305,107 | 6,836 (2.2\%) | 32,959 (10.8\%) | 212,706 (69.7\%) | 52,606 (17.2\%) |
| White - Other | 4,364,388 | 117,373 (2.7\%) | 758,638 (17.4\%) | 2,011,587 (46.1\%) | 1,476,790 (33.8\%) |
| Mixed - White and Black Caribbean | 163,185 | 7,854 (4.8\%) | 34,452 (21.1\%) | 58,500 (35.8\%) | 62,379 (38.2\%) |
| Mixed - White and Black African | 125,836 | 6,193 (4.9\%) | 32,845 (26.1\%) | 50,148 (39.9\%) | 36,650 (29.1\%) |
| Mixed - White and Asian | 141,390 | 5,274 (3.7\%) | 26,766 (18.9\%) | 78,564 (55.6\%) | 30,786 (21.8\%) |
| Mixed - Any other mixed background | 307,921 | 12,813 (4.2\%) | 60,728 (19.7\%) | 148,242 (48.1\%) | 86,138 (28.0\%) |
| Asian or Asian British - Indian | 1,459,219 | 46,807 (3.2\%) | 268,328 (18.4\%) | 896,598 (61.4\%) | 247,486 (17.0\%) |
| Asian or Asian British - Pakistani | 1,047,413 | 60,910 (5.8\%) | 387,666 (37.0\%) | 366,405 (35.0\%) | 232,432 (22.2\%) |
| Asian or Asian British - Bangladeshi | 379,935 | 18,740 (4.9\%) | 117,464 (30.9\%) | 176,429 (46.4\%) | 67,302 (17.7\%) |
| Asian or Asian British - Any other Asian background | 885,577 | 36,255 (4.1\%) | 192,281 (21.7\%) | 483,804 (54.6\%) | 173,237 (19.6\%) |
| Black or Black British - Caribbean | 413,011 | 16,529 (4.0\%) | 79,798 (19.3\%) | 145,374 (35.2\%) | 171,310 (41.5\%) |
| Black or Black British - African | 911,671 | 50,450 (5.5\%) | 264,944 (29.1\%) | 317,774 (34.9\%) | 278,503 (30.5\%) |
| Black or Black British - Any other Black background | 346,270 | 18,713 (5.4\%) | 88,468 (25.5\%) | 108,548 (31.3\%) | 130,541 (37.7\%) |
| Chinese | 451,559 | 24,059 (5.3\%) | 52,763 (11.7\%) | 203,476 (45.1\%) | 171,261 (37.9\%) |
| Other ethnic groups - Any other ethnic group | 1,122,853 | 46,019 (4.1\%) | 238,690 (21.3\%) | 475,598 (42.4\%) | 362,546 (32.3\%) |
| Not Stated/Unknown | 6,461,320 | 323,991 (5.0\%) | 949,393 (14.7\%) | 2,956,131 (45.8\%) | 2,231,805 (34.5\%) |
| Non-white ethnic groups (all) | 12,425,335 | 350,616 (4.5\%) | 1,845,193 (23.8\%) | 3,509,460 (45.2\%) | 2,050,571 (26.4\%) |
| 18+ years of Age |  | Vaccination status |  |  |  |
| IMD decile |  | 1 dose only | 2 doses only | Third dose | Unvaccinated |
| 1 (most deprived) |  | 231,099 (5.6\%) | 1,036,060 (25.2\%) | 2,266,843 (55.2\%) | 13.9\% |
| 2 |  | 206,422 (4.8\%) | 1,000,801 (23.2\%) | 2,575,207 (59.7\%) | 12.3\% |
| 3 |  | 192,948 (4.3\%) | 954,499 (21.1\%) | 2,853,084 (63.0\%) | 11.6\% |


| 4 | 172,467 (3.7\%) | 853,092 (18.5\%) | 3,117,666 (67.7\%) | 10.0\% |
| :---: | :---: | :---: | :---: | :---: |
| 5 | 144,138 (3.2\%) | 750,866 (16.4\%) | 3,289,305 (72.0\%) | 8.4\% |
| 6 | 130,418 (2.8\%) | 688,136 (14.9\%) | 3,491,214 (75.4\%) | 6.9\% |
| 7 | 110,690 (2.5\%) | 610,577 (13.6\%) | 3,539,976 (78.6\%) | 5.3\% |
| 8 | 103,928 (2.3\%) | 582,920 (13.0\%) | 3,637,946 (81.1\%) | 3.6\% |
| 9 | 86,911 (2.0\%) | 522,274 (11.9\%) | 3,672,750 (83.4\%) | 2.8\% |
| 10 (least deprived) | 74,766 (1.7\%) | 440,433 (10.2\%) | 3,744,140 (86.7\%) | 1.4\% |

Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IMD score of the over 18 years of age NIMS population as of May 1, 2022.

Table S4: Population of United Kingdom based on mid 2020 census estimate

|  | United Kingdom | England and <br> Wales | England |
| :--- | :--- | :--- | :--- |
| Total <br> population | $67,081,234$ |  | 5 |
| Age group |  | $59,719,724$ | $56,550,138$ |
| $\mathbf{0 - 1 9}$ yrs | $15,658,537(23.3 \%)$ | $14,032,132(23.5 \%)$ | $13,330,355(23.6 \%)$ |
| $\mathbf{2 0 - 2 9}$ yrs | $8,609,788(12.8 \%)$ | $7,658,686(12.8 \%)$ | $7,244,015(12.8 \%)$ |
| $\mathbf{3 0 - 4 9}$ yrs | $17,321,585(25.8 \%)$ | $15,425,743(25.8 \%)$ | $14,677,803(26.0 \%)$ |
| $\mathbf{5 0 - 6 9}$ yrs | $16,338,067(24.4 \%)$ | $14,434,809(24.2 \%)$ | $13,618,246(24.1 \%)$ |
| $\mathbf{\geq 5 0}$ yrs | $25,491,324(38.0 \%)$ | $22,603,163(37.8 \%)$ | $21,297,965(37.7 \%)$ |
| $\mathbf{\geq 7 0}$ yrs | $9,153,257(13.6 \%)$ | $8,168,354(13.7 \%)$ | $7,679,719(13.6 \%)$ |
| $\geq \mathbf{7 5}$ yrs | $5,789,351(8.6 \%)$ | $5,172,340(8.7 \%)$ | $4,865,591(8.6 \%)$ |
| $\geq \mathbf{8 0}$ yrs | $3,385,592(5.0 \%)$ | $3,031,325(5.1 \%)$ | $2,855,599(5.0 \%)$ |

Table S4: Population of United Kingdom based on mid 2020 census estimate. Age group distribution of population in UK, England; England and Wales.

Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths

| Study period | Age (yrs) | Outcome | Total ( $\mathrm{n}=\%$ of all ages) | Unvaccinated ( $\mathrm{n}=\%$ of age group) | Vaccinated ( $\mathrm{n}=\%$ of age group) |  |  | Vaccination status unknown ( $\mathrm{n}=\%$ of age group) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | All Vaccinated | 1 dose* | Two doses ${ }^{\ddagger}$ |  |
| $\begin{aligned} & \text { Feb 1- June 20, } \\ & 2021 \end{aligned}$ | All ages | Cases | 123,620 (100\%) | 71,932 (58.2\%) | 37,329 (30.2\%) | 26,495 (21.4\%) | 10,834 (8.8\%) | 14,359 (11.6\%) |
|  |  | Hospitalizations | 1,904 (100\%) | 1,182 (62.1\%) | 688 (36.1\%) | 375 (19.7\%) | 313 (16.4\%) | 34 (1.8\%) |
|  |  | Deaths | 257 (100\%) | 92 (35.8\%) | 163 (63.4\%) | 45 (17.5\%) | 118 (45.9\%) | 2 (0.8\%) |
|  | <50 yrs | Cases | 111,008 (89.8\%) | 70,664 (63.7\%) | 27,444 (24.7\%) | 21,844 (19.7\%) | 5,600 (5.0\%) | 12,900 (11.6\%) |
|  |  | Hospitalizations | 1,283 (67.4\%) | 987 (76.9\%) | 272 (21.2\%) | 224 (17.5\%) | 48 (3.7\%) | 24 (1.9\%) |
|  |  | Deaths | 26 (10.1\%) | 21 (80.8\%) | 5 (19.2\%) | 3 (11.5\%) | 2 (7.7\%) | 0 (0.0\%) |
|  | $\geq 50 \mathrm{yrs}$ | Cases | 12,404 (10.0\%) | 1,267 (10.2\%) | 9,885 (79.7\%) | 4,651 (37.5\%) | 5,234 (42.2\%) | 1,252 (10.1\%) |
|  |  | Hospitalizations | 615 (32.3\%) | 195 (31.7\%) | 416 (67.6\%) | 151 (24.6\%) | 265 (43.1\%) | 4 (0.7\%) |
|  |  | Deaths | 231 (89.9\%) | 71 (30.7\%) | 158 (68.4\%) | 42 (18.2\%) | 116 (50.2\%) | 2 (0.9\%) |
| June 21-July 18, 2021 | All ages | Cases | 105,598 (100\%) | 49,470 (46.8\%) | 45,535 (43.1\%) | 27,596 (26.1\%) | 17,939 (17.0\%) | 10,593 (10.0\%) |
|  |  | Hospitalizations | 1,788 (100\%) | 970 (54.3\%) | 788 (44.1\%) | 258 (14.4\%) | 530 (29.6\%) | 30 (1.7\%) |
|  |  | Deaths | 203 (100\%) | 73 (36.0\%) | 126 (62.1\%) | 20 (9.9\%) | 106 (52.2\%) | 4 (2.0\%) |
|  | <50 yrs | Cases | 94,541 (89.5\%) | 48,399 (51.2\%) | 36,546 (38.7\%) | 26,800 (28.3\%) | 9,746 (10.3\%) | 9,586 (10.1\%) |
|  |  | Hospitalizations | 1,044 (58.4\%) | 725 (69.4\%) | 292 (28.0\%) | 200 (19.2\%) | 92 (8.8\%) | 27 (2.6\%) |
|  |  | Deaths | 19 (9.4\%) | 13 (68.4\%) | 5 (26.3\%) | 3 (15.8\%) | 2 (10.5\%) | 1 (5.3\%) |
|  | $\geq 50 \mathrm{yrs}$ | Cases | 10,975 (10.4\%) | 1,070 (9.7\%) | 8,988 (81.9\%) | 795 (7.2\%) | 8,193 (74.7\%) | 917 (8.4\%) |
|  |  | Hospitalizations | 750 (41.9\%) | 245 (32.7\%) | 496 (66.1\%) | 58 (7.7\%) | 438 (58.4\%) | 9 (1.2\%) |
|  |  | Deaths | 184 (90.6\%) | 60 (32.6\%) | 121 (65.8\%) | 17 (9.2\%) | 104 (56.5\%) | 3 (1.6\%) |
| $\begin{aligned} & \text { July 19-Aug 1, } \\ & 2021 \end{aligned}$ | All ages | Cases | 70,792 (100\%) | 29,652 (41.9\%) | 34,251 (48.4\%) | 16,016 (22.6\%) | 18,235 (25.8\%) | 6,889 (9.7\%) |
|  |  | Hospitalizations | 1,467 (100\%) | 808 (55.1\%) | 641 (43.7\%) | 129 (8.8\%) | 512 (34.9\%) | 18 (1.2\%) |
|  |  | Deaths | 282 (100\%) | 88 (31.2\%) | 192 (68.1\%) | 14 (5.0\%) | 178 (63.1\%) | 2 (0.7\%) |
|  | <50 yrs | Cases | 60,200 (85.0\%) | 28,549 (47.4\%) | 25,817 (42.9\%) | 15,627 (26.0\%) | 10,190 (16.9\%) | 5,834 (9.7\%) |


|  |  | Hospitalizations | 757 (51.6\%) | 578 (76.4\%) | 169 (22.3\%) | 85 (11.2\%) | 84 (11.1\%) | 10 (1.3\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Deaths | 26 (9.2\%) | 14 (53.8\%) | 11 (42.3\%) | 2 (7.7\%) | 9 (34.6\%) | 1 (3.8\%) |
|  | $\geq 50 \mathrm{yrs}$ | Cases | 10,357 (14.6\%) | 1,103 (10.6\%) | 8,434 (81.4\%) | 389 (3.8\%) | 8,045 (77.7\%) | 820 (7.9\%) |
|  |  | Hospitalizations | 709 (48.3\%) | 230 (32.4\%) | 472 (66.6\%) | 44 (6.2\%) | 428 (60.4\%) | 7 (1.0\%) |
|  |  | Deaths | 255 (90.4\%) | 74 (29.0\%) | 181 (71.0\%) | 12 (4.7\%) | 169 (66.3\%) | - (0.0\%) |
| $\begin{aligned} & \text { Aug 2-Aug 15, } \\ & 2021 \end{aligned}$ | All ages | Cases | 86,725 (100\%) | 32,079 (37.0\%) | 46,214 (53.3\%) | 19,850 (22.9\%) | 26,364 (30.4\%) | 8,432 (9.7\%) |
|  |  | Hospitalizations | 2,126 (100\%) | 1,073 (50.5\%) | 1,036 (48.7\%) | 187 (8.8\%) | 849 (39.9\%) | 17 (0.8\%) |
|  |  | Deaths | 447 (100\%) | 137 (30.6\%) | 302 (67.6\%) | 25 (5.6\%) | 277 (62.0\%) | 8 (1.8\%) |
|  | <50 yrs | Cases | 72,085 (83.1\%) | 30,628 (42.5\%) | 34,390 (47.7\%) | 19,382 (26.9\%) | 15,008 (20.8\%) | 7,067 (9.8\%) |
|  |  | Hospitalizations | 1,028 (48.4\%) | 754 (73.3\%) | 264 (25.7\%) | 122 (11.9\%) | 142 (13.8\%) | 10 (1.0\%) |
|  |  | Deaths | 42 (9.4\%) | 24 (57.1\%) | 17 (40.5\%) | 3 (7.1\%) | 14 (33.3\%) | 1 (2.4\%) |
|  | $\geq 50 \mathrm{yrs}$ | Cases | 14,528 (16.8\%) | 1,451 (10.0\%) | 11,824 (81.4\%) | 468 (3.2\%) | 11,356 (78.2\%) | 1,253 (8.6\%) |
|  |  | Hospitalizations | 1,099 (51.7\%) | 319 (29.0\%) | 772 (70.2\%) | 65 (5.9\%) | 707 (64.3\%) | 8 (0.7\%) |
|  |  | Deaths | 406 (90.8\%) | 113 (27.8\%) | 285 (70.2\%) | 22 (5.4\%) | 263 (64.8\%) | 8 (2.0\%) |
| $\begin{aligned} & \text { Aug 16-Aug 29, } \\ & 2021 \end{aligned}$ | All ages | Cases | 105,793 (100\%) | 36,583 (34.6\%) | 59,364 (56.1\%) | 18,913 (17.9\%) | 40,451 (38.2\%) | 9,846 (9.3\%) |
|  |  | Hospitalizations | 2,187 (100\%) | 1,031 (47.1\%) | 1,115 (51.0\%) | 147 (6.7\%) | 968 (44.3\%) | 41 (1.9\%) |
|  |  | Deaths | 609 (100\%) | 146 (24.0\%) | 450 (73.9\%) | 38 (6.2\%) | 412 (67.7\%) | 13 (2.1\%) |
|  | <50 yrs | Cases | 82,855 (78.3\%) | 34,749 (41.9\%) | 40,176 (48.5\%) | 18,317 (22.1\%) | 21,859 (26.4\%) | 7,930 (9.6\%) |
|  |  | Hospitalizations | 986 (45.1\%) | 698 (70.8\%) | 248 (25.2\%) | 93 (9.4\%) | 155 (15.7\%) | 40 (4.1\%) |
|  |  | Deaths | 41 (6.7\%) | 27 (65.9\%) | 13 (31.7\%) | 3 (7.3\%) | 10 (24.4\%) | 1 (2.4\%) |
|  | $\geq 50 \mathrm{yrs}$ | Cases | 22,843 (21.6\%) | 1,833 (8.0\%) | 19,188 (84.0\%) | 596 (2.6\%) | 18,592 (81.4\%) | 1,822 (8.0\%) |
|  |  | Hospitalizations | 1,201 (54.9\%) | 333 (27.7\%) | 867 (72.2\%) | 54 (4.5\%) | 813 (67.7\%) | 1 (0.1\%) |
|  |  | Deaths | 568 (93.3\%) | 119 (21.0\%) | 437 (76.9\%) | 35 (6.2\%) | 402 (70.8\%) | 12 (2.1\%) |
| $\begin{aligned} & \text { Aug 30-Sept 12, } \\ & 2021 \end{aligned}$ | All ages | Cases | 101,044 (100\%) | 37,641 (37.3\%) | 55,519 (54.9\%) | 11,942 (11.8\%) | 43,577 (43.1\%) | 7,884 (7.8\%) |
|  |  | Hospitalizations | 2,935 (100\%) | 1,239 (42.2\%) | 1,649 (56.2\%) | 187 (6.4\%) | 1,462 (49.8\%) | 47 (1.6\%) |
|  |  | Deaths | 744 (100\%) | 186 (25.0\%) | 546 (73.4\%) | 24 (3.2\%) | 522 (70.2\%) | 12 (1.6\%) |
|  | <50 yrs | Cases | 76,416 (75.6\%) | 35,814 (46.9\%) | 34,402 (45.0\%) | 11,398 (14.9\%) | 23,004 (30.1\%) | 6,200 (8.1\%) |
|  |  | Hospitalizations | 1,132 (38.6\%) | 775 (68.5\%) | 324 (28.6\%) | 124 (11.0\%) | 200 (17.7\%) | 33 (2.9\%) |


|  | Deaths | 50 (6.7\%) | 33 (66.0\%) | 14 (28.0\%) | 3 (6.0\%) | 11 (22.0\%) | 3 (6.0\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\geq 50 \mathrm{yrs}$ | Cases | 24,480 (24.2\%) | 1,827 (7.5\%) | 21,115 (86.3\%) | 544 (2.2\%) | 20,571 (84.0\%) | 1,538 (6.3\%) |
|  | Hospitalizations | 1,793 (61.1\%) | 464 (25.9\%) | 1,325 (73.9\%) | 63 (3.5\%) | 1,262 (70.4\%) | 4 (0.2\%) |
|  | Deaths | 692 (93.0\%) | 153 (22.1\%) | 532 (76.9\%) | 21 (3.0\%) | 511 (73.8\%) | 7 (1.0\%) |

Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths based on the vaccination status reported in Public Health England technical briefings until September 12, 2021. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. $\ddagger$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses.

Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status

| Outcome | Study period (rolling four weeks ending) | Age <br> (yrs) | Total cases ( $\mathrm{n}=\%$ of cases all ages) | Unvaccinated <br> Cases ( $\mathrm{n}=\%$ <br> for age <br> group) | Vaccinated cases (cases) ( $\mathrm{n}=\%$ for age group) |  |  |  | Vaccination status unknown ( $\mathrm{n}=\%$ for age group) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | All vaccinated | 1 dose* | Two doses ${ }^{\ddagger}$ | Third dose ${ }^{\varnothing}$ |  |
| Cases | 12-Sep-21 | All ages | 711,304 (100\%) | 711,304 (37.0\%) | 382,422 (53.8\%) | $\begin{aligned} & \hline 93,143 \\ & (13.1 \%) \\ & \hline \end{aligned}$ | 289,279 (40.7\%) |  | 65,597 (9.2\%) |
|  |  | $\geq 18$ | 520,441 (73.2\%) | 101,867 (19.6\%) | 369,802 (71.1\%) | $\begin{aligned} & \hline 81,332 \\ & (15.6 \%) \\ & \hline \end{aligned}$ | 288,470 (55.4\%) |  | 48,772 (9.4\%) |
|  |  | $\geq 50$ | 170,525 (24.0\%) | 11,265 (6.6\%) | 146,085 (85.7\%) | 3,575 (2.1\%) | 142,510 (83.6\%) |  | 13,175 (7.7\%) |
| Cases | 19-Sep-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 680,582 (100\%) | 680,582 (40.5\%) | 344,691 (50.6\%) | 67,187 (9.9\%) | 277,504 (40.8\%) |  | 60,046 (8.8\%) |
|  |  | $\geq 18$ | 461,551 (67.8\%) | 87,377 (18.9\%) | 331,990 (71.9\%) | $\begin{aligned} & \hline 55,159 \\ & (12.0 \%) \\ & \hline \end{aligned}$ | 276,831 (60.0\%) |  | 42,184 (9.1\%) |
|  |  | $\geq 50$ | 160,432 (23.6\%) | 10,247 (6.4\%) | 138,185 (86.1\%) | 3,129 (2.0\%) | 135,056 (84.2\%) |  | 12,000 (7.5\%) |
| Cases | 26-Sep-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \end{aligned}$ | 699,489 (100\%) | 699,489 (45.2\%) | 326,250 (46.6\%) | 53,070 (7.6\%) | 273,180 (39.1\%) |  | 57,237 (8.2\%) |
|  |  | $\geq 18$ | 425,804 (60.9\%) | 75,925 (17.8\%) | 312,932 (73.5\%) | 40,434 (9.5\%) | 272,498 (64.0\%) |  | 36,947 (8.7\%) |
|  |  | $\geq 50$ | 149,993 (21.4\%) | 9,131 (6.1\%) | 130,176 (86.8\%) | 2,790 (1.9\%) | 127,386 (84.9\%) |  | 10,686 (7.1\%) |
| Cases | 3-Oct-21 | $\begin{array}{\|l\|} \hline \text { All } \\ \text { ages } \\ \hline \end{array}$ | 696,281 (100\%) | 696,281 (48.5\%) | 305,326 (43.9\%) | 39,232 (5.6\%) | 266,094 (38.2\%) |  | 53,385 (7.7\%) |
|  |  | $\geq 18$ | 390,853 (56.1\%) | 64,589 (16.5\%) | 293,846 (75.2\%) | 28,361 (7.3\%) | 265,485 (67.9\%) |  | 32,418 (8.3\%) |
|  |  | $\geq 50$ | 140,407 (20.2\%) | 8,038 (5.7\%) | 122,880 (87.5\%) | 2,541 (1.8\%) | 120,339 (85.7\%) |  | 9,489 (6.8\%) |
| Cases | 10-Oct-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 750,518 (100\%) | 750,518 (49.5\%) | 325,759 (43.4\%) | 37,578 (5.0\%) | 288,181 (38.4\%) |  | 53,063 (7.1\%) |
|  |  | $\geq 18$ | 402,004 (53.6\%) | 60,497 (15.0\%) | 310,745 (77.3\%) | 23,218 (5.8\%) | 287,527 (71.5\%) |  | 30,762 (7.7\%) |
|  |  | $\geq 50$ | 147,044 (19.6\%) | 7,689 (5.2\%) | 130,192 (88.5\%) | 2,496 (1.7\%) | 127,696 (86.8\%) |  | 9,163 (6.2\%) |
| Cases | 17-Oct-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 856,370 (100\%) | 856,370 (48.5\%) | 384,997 (45.0\%) | 44,937 (5.2\%) | 340,060 (39.7\%) |  | 56,264 (6.6\%) |
|  |  | $\geq 18$ | 458,488 (53.5\%) | 63,961 (14.0\%) | 362,555 (79.1\%) | 23,238 (5.1\%) | 339,317 (74.0\%) |  | 31,972 (7.0\%) |


|  |  | $\geq 50$ | 172,442 (20.1\%) | 8,311 (4.8\%) | 154,314 (89.5\%) | 2,802 (1.6\%) | 151,512 (87.9\%) | 9,817 (5.7\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cases | 24-Oct-21 | All ages | 930,013 (100\%) | 930,013 (45.7\%) | 445,585 (47.9\%) | 54,490 (5.9\%) | 391,095 (42.1\%) | 59,414 (6.4\%) |
|  |  | $\geq 18$ | 518,934 (55.8\%) | 70,006 (13.5\%) | 414,312 (79.8\%) | 24,038 (4.6\%) | 390,274 (75.2\%) | 34,616 (6.7\%) |
|  |  | $\geq 50$ | 202,169 (21.7\%) | 9,486 (4.7\%) | 181,627 (89.8\%) | 3,066 (1.5\%) | 178,561 (88.3\%) | 11,056 (5.5\%) |
| Cases | 31-Oct-21 | All ages | 975,224 (100\%) | 975,224 (42.4\%) | 501,078 (51.4\%) | 61,288 (6.3\%) | 439,790 (45.1\%) | 61,034 (6.3\%) |
|  |  | $\geq 18$ | 577,740 (59.2\%) | 76,219 (13.2\%) | 464,265 (80.4\%) | 25,293 (4.4\%) | 438,972 (76.0\%) | 37,256 (6.4\%) |
|  |  | $\geq 50$ | 229,334 (23.5\%) | 10,573 (4.6\%) | 206,516 (90.1\%) | 3,371 (1.5\%) | 203,145 (88.6\%) | 12,245 (5.3\%) |
| Cases | 7-Nov-21 | All ages | 950,837 (100\%) | 950,837 (39.8\%) | 513,146 (54.0\%) | 62,154 (6.5\%) | 450,992 (47.4\%) | 59,668 (6.3\%) |
|  |  | $\geq 18$ | 593,357 (62.4\%) | 79,516 (13.4\%) | 475,740 (80.2\%) | 25,554 (4.3\%) | 450,186 (75.9\%) | 38,101 (6.4\%) |
|  |  | $\geq 50$ | 235,549 (24.8\%) | 11,088 (4.7\%) | 212,064 (90.0\%) | 3,431 (1.5\%) | 208,633 (88.6\%) | 12,397 (5.3\%) |
| Cases | 14-Nov-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 907,478 (100\%) | 907,478 (37.2\%) | 513,094 (56.5\%) | 63,339 (7.0\%) | 449,755 (49.6\%) | 57,040 (6.3\%) |
|  |  | $\geq 18$ | 593,762 (65.4\%) | 81,589 (13.7\%) | 474,266 (79.9\%) | 25,350 (4.3\%) | 448,916 (75.6\%) | 37,907 (6.4\%) |
|  |  | $\geq 50$ | 232,221 (25.6\%) | 11,498 (5.0\%) | 208,679 (89.9\%) | 3,405 (1.5\%) | 205,274 (88.4\%) | 12,044 (5.2\%) |
| Cases | 21-Nov-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 888,449 (100\%) | 888,449 (36.8\%) | 506,459 (57.0\%) | 62,428 (7.0\%) | 444,031 (50.0\%) | 55,147 (6.2\%) |
|  |  | $\geq 18$ | 588,131 (66.2\%) | 83,121 (14.1\%) | 468,060 (79.6\%) | 24,894 (4.2\%) | 443,166 (75.4\%) | 36,950 (6.3\%) |
|  |  | $\geq 50$ | 219,859 (24.7\%) | 11,586 (5.3\%) | 197,217 (89.7\%) | 3,375 (1.5\%) | 193,842 (88.2\%) | 11,056 (5.0\%) |
| Cases | 28-Nov-21 | All ages | 905,267 (100\%) | 905,267 (38.1\%) | 503,519 (55.6\%) | 65,115 (7.2\%) | 438,404 (48.4\%) | 56,836 (6.3\%) |
|  |  | $\geq 18$ | 584,205 (64.5\%) | 85,038 (14.6\%) | 461,939 (79.1\%) | 24,489 (4.2\%) | 437,450 (74.9\%) | 37,228 (6.4\%) |
|  |  | $\geq 50$ | 205,829 (22.7\%) | 11,804 (5.7\%) | 183,675 (89.2\%) | 3,248 (1.6\%) | 180,427 (87.7\%) | 10,350 (5.0\%) |
| Cases | 5-Dec-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | 997,322 (100\%) | 997,322 (39.1\%) | 544,391 (54.6\%) | 73,786 (7.4\%) | 470,605 (47.2\%) | 62,835 (6.3\%) |
|  |  | $\geq 18$ | 628,872 (63.1\%) | 92,746 (14.7\%) | 495,707 (78.8\%) | 26,242 (4.2\%) | 469,465 (74.7\%) | 40,419 (6.4\%) |
|  |  | $\geq 50$ | 204,824 (20.5\%) | 12,754 (6.2\%) | 181,506 (88.6\%) | 3,447 (1.7\%) | 178,059 (86.9\%) | 10,564 (5.2\%) |
| Cases | 12-Dec-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,086,083 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,086,083 \\ & (38.5 \%) \\ & \hline \end{aligned}$ | 597,751 (55.0\%) | 79,378 (7.3\%) | 518,373 (47.7\%) | 70,726 (6.5\%) |
|  |  | $\geq 18$ | 697,726 (64.2\%) | 104,612 (15.0\%) | 546,335 (78.3\%) | 29,274 (4.2\%) | 517,061 (74.1\%) | 46,779 (6.7\%) |
|  |  | $\geq 50$ | 201,843 (18.6\%) | 13,710 (6.8\%) | 177,349 (87.9\%) | 3,615 (1.8\%) | 173,734 (86.1\%) | 10,784 (5.3\%) |
| Cases | 19-Dec-21 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 1,371,157 } \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,371,157 \\ & (32.5 \%) \\ & \hline \end{aligned}$ | 832,918 (60.7\%) | 94,734 (6.9\%) | 738,184 (53.8\%) | 92,902 (6.8\%) |
|  |  | $\geq 18$ | 975,822 (71.2\%) | 132,809 (13.6\%) | 775,634 (79.5\%) | 39,618 (4.1\%) | 736,016 (75.4\%) | 67,379 (6.9\%) |


|  |  | $\geq 50$ | 233,191 (17.0\%) | 15,774 (6.8\%) | 204,398 (87.7\%) | 4,116 (1.8\%) | 200,282 (85.9\%) |  | 13,019 (5.6\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cases | 2-Jan-22 | All ages | $\begin{aligned} & \hline 2,556,580 \\ & (100 \%) \end{aligned}$ | $\begin{aligned} & 2,556,580 \\ & (21.5 \%) \end{aligned}$ | $\begin{aligned} & 1,827,454 \\ & (71.5 \%) \end{aligned}$ | $\begin{aligned} & 163,826 \\ & (6.4 \%) \end{aligned}$ | $\begin{aligned} & 1,663,628 \\ & (65.1 \%) \end{aligned}$ |  | 180,064 (7.0\%) |
|  |  | $\geq 18$ | 2,127 (83.2\%) | 240,879 (11.3\%) | $\begin{aligned} & \hline 1,738,627 \\ & (81.7 \%) \end{aligned}$ | 84,102 (4.0\%) | $\begin{aligned} & 1,654,525 \\ & (77.8 \%) \end{aligned}$ |  | 147,919 (7.0\%) |
|  |  | $\geq 50$ | 560,458 (21.9\%) | 27,116 (4.8\%) | 500,304 (89.3\%) | 8,046 (1.4\%) | 492,258 (87.8\%) |  | 33,038 (5.9\%) |
| Cases | 9-Jan-22 | All ages | $\begin{aligned} & \hline 3,161,258 \\ & (100 \%) \end{aligned}$ | $\begin{aligned} & 3,161,258 \\ & (20.3 \%) \end{aligned}$ | $\begin{aligned} & \hline 2,291,288 \\ & (72.5 \%) \end{aligned}$ | $\begin{aligned} & \text { 202,336 } \\ & (6.4 \%) \end{aligned}$ | $\begin{aligned} & \text { 2,088,952 } \\ & (66.1 \%) \end{aligned}$ |  | 229,101 (7.2\%) |
|  |  | $\geq 18$ | 2,659 (84.1\%) | 292,438 (11.0\%) | $\begin{aligned} & 2,177,293 \\ & (81.9 \%) \end{aligned}$ | $\begin{aligned} & 103,771 \\ & (3.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 2,073,522 \\ & (78.0 \%) \end{aligned}$ |  | 189,614 (7.1\%) |
|  |  | $\geq 50$ | 749,614 (23.7\%) | 33,156 (4.4\%) | 670,870 (89.5\%) | 9,977 (1.3\%) | 660,893 (88.2\%) |  | 45,588 (6.1\%) |
| Cases | 16-Jan-22 | All ages | $\begin{aligned} & \hline 3,183,566 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,183,566 \\ & (21.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,254,937 \\ & (70.8 \%) \end{aligned}$ | $\begin{aligned} & \hline 206,329 \\ & (6.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,112,775 \\ & (35.0 \%) \end{aligned}$ | 935,833 (29.4\%) | 230,878 (7.3\%) |
|  |  | $\geq 18$ | 2,605 (81.8\%) | 285,948 (11.0\%) | $\begin{aligned} & \text { 2,131,103 } \\ & (81.8 \%) \end{aligned}$ | $\begin{aligned} & 100,960 \\ & (3.9 \%) \end{aligned}$ | $\begin{aligned} & 1,095,228 \\ & (42.0 \%) \end{aligned}$ | 934,915 (35.9\%) | 188,677 (7.2\%) |
|  |  | $\geq 50$ | 786,950 (24.7\%) | 33,742 (4.3\%) | 704,355 (89.5\%) | 10,093 (1.3\%) | 153,439 (19.5\%) | 540,823 (68.7\%) | 48,853 (6.2\%) |
| Cases | 23-Jan-22 | All ages | $\begin{aligned} & \hline 3,034,409 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3,034,409 \\ & (25.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,058,948 \\ & (67.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 199,979 \\ & (6.6 \%) \\ & \hline \end{aligned}$ | 844,861 (27.8\%) | 1,014,108 (33.4\%) | 213,040 (7.0\%) |
|  |  | $\geq 18$ | 2,351 (77.5\%) | 255,701 (10.9\%) | $\begin{aligned} & \hline 1,926,523 \\ & (81.9 \%) \\ & \hline \end{aligned}$ | 88,213 (3.8\%) | 825,293 (35.1\%) | 1,013,017 (43.1\%) | 168,964 (7.2\%) |
|  |  | $\geq 50$ | 735,711 (24.2\%) | 30,660 (4.2\%) | 659,811 (89.7\%) | 8,958 (1.2\%) | 114,649 (15.6\%) | 536,204 (72.9\%) | 45,240 (6.1\%) |
| Cases | 30-Jan-22 | $\begin{aligned} & \hline \begin{array}{l} \text { All } \\ \text { ages } \end{array} \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 2,872,077 } \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 2,872,077 \\ & (29.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,832,328 \\ & (63.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 205,387 \\ & (7.2 \%) \\ & \hline \end{aligned}$ | 607,331 (21.1\%) | 1,019,610 (35.5\%) | 195,470 (6.8\%) |
|  |  | $\geq 18$ | 2,057 (71.6\%) | 231,750 (11.3\%) | $\begin{aligned} & 1,677,414 \\ & (81.5 \%) \end{aligned}$ | 75,802 (3.7\%) | 583,313 (28.3\%) | 1,018,299 (49.5\%) | 148,566 (7.2\%) |
|  |  | $\geq 50$ | 600,808 (20.9\%) | 25,917 (4.3\%) | 535,661 (89.2\%) | 7,130 (1.2\%) | 74,353 (12.4\%) | 454,178 (75.6\%) | 39,230 (6.5\%) |
| Cases | 6-Feb-22 | $\begin{aligned} & \hline \text { All } \\ & \text { ages } \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 2,293,771 \\ (100 \%) \\ \hline \end{array}$ | $\begin{aligned} & \hline 2,293,771 \\ & (31.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,426,498 \\ & (62.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 171,086 \\ & (7.5 \%) \\ & \hline \end{aligned}$ | 369,295 (16.1\%) | 886,117 (38.6\%) | 140,444 (6.1\%) |
|  |  | $\geq 18$ | 1,544 (67.3\%) | 159,596 (10.3\%) | $\begin{aligned} & 1,281,180 \\ & (83.0 \%) \\ & \hline \end{aligned}$ | 51,615 (3.3\%) | 344,772 (22.3\%) | 884,793 (57.3\%) | 103,389 (6.7\%) |
|  |  | $\geq 50$ | 448,840 (19.6\%) | 18,505 (4.1\%) | 402,612 (89.7\%) | 5,060 (1.1\%) | 43,512 (9.7\%) | 354,040 (78.9\%) | 27,723 (6.2\%) |
| Cases | 13-Feb-22 | All ages | $\begin{array}{\|l\|} \hline 1,980,778 \\ (100 \%) \end{array}$ | $\begin{aligned} & 1,980,778 \\ & (29.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,277,533 \\ & (64.5 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 146,856 \\ & (7.4 \%) \\ & \hline \end{aligned}$ | 289,924 (14.6\%) | 840,753 (42.4\%) | 113,796 (5.7\%) |
|  |  | $\geq 18$ | 1,358 (68.6\%) | 128,278 (9.4\%) | $\begin{aligned} & 1,145,794 \\ & (84.3 \%) \\ & \hline \end{aligned}$ | 42,017 (3.1\%) | 264,366 (19.5\%) | 839,411 (61.8\%) | 84,457 (6.2\%) |
|  |  | $\geq 50$ | 402,677 (20.3\%) | 14,945 (3.7\%) | 365,185 (90.7\%) | 4,197 (1.0\%) | 32,500 (8.1\%) | 328,488 (81.6\%) | 22,547 (5.6\%) |
| Cases | 20-Feb-22 | All ages | $\begin{aligned} & \hline 1,578,203 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,578,203 \\ & (25.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,086,434 \\ & (68.8 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 109,803 \\ & (7.0 \%) \end{aligned}$ | 224,505 (14.2\%) | 752,126 (47.7\%) | 87,739 (5.6\%) |


|  |  | $\geq 18$ | 1,153 (73.1\%) | 100,923 (8.7\%) | 984,555 (85.4\%) | 33,209 (2.9\%) | 200,489 (17.4\%) | 750,857 (65.1\%) | 68,036 (5.9\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\geq 50$ | 366,989 (23.3\%) | 12,308 (3.4\%) | 335,767 (91.5\%) | 3,484 (0.9\%) | 25,606 (7.0\%) | 306,677 (83.6\%) | 18,914 (5.2\%) |
| Cases | 27-Feb-22 | All ages | $\begin{aligned} & \hline 1,154,859 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1,154,859 \\ & (21.2 \%) \\ & \hline \end{aligned}$ | 846,616 (73.3\%) | 67,669 (5.9\%) | 162,998 (14.1\%) | 615,949 (53.3\%) | 63,930 (5.5\%) |
|  |  | $\geq 18$ | 910,456 (78.8\%) | 74,831 (8.2\%) | 783,337 (86.0\%) | 24,454 (2.7\%) | 144,037 (15.8\%) | 614,846 (67.5\%) | 52,288 (5.7\%) |
|  |  | $\geq 50$ | 314,123 (27.2\%) | 9,821 (3.1\%) | 288,812 (91.9\%) | 2,775 (0.9\%) | 19,389 (6.2\%) | 266,648 (84.9\%) | 15,490 (4.9\%) |
| Cases | 6-Mar-22 | All ages | 927,841 (100\%) | 927,841 (18.0\%) | 710,601 (76.6\%) | 41,523 (4.5\%) | 124,333 (13.4\%) | 544,745 (58.7\%) | 49,838 (5.4\%) |
|  |  | $\geq 18$ | 774,595 (83.5\%) | 59,904 (7.7\%) | 672,261 (86.8\%) | 18,878 (2.4\%) | 109,575 (14.1\%) | 543,808 (70.2\%) | 42,430 (5.5\%) |
|  |  | $\geq 50$ | 291,177 (31.4\%) | 8,351 (2.9\%) | 269,443 (92.5\%) | 2,305 (0.8\%) | 16,012 (5.5\%) | 251,126 (86.2\%) | 13,383 (4.6\%) |
| Cases | 13-Mar-22 | All ages | 995,166 (100\%) | 995,166 (17.3\%) | 774,991 (77.9\%) | 35,325 (3.5\%) | 120,538 (12.1\%) | 619,128 (62.2\%) | 47,611 (4.8\%) |
|  |  | $\geq 18$ | 841,958 (84.6\%) | 60,372 (7.2\%) | 740,601 (88.0\%) | 18,039 (2.1\%) | 104,580 (12.4\%) | 617,982 (73.4\%) | 40,985 (4.9\%) |
|  |  | $\geq 50$ | 339,806 (34.1\%) | 8,713 (2.6\%) | 317,352 (93.4\%) | 2,356 (0.7\%) | 16,427 (4.8\%) | 298,569 (87.9\%) | 13,741 (4.0\%) |
| Cases | 20-Mar-22 | All ages | $\begin{aligned} & \hline 1,237,498 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,237,498 \\ & (17.1 \%) \\ & \hline \end{aligned}$ | 970,347 (78.4\%) | 39,117 (3.2\%) | 139,110 (11.2\%) | 792,120 (64.0\%) | 55,172 (4.5\%) |
|  |  | $\geq 18$ | 1,045 (84.5\%) | 70,018 (6.7\%) | 928,447 (88.8\%) | 20,229 (1.9\%) | 117,728 (11.3\%) | 790,490 (75.6\%) | 47,259 (4.5\%) |
|  |  | $\geq 50$ | 442,044 (35.7\%) | 10,397 (2.4\%) | 415,176 (93.9\%) | 2,733 (0.6\%) | 19,477 (4.4\%) | 392,966 (88.9\%) | 16,471 (3.7\%) |
| Cases | 27-Mar-22 | All ages | $\begin{aligned} & \hline 1,553,609 \\ & (100 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,553,609 \\ & (16.6 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & 1,228,616 \\ & (79.1 \%) \\ & \hline \end{aligned}$ | 46,866 (3.0\%) | 170,597 (11.0\%) | 1,011,153 (65.1\%) | 66,636 (4.3\%) |
|  |  | $\geq 18$ | 1,318 (84.9\%) | 85,614 (6.5\%) | $\begin{aligned} & \hline 1,176,134 \\ & (89.2 \%) \\ & \hline \end{aligned}$ | 24,334 (1.8\%) | 142,964 (10.8\%) | 1,008,836 (76.5\%) | 56,942 (4.3\%) |
|  |  | $\geq 50$ | 572,612 (36.9\%) | 12,871 (2.2\%) | 539,347 (94.2\%) | 3,396 (0.6\%) | 24,122 (4.2\%) | 511,829 (89.4\%) | 20,394 (3.6\%) |

Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARS-CoV2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission in NIMS-database based on vaccination status

| Outcome | Study period (rolling four weeks ending) | Age | Total hospitalizations | Hospitalizations Unvaccinated | Hospitalizations Vaccinated |  |  |  | Vaccination status unknown |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | All <br> vaccinated | 1 dose* | Two doses ${ }^{\ddagger}$ | Third dose <br> $\varnothing$ |  |
| Hospitalizations | 12-Sep-21 | All ages | 8,356 (100\%) | 3,425 (41.0\%) | 4,810 (57.6\%) | 434 (5.2\%) | 4,376 (52.4\%) |  | 121 (1.4\%) |
|  |  | $\geq 18$ | 7,817 (93.5\%) | 2,931 (37.5\%) | 4,794 (61.3\%) | 418 (5.3\%) | 4,376 (56.0\%) |  | 92 (1.2\%) |
|  |  | $\geq 50$ | 5,431 (65.0\%) | 1,358 (25.0\%) | 4,043 (74.4\%) | 175 (3.2\%) | 3,868 (71.2\%) |  | 30 (0.6\%) |
| Hospitalizations | 19-Sep-21 | All ages | 8,255 (100\%) | 3,220 (39.0\%) | 4,940 (59.8\%) | 383 (4.6\%\%) | 4,557 (55.2\%) |  | 95 (1.2\%) |
|  |  | $\geq 18$ | 7,744 (93.8\%) | 2,742 (35.4\%) | 4,925 (63.6\%) | 368 (4.8\%) | 4,557 (58.8\%) |  | 77 (1.0\%) |
|  |  | $\geq 50$ | 5,589 (67.7\%) | 1,339 (24.0\%) | 4,227 (75.6\%) | 164 (2.9\%) | 4,063 (72.7\%) |  | 23 (0.4\%) |
| Hospitalizations | 26-Sep-21 | All ages | 7,729 (100\%) | 2,922 (37.8\%) | 4,734 (61.2\%) | 356 (4.6\%\%) | 4,378 (56.6\%) |  | 73 (0.9\%) |
|  |  | $\geq 18$ | 7,204 (93.2\%) | 2,435 (33.8\%) | 4,710 (65.4\%) | 332 (4.6\%) | 4,378 (60.8\%) |  | 59 (0.8\%) |
|  |  | $\geq 50$ | 5,227 (67.6\%) | 1,185 (22.7\%) | 4,024 (77.0\%) | 158 (3.0\%) | 3,866 (74.0\%) |  | 18 (0.3\%) |
| Hospitalizations | 3-Oct-21 | All ages | 6,691 (100\%) | 2,411 (36.0\%) | 4,206 (62.9\%) | 296 (4.4\%\%) | 3,910 (58.4\%) |  | 74 (1.1\%) |
|  |  | $\geq 18$ | 6,205 (92.7\%) | 1,956 (31.5\%) | 4,195 (67.6\%) | 286 (4.6\%) | 3,909 (63.0\%) |  | 54 (0.9\%) |
|  |  | $\geq 50$ | 4,500 (67.3\%) | 931 (20.7\%) | 3,551 (78.9\%) | 139 (3.1\%) | 3,412 (75.8\%) |  | 18 (0.4\%) |
| Hospitalizations | 10-Oct-21 | All ages | 5,148 (100\%) | 1,842 (35.8\%) | 3,258 (63.3\%) | 224 (4.4\%\%) | 3,034 (58.9\%) |  | 48 (0.9\%) |
|  |  | $\geq 18$ | 4,740 (92.1\%) | 1,456 (30.7\%) | 3,247 (68.5\%) | 214 (4.5\%) | 3,033 (64.0\%) |  | 37 (0.8\%) |
|  |  | $\geq 50$ | 3,360 (65.3\%) | 660 (19.6\%) | 2,689 (80.0\%) | 106 (3.2\%) | 2,583 (76.9\%) |  | 11 (0.3\%) |
| Hospitalizations | 17-Oct-21 | All ages | 7,392 (100\%) | 2,534 (34.3\%) | 4,791 (64.8\%) | 305 (4.1\%\%) | 4,486 (60.7\%) |  | 67 (0.9\%) |
|  |  | $\geq 18$ | 6,791 (91.9\%) | 1,974 (29.1\%) | 4,770 (70.2\%) | 286 (4.2\%) | 4,484 (66.0\%) |  | 47 (0.7\%) |
|  |  | $\geq 50$ | 4,946 (66.9\%) | 926 (18.7\%) | 3,997 (80.8\%) | 169 (3.4\%) | 3,828 (77.4\%) |  | 23 (0.5\%) |
| Hospitalizations | 24-Oct-21 | All ages | 8,338 (100\%) | 2,832 (34.0\%) | 5,429 (65.1\%) | 305 (3.7\%\%) | 5,124 (61.5\%) |  | 77 (0.9\%) |
|  |  | $\geq 18$ | 7,705 (92.4\%) | 2,240 (29.1\%) | 5,405 (70.1\%) | 282 (3.7\%) | 5,123 (66.5\%) |  | 60 (0.8\%) |
|  |  | $\geq 50$ | 5,682 (68.1\%) | 1,087 (19.1\%) | 4,567 (80.4\%) | 158 (2.8\%) | 4,409 (77.6\%) |  | 28 (0.5\%) |


| Hospitalizations | 31-Oct-21 | All ages | 8,722 (100\%) | 2,806 (32.2\%) | 5,831 (66.9\%) | 297 (3.4\%\%) | 5,534 (63.4\%) | 85 (1.0\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\geq 18$ | 8,141 (93.3\%) | 2,267 (27.8\%) | 5,809 (71.4\%) | 276 (3.4\%) | 5,533 (68.0\%) | 65 (0.8\%) |
|  |  | $\geq 50$ | 6,147 (70.5\%) | 1,158 (18.8\%) | 4,956 (80.6\%) | 151 (2.5\%) | 4,805 (78.2\%) | 33 (0.5\%) |
| Hospitalizations | 7-Nov-21 | All ages | 10,179 (100\%) | 3,313 (32.5\%) | 6,786 (66.7\%) | 325 (3.2\%\%) | 6,461 (63.5\%) | 80 (0.8\%) |
|  |  | $\geq 18$ | 9,548 (93.8\%) | 2,722 (28.5\%) | 6,759 (70.8\%) | 300 (3.1\%) | 6,459 (67.6\%) | 67 (0.7\%) |
|  |  | $\geq 50$ | 7,179 (70.5\%) | 1,390 (19.4\%) | 5,753 (80.1\%) | 153 (2.1\%) | 5,600 (78.0\%) | 36 (0.5\%) |
| Hospitalizations | 14-Nov-21 | All ages | 9,831 (100\%) | 3,200 (32.6\%) | 6,560 (66.7\%) | 327 (3.3\%\%) | 6,233 (63.4\%) | 71 (0.7\%) |
|  |  | $\geq 18$ | 9,278 (94.4\%) | 2,692 (29.0\%) | 6,529 (70.4\%) | 296 (3.2\%) | 6,233 (67.2\%) | 57 (0.6\%) |
|  |  | $\geq 50$ | 6,956 (70.8\%) | 1,391 (20.0\%) | 5,538 (79.6\%) | 149 (2.1\%) | 5,389 (77.5\%) | 27 (0.4\%) |
| Hospitalizations | 21-Nov-21 | All ages | 9,174 (100\%) | 3,071 (33.5\%) | 6,023 (65.7\%) | 334 (3.6\%\%) | 5,689 (62.0\%) | 80 (0.9\%) |
|  |  | $\geq 18$ | 8,658 (94.4\%) | 2,604 (30.1\%) | 5,991 (69.2\%) | 303 (3.5\%) | 5,688 (65.7\%) | 63 (0.7\%) |
|  |  | $\geq 50$ | 6,420 (70.0\%) | 1,358 (21.2\%) | 5,027 (78.3\%) | 154 (2.4\%) | 4,873 (75.9\%) | 35 (0.5\%) |
| Hospitalizations | 28-Nov-21 | All ages | 6,639 (100\%) | 2,355 (35.5\%) | 4,231 (63.7\%) | 233 (3.5\%\%) | 3,998 (60.2\%) | 53 (0.8\%) |
|  |  | $\geq 18$ | 6,254 (94.2\%) | 2,004 (32.0\%) | 4,211 (67.3\%) | 214 (3.4\%) | 3,997 (63.9\%) | 39 (0.6\%) |
|  |  | $\geq 50$ | 4,618 (69.6\%) | 1,077 (23.3\%) | 3,520 (76.2\%) | 110 (2.4\%) | 3,410 (73.8\%) | 21 (0.5\%) |
| Hospitalizations | 5-Dec-21 | All ages | 8,156 (100\%) | 3,187 (39.1\%) | 4,875 (59.8\%) | 340 (4.2\%\%) | 4,535 (55.6\%) | 94 (1.2\%\%) |
|  |  | $\geq 18$ | 7,575 (92.9\%) | 2,676 (35.3\%) | 4,830 (63.8\%) | 304 (4.0\%) | 4,526 (59.7\%) | 69 (0.9\%) |
|  |  | $\geq 50$ | 5,330 (65.4\%) | 1,451 (27.2\%) | 3,845 (72.1\%) | 158 (3.0\%) | 3,687 (69.2\%) | 34 (0.6\%) |
| Hospitalizations | 12-Dec-21 | All ages | 8,235 (100\%) | 3,532 (42.9\%) | 4,602 (55.9\%) | 346 (4.2\%\%) | 4,256 (51.7\%) | 101 (1.2\%) |
|  |  | $\geq 18$ | 7,601 (92.3\%) | 2,965 (39.0\%) | 4,556 (59.9\%) | 309 (4.1\%) | 4,247 (55.9\%) | 80 (1.1\%) |
|  |  | $\geq 50$ | 5,153 (62.6\%) | 1,591 (30.9\%) | 3,524 (68.4\%) | 170 (3.3\%) | 3,354 (65.1\%) | 38 (0.7\%) |
| Hospitalizations | 19-Dec-21 | All ages | 8,190 (100\%) | 3,693 (45.1\%) | 4,388 (53.6\%) | 361 (4.4\%\%) | 4,027 (49.2\%) | 109 (1.3\%) |
|  |  | $\geq 18$ | 7,542 (92.1\%) | 3,115 (41.3\%) | 4,339 (57.5\%) | 319 (4.2\%) | 4,020 (53.3\%) | 88 (1.2\%) |
|  |  | $\geq 50$ | 5,007 (61.1\%) | 1,708 (34.1\%) | 3,253 (65.0\%) | 177 (3.5\%) | 3,076 (61.4\%) | 46 (0.9\%) |
| Hospitalizations | 2-Jan-22 | All ages | 9,981 (100\%) | 4,056 (40.6\%) | 5,791 (58.0\%) | 508 (5.1\%\%) | 5,283 (52.9\%) | 134 (1.3\%) |
|  |  | $\geq 18$ | 9,082 (91.0\%) | 3,260 (35.9\%) | 5,735 (63.1\%) | 462 (5.1\%) | 5,273 (58.1\%) | 87 (1.0\%) |
|  |  | $\geq 50$ | 5,955 (59.7\%) | 1,756 (29.5\%) | 4,159 (69.8\%) | 234 (3.9\%) | 3,925 (65.9\%) | 40 (0.7\%) |
| Hospitalizations | 9-Jan-22 | All ages | 13,514 (100\%) | 4,738 (35.1\%) | 8,566 (63.4\%) | 689 (5.1\%\%) | 7,877 (58.3\%) | 210 (1.6\%) |
|  |  | $\geq 18$ | 12,219 (90.4\%) | 3,614 (29.6\%) | 8,473 (69.3\%) | 608 (5.0\%) | 7,865 (64.4\%) | 132 (1.1\%) |
|  |  | $\geq 50$ | 8,206 (60.7\%) | 1,966 (24.0\%) | 6,192 (75.5\%) | 309 (3.8\%) | 5,883 (71.7\%) | 48 (0.6\%) |


| Hospitalizations | 16-Jan-22 | All ages | 15,012 (100\%) | 4,752 (31.7\%) | 10,051 (67.0\%) | 781 (5.2\%\%) | 4,127 (27.5\%) | 5,143 (34.3\%) | 209 (1.4\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\geq 18$ | 13,503 (89.9\%) | 3,445 (25.5\%) | 9,925 (73.5\%) | 670 (5.0\%) | 4,116 (30.5\%) | 5,139 (38.1\%) | 133 (1.0\%) |
|  |  | $\geq 50$ | 9,311 (62.0\%) | 1,880 (20.2\%) | 7,389 (79.4\%) | 340 (3.7\%) | 2,438 (26.2\%) | 4,611 (49.5\%) | 42 (0.5\%) |
| Hospitalizations | 23-Jan-22 | All ages | 16,294 (100\%) | 4,807 (29.5\%) | 11,277 (69.2\%) | 829 (5.1\%\%) | 3,999 (24.5\%) | 6,449 (39.6\%) | 210 (1.3\%) |
|  |  | $\geq 18$ | 14,459 (88.7\%) | 3,210 (22.2\%) | 11,124 (76.9\%) | 701 (4.8\%) | 3,978 (27.5\%) | 6,445 (44.6\%) | 125 (0.9\%) |
|  |  | $\geq 50$ | 10,270 (63.0\%) | 1,753 (17.1\%) | 8,462 (82.4\%) | 338 (3.3\%) | 2,403 (23.4\%) | 5,721 (55.7\%) | 55 (0.5\%) |
| Hospitalizations | 6-Feb-22 | All ages | 11,197 (100\%) | 3,261 (29.1\%) | 7,804 (69.7\%) | 607 (5.4\%\%) | 2,121 (18.9\%) | 5,076 (45.3\%) | 132 (1.2\%) |
|  |  | $\geq 18$ | 9,463 (84.5\%) | 1,737 (18.4\%) | 7,641 (80.7\%) | 476 (5.0\%) | 2,092 (22.1\%) | 5,073 (53.6\%) | 85 (0.9\%) |
|  |  | $\geq 50$ | 6,814 (60.9\%) | 946 (13.9\%) | 5,827 (85.5\%) | 225 (3.3\%) | 1,235 (18.1\%) | 4,367 (64.1\%) | 41 (0.6\%) |
| Hospitalizations | 13-Feb-22 | All ages | 10,222 (100\%) | 2,858 (28.0\%) | 7,294 (71.4\%) | 545 (5.3\%\%) | 1,810 (17.7\%) | 4,939 (48.3\%) | 70 (0.7\%) |
|  |  | $\geq 18$ | 8,599 (84.1\%) | 1,441 (16.8\%) | 7,118 (82.8\%) | 411 (4.8\%) | 1,769 (20.6\%) | 4,938 (57.4\%) | 40 (0.5\%) |
|  |  | $\geq 50$ | 6,158 (60.2\%) | 791 (12.8\%) | 5,349 (86.9\%) | 199 (3.2\%) | 996 (16.2\%) | 4,154 (67.5\%) | 18 (0.3\%) |
| Hospitalizations | 20-Feb-22 | All ages | 9,309 (100\%) | 2,341 (25.1\%) | 6,889 (74.0\%) | 463 (5.0\%\%) | 1,490 (16.0\%) | 4,936 (53.0\%) | 79 (0.8\%) |
|  |  | $\geq 18$ | 7,978 (85.7\%) | 1,209 (15.2\%) | 6,723 (84.3\%) | 340 (4.3\%) | 1,449 (18.2\%) | 4,934 (61.8\%) | 46 (0.6\%) |
|  |  | $\geq 50$ | 5,858 (62.9\%) | 662 (11.3\%) | 5,183 (88.5\%) | 166 (2.8\%) | 844 (14.4\%) | 4,173 (71.2\%) | 12 (0.2\%) |
| Hospitalizations | 27-Feb-22 | All ages | 7,975 (100\%) | 1,832 (23.0\%) | 6,098 (76.5\%) | 362 (4.5\%\%) | 1,178 (14.8\%) | 4,558 (57.2\%) | 45 (0.6\%) |
|  |  | $\geq 18$ | 7,015 (88.0\%) | 1,020 (14.5\%) | 5,973 (85.1\%) | 268 (3.8\%) | 1,149 (16.4\%) | 4,556 (64.9\%) | 22 (0.3\%) |
|  |  | $\geq 50$ | 5,291 (66.3\%) | 560 (10.6\%) | 4,726 (89.3\%) | 135 (2.6\%) | 692 (13.1\%) | 3,899 (73.7\%) | 5 (0.1\%) |
| Hospitalizations | 6-Mar-22 | All ages | 7,378 (100\%) | 1,504 (20.4\%) | 5,831 (79.0\%) | 301 (4.1\%\%) | 1,025 (13.9\%) | 4,505 (61.1\%) | 43 (0.6\%) |
|  |  | $\geq 18$ | 6,644 (90.1\%) | 882 (13.3\%) | 5,740 (86.4\%) | 238 (3.6\%) | 1,000 (15.1\%) | 4,502 (67.8\%) | 22 (0.3\%) |
|  |  | $\geq 50$ | 5,095 (69.1\%) | 483 (9.5\%) | 4,607 (90.4\%) | 111 (2.2\%) | 627 (12.3\%) | 3,869 (75.9\%) | 5 (0.1\%) |
| Hospitalizations | 13-Mar-22 | All ages | 6,573 (100\%) | 1,349 (20.5\%) | 5,193 (79.0\%) | 241 (3.7\%\%) | 837 (12.7\%) | 4,115 (62.6\%) | 31 (0.5\%) |
|  |  | $\geq 18$ | 5,915 (90.0\%) | 774 (13.1\%) | 5,124 (86.6\%) | 190 (3.2\%) | 822 (13.9\%) | 4,112 (69.5\%) | 17 (0.3\%) |
|  |  | $\geq 50$ | 4,606 (70.1\%) | 409 (8.9\%) | 4,192 (91.0\%) | 94 (2.0\%) | 518 (11.2\%) | 3,580 (77.7\%) | 5 (0.1\%) |
| Hospitalizations | 20-Mar-22 | All ages | 8,990 (100\%) | 1,848 (20.6\%) | 7,088 (78.8\%) | 309 (3.4\%\%) | 1,025 (11.4\%) | 5,754 (64.0\%) | 54 (0.6\%) |
|  |  | $\geq 18$ | 8,043 (89.5\%) | 1,015 (12.6\%) | 6,996 (87.0\%) | 252 (3.1\%) | 993 (12.3\%) | 5,751 (71.5\%) | 32 (0.4\%) |
|  |  | $\geq 50$ | 6,328 (70.4\%) | 509 (8.0\%) | 5,807 (91.8\%) | 132 (2.1\%) | 615 (9.7\%) | 5,060 (80.0\%) | 12 (0.2\%) |
| Hospitalizations | 27-Mar-22 | All ages | 10,389 (100\%) | 2,065 (19.9\%) | 8,261 (79.5\%) | 331 (3.2\%\%) | 1,180 (11.4\%) | 6,750 (65.0\%) | 63 (0.6\%) |
|  |  | $\geq 18$ | 9,293 (89.5\%) | 1,100 (11.8\%) | 8,157 (87.8\%) | 270 (2.9\%) | 1,142 (12.3\%) | 6,745 (72.6\%) | 36 (0.4\%) |
|  |  | $\geq 50$ | 7,329 (70.5\%) | 530 (7.2\%) | 6,786 (92.6\%) | 148 (2.0\%) | 685 (9.3\%) | 5,953 (81.2\%) | 12 (0.2\%) |

Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARSCoV 2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. $\ddagger$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death in NIMS-database based on vaccination

| Outcome | Study period (rolling four weeks ending) | Age(yrs) | Total deaths ( $\mathrm{n}=\%$ of all ages) | Unvaccinated deaths ( $\mathrm{n}=\%$ for age group) | Vaccinated deaths ( $\mathrm{n}=\%$ for age group) |  |  |  | Vaccination status unknown |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | All <br> Vaccinated | 1 dose* | Two doses ${ }^{\ddagger}$ | Third dose $\varnothing$ |  |
| Deaths | 12-Sep-21 | All ages | 2,961 (100\%) | 726 (24.5\%) | 2,206 (74.5\%) | 112 (3.8\%) | 2,094 (70.7\%) |  | 29 (1.0\%) |
|  |  | $\geq 18$ | 2,957 (99.9\%) | 723 (24.5\%) | 2,206 (74.6\%) | 112 (3.8\%) | 2,094 (70.8\%) |  | 28 (0.9\%) |
|  |  | $\geq 50$ | 2,775 (93.7\%) | 599 (21.6\%) | 2,153 (77.6\%) | 101 (3.6\%) | 2,052 (73.9\%) |  | 23 (0.8\%) |
| Deaths | 19-Sep-21 | All ages | 3,158 (100\%) | 730 (23.1\%) | 2,395 (75.8\%) | 111 (3.5\%) | 2,284 (72.3\%) |  | 33 (1.0\%) |
|  |  | $\geq 18$ | 3,152 (99.8\%) | 726 (23.0\%) | 2,395 (76.0\%) | 111 (3.5\%) | 2,284 (72.5\%) |  | 31 (1.0\%) |
|  |  | $\geq 50$ | 2,983 (94.5\%) | 615 (20.6\%) | 2,342 (78.5\%) | 103 (3.5\%) | 2,239 (75.1\%) |  | 26 (0.9\%) |
| Deaths | 26-Sep-21 | All ages | 3,165 (100\%) | 687 (21.7\%) | 2,448 (77.3\%) | 110 (3.5\%) | 2,338 (73.9\%) |  | 30 (0.9\%) |
|  |  | $\geq 18$ | 3,159 (99.8\%) | 683 (21.6\%) | 2,448 (77.5\%) | 110 (3.5\%) | 2,338 (74.0\%) |  | 28 (0.9\%) |
|  |  | $\geq 50$ | 3,005 (94.9\%) | 586 (19.5\%) | 2,396 (79.7\%) | 103 (3.4\%) | 2,293 (76.3\%) |  | 23 (0.8\%) |
| Deaths | 3-Oct-21 | All ages | 3,026 (100\%) | 611 (20.2\%) | 2,382 (78.7\%) | 101 (3.3\%) | 2,281 (75.4\%) |  | 33 (1.1\%) |
|  |  | $\geq 18$ | 3,020 (99.8\%) | 609 (20.2\%) | 2,381 (78.8\%) | 100 (3.3\%) | 2,281 (75.5\%) |  | 30 (1.0\%) |
|  |  | $\geq 50$ | 2,887 (95.4\%) | 522 (18.1\%) | 2,341 (81.1\%) | 95 (3.3\%) | 2,246 (77.8\%) |  | 24 (0.8\%) |
| Deaths | 10-Oct-21 | All ages | 2,805 (100\%) | 557 (19.9\%) | 2,228 (79.4\%) | 92 (3.3\%) | 2,136 (76.1\%) |  | 20 (0.7\%) |
|  |  | $\geq 18$ | 2,801 (99.9\%) | 554 (19.8\%) | 2,227 (79.5\%) | 91 (3.2\%) | 2,136 (76.3\%) |  | 20 (0.7\%) |
|  |  | $\geq 50$ | 2,689 (95.9\%) | 487 (18.1\%) | 2,185 (81.3\%) | 88 (3.3\%) | 2,097 (78.0\%) |  | 17 (0.6\%) |
| Deaths | 17-Oct-21 | All ages | 2,745 (100\%) | 502 (18.3\%) | 2,224 (81.0\%) | 88 (3.2\%) | 2,136 (77.8\%) |  | 19 (0.7\%) |
|  |  | $\geq 18$ | 2,740 (99.8\%) | 498 (18.2\%) | 2,223 (81.1\%) | 87 (3.2\%) | 2,136 (78.0\%) |  | 19 (0.7\%) |
|  |  | $\geq 50$ | 2,635 (96.0\%) | 433 (16.4\%) | 2,186 (83.0\%) | 86 (3.3\%) | 2,100 (79.7\%) |  | 16 (0.6\%) |
| Deaths | 24-Oct-21 | All ages | 2,772 (100\%) | 487 (17.6\%) | 2,270 (81.9\%) | 85 (3.1\%) | 2,185 (78.8\%) |  | 15 (0.5\%) |
|  |  | $\geq 18$ | 2,767 (99.8\%) | 483 (17.5\%) | 2,269 (82.0\%) | 84 (3.0\%) | 2,185 (79.0\%) |  | 15 (0.5\%) |
|  |  | $\geq 50$ | 2,666 (96.2\%) | 423 (15.9\%) | 2,230 (83.6\%) | 82 (3.1\%) | 2,148 (80.6\%) |  | 13 (0.5\%) |


| Deaths | 31-Oct-21 | All ages | 3,085 (100\%) | 538 (17.4\%) | 2,532 (82.1\%) | 85 (2.8\%) | 2,447 (79.3\%) | 15 (0.5\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\geq 18$ | 3,079 (99.8\%) | 532 (17.3\%) | 2,532 (82.2\%) | 85 (2.8\%) | 2,447 (79.5\%) | 15 (0.5\%) |
|  |  | $\geq 50$ | 2,972 (96.3\%) | 471 (15.8\%) | 2,488 (83.7\%) | 82 (2.8\%) | 2,406 (81.0\%) | 13 (0.4\%) |
| Deaths | 7-Nov-21 | All ages | 3,430 (100\%) | 587 (17.1\%) | 2,822 (82.3\%) | 90 (2.6\%) | 2,732 (79.7\%) | 21 (0.6\%) |
|  |  | $\geq 18$ | 3,422 (99.8\%) | 580 (16.9\%) | 2,822 (82.5\%) | 90 (2.6\%) | 2,732 (79.8\%) | 20 (0.6\%) |
|  |  | $\geq 50$ | 3,297 (96.1\%) | 511 (15.5\%) | 2,769 (84.0\%) | 86 (2.6\%) | 2,683 (81.4\%) | 17 (0.5\%) |
| Deaths | 14-Nov-21 | All ages | 3,676 (100\%) | 675 (18.4\%) | 2,975 (80.9\%) | 100 (2.7\%) | 2,875 (78.2\%) | 26 (0.7\%) |
|  |  | $\geq 18$ | 3,665 (99.7\%) | 665 (18.1\%) | 2,975 (81.2\%) | 100 (2.7\%) | 2,875 (78.4\%) | 25 (0.7\%) |
|  |  | $\geq 50$ | 3,522 (95.8\%) | 587 (16.7\%) | 2,914 (82.7\%) | 91 (2.6\%) | 2,823 (80.2\%) | 21 (0.6\%) |
| Deaths | 21-Nov-21 | All ages | 3,726 (100\%) | 708 (19.0\%) | 2,992 (80.3\%) | 89 (2.4\%) | 2,903 (77.9\%) | 26 (0.7\%) |
|  |  | $\geq 18$ | 3,717 (99.8\%) | 700 (18.8\%) | 2,992 (80.5\%) | 89 (2.4\%) | 2,903 (78.1\%) | 25 (0.7\%) |
|  |  | $\geq 50$ | 3,556 (95.4\%) | 612 (17.2\%) | 2,923 (82.2\%) | 79 (2.2\%) | 2,844 (80.0\%) | 21 (0.6\%) |
| Deaths | 28-Nov-21 | All ages | 3,571 (100\%) | 695 (19.5\%) | 2,846 (79.7\%) | 96 (2.7\%) | 2,750 (77.0\%) | 30 (0.8\%) |
|  |  | $\geq 18$ | 3,563 (99.8\%) | 688 (19.3\%) | 2,846 (79.9\%) | 96 (2.7\%) | 2,750 (77.2\%) | 29 (0.8\%) |
|  |  | $\geq 50$ | 3,415 (95.6\%) | 606 (17.7\%) | 2,785 (81.6\%) | 87 (2.5\%) | 2,698 (79.0\%) | 24 (0.7\%) |
| Deaths | 5-Dec-21 | All ages | 3,310 (100\%) | 708 (21.4\%) | 2,572 (77.7\%) | 92 (2.8\%) | 2,480 (74.9\%) | 30 (0.9\%) |
|  |  | $\geq 18$ | 3,306 (99.9\%) | 704 (21.3\%) | 2,572 (77.8\%) | 92 (2.8\%) | 2,480 (75.0\%) | 30 (0.9\%) |
|  |  | $\geq 50$ | 3,151 (95.2\%) | 619 (19.6\%) | 2,506 (79.5\%) | 85 (2.7\%) | 2,421 (76.8\%) | 26 (0.8\%) |
| Deaths | 12-Dec-21 | All ages | 3,087 (100\%) | 718 (23.3\%) | 2,341 (75.8\%) | 82 (2.7\%) | 2,259 (73.2\%) | 28 (0.9\%) |
|  |  | $\geq 18$ | 3,083 (99.9\%) | 715 (23.2\%) | 2,340 (75.9\%) | 82 (2.7\%) | 2,258 (73.2\%) | 28 (0.9\%) |
|  |  | $\geq 50$ | 2,920 (94.6\%) | 618 (21.2\%) | 2,277 (78.0\%) | 76 (2.6\%) | 2,201 (75.4\%) | 25 (0.9\%) |
| Deaths | 19-Dec-21 | All ages | 2,956 (100\%) | 782 (26.5\%) | 2,140 (72.4\%) | 90 (3.0\%) | 2,050 (69.4\%) | 34 (1.2\%) |
|  |  | $\geq 18$ | 2,952 (99.9\%) | 779 (26.4\%) | 2,139 (72.5\%) | 90 (3.0\%) | 2,049 (69.4\%) | 34 (1.2\%) |
|  |  | $\geq 50$ | 2,772 (93.8\%) | 667 (24.1\%) | 2,074 (74.8\%) | 84 (3.0\%) | 1,990 (71.8\%) | 31 (1.1\%) |
| Deaths | 2-Jan-22 | All ages | 2,890 (100\%) | 809 (28.0\%) | 2,055 (71.1\%) | 106 (3.7\%) | 1,949 (67.4\%) | 26 (0.9\%) |
|  |  | $\geq 18$ | 2,885 (99.8\%) | 805 (27.9\%) | 2,054 (71.2\%) | 106 (3.7\%) | 1,948 (67.5\%) | 26 (0.9\%) |
|  |  | $\geq 50$ | 2,703 (93.5\%) | 694 (25.7\%) | 1,985 (73.4\%) | 99 (3.7\%) | 1,886 (69.8\%) | 24 (0.9\%) |
| Deaths | 9-Jan-22 | All ages | 3,174 (100\%) | 924 (29.1\%) | 2,219 (69.9\%) | 130 (4.1\%) | 2,089 (65.8\%) | 31 (1.0\%) |
|  |  | $\geq 18$ | 3,166 (99.7\%) | 916 (28.9\%) | 2,219 (70.1\%) | 130 (4.1\%) | 2,089 (66.0\%) | 31 (1.0\%) |
|  |  | $\geq 50$ | 2,964 (93.4\%) | 795 (26.8\%) | 2,140 (72.2\%) | 122 (4.1\%) | 2,018 (68.1\%) | 29 (1.0\%) |


| Deaths | 16-Jan-22 | All ages | 3,893 (100\%) | 1,015 (26.1\%) | 2,845,73 (1\%) | 171,4 (4\%) | 1,418 (36.4\%) | 1,256 (32.3\%) | 33 (0.8\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\geq 18$ | 3,884 (99.8\%) | 1,006 (25.9\%) | 2,845,73 (2\%) | 171 (4.4\%) | 1,418 (36.5\%) | 1,256 (32.3\%) | 33 (0.8\%) |
|  |  | $\geq 50$ | 3,672 (94.3\%) | 898 (24.5\%) | 2,743 (74.7\%) | 158 (4.3\%) | 1,344 (36.6\%) | 1,241 (33.8\%) | 31 (0.8\%) |
| Deaths | 23-Jan-22 | All ages | 4,637 (100\%) | 1,010 (21.8\%) | 3,591,77 (4\%) | 190 (4.1\%) | 1,561 (33.7\%) | 1,840 (39.7\%) | 36 (0.8\%) |
|  |  | $\geq 18$ | 4,624 (99.7\%) | 1,000 (21.6\%) | 3,588,77 (6\%) | 188 (4.1\%\%) | 1,560 (33.7\%) | 1,840 (39.8\%) | 36 (0.8\%) |
|  |  | $\geq 50$ | 4,423 (95.4\%) | 903 (20.4\%) | 3,486 (78.8\%) | 174 (3.9\%) | 1,489 (33.7\%) | 1,823 (41.2\%) | 34 (0.8\%) |
| Deaths | 30-Jan-22 | All ages | 5,554 (100\%) | 1,015 (18.3\%) | 4,501,81 (0\%) | 213 (3.8\%) | 1,703 (30.7\%) | 2,585 (46.5\%) | 38 (0.7\%) |
|  |  | $\geq 18$ | 5,542 (99.8\%) | 1,007 (18.2\%) | 4,497,81 (1\%) | 211 (3.8\%) | 1,701 (30.7\%) | 2,585 (46.6\%) | 38 (0.7\%) |
|  |  | $\geq 50$ | 5,310 (95.6\%) | 912 (17.2\%) | 4,362 (82.1\%) | 191 (3.6\%) | 1,624 (30.6\%) | 2,547 (48.0\%) | 36 (0.7\%) |
| Deaths | 6-Feb-22 | All ages | 5,978 (100\%) | 911 (15.2\%) | 5,035 (84.2\%) | 208 (3.5\%) | 1,631 (27.3\%) | 3,196 (53.5\%) | 32 (0.5\%) |
|  |  | $\geq 18$ | 5,967 (99.8\%) | 904 (15.1\%) | 5,031 (84.3\%) | 206 (3.5\%) | 1,629 (27.3\%) | 3,196 (53.6\%) | 32 (0.5\%) |
|  |  | $\geq 50$ | 5,752 (96.2\%) | 829 (14.4\%) | 4,894 (85.1\%) | 189 (3.3\%) | 1,556 (27.1\%) | 3,149 (54.7\%) | 29 (0.5\%) |
| Deaths | 13-Feb-22 | All ages | 5,592 (100\%) | 728 (13.0\%) | 4,836 (86.5\%) | 179 (3.2\%) | 1,350 (24.1\%) | 3,307 (59.1\%) | 28 (0.5\%) |
|  |  | $\geq 18$ | 5,584 (99.9\%) | 723 (12.9\%) | 4,833 (86.6\%) | 178 (3.2\%) | 1,348 (24.1\%) | 3,307 (59.2\%) | 28 (0.5\%) |
|  |  | $\geq 50$ | 5,404 (96.6\%) | 659 (12.2\%) | 4,720 (87.3\%) | 161 (3.0\%) | 1,299 (24.0\%) | 3,260 (60.3\%) | 25 (0.5\%) |
| Deaths | 20-Feb-22 | All ages | 4,883 (100\%) | 559 (11.4\%) | 4,302 (88.1\%) | 147 (3.0\%) | 1,035 (21.2\%) | 3,120 (63.9\%) | 22 (0.5\%) |
|  |  | $\geq 18$ | 4,877 (99.9\%) | 555 (11.4\%) | 4,300 (88.2\%) | 147 (3.0\%) | 1,033 (21.2\%) | 3,120 (64.0\%) | 22 (0.5\%) |
|  |  | $\geq 50$ | 4,731 (96.9\%) | 506 (10.7\%) | 4,206 (88.9\%) | 131 (2.8\%) | 991 (20.9\%) | 3,084 (65.2\%) | 19 (0.4\%) |
| Deaths | 27-Feb-22 | All ages | 3,957 (100\%) | 397 (10.0\%) | 3,542 (89.5\%) | 113 (2.9\%) | 725 (18.3\%) | 2,704 (68.3\%) | 18 (0.5\%) |
|  |  | $\geq 18$ | 3,953 (99.9\%) | 394 (10.0\%) | 3,541 (89.6\%) | 112 (2.8\%) | 725 (18.3\%) | 2,704 (68.4\%) | 18 (0.5\%) |
|  |  | $\geq 50$ | 3,843 (97.1\%) | 359 (9.3\%) | 3,469 (90.3\%) | 103 (2.7\%) | 689 (17.9\%) | 2,677 (69.7\%) | 15 (0.4\%) |
| Deaths | 6-Mar-22 | All ages | 2,943 (100\%) | 286 (9.7\%) | 2,643 (89.8\%) | 79 (2.7\%) | 482 (16.4\%) | 2,082 (70.7\%) | 14 (0.5\%) |
|  |  | $\geq 18$ | 2,940 (99.9\%) | 284 (9.7\%) | 2,642 (89.9\%) | 78 (2.7\%) | 482 (16.4\%) | 2,082 (70.8\%) | 14 (0.5\%) |
|  |  | $\geq 50$ | 2,867 (97.4\%) | 260 (9.1\%) | 2,594 (90.5\%) | 70 (2.4\%) | 458 (16.0\%) | 2,066 (72.1\%) | 13 (0.5\%) |
| Deaths | 13-Mar-22 | All ages | 2,421 (100\%) | 237 (9.8\%) | 2,173 (89.8\%) | 58 (2.4\%) | 382 (15.8\%) | 1,733 (71.6\%) | 11 (0.5\%) |
|  |  | $\geq 18$ | 2,419 (99.9\%) | 236 (9.8\%) | 2,172 (89.8\%) | 57 (2.4\%) | 382 (15.8\%) | 1,733 (71.6\%) | 11 (0.5\%) |
|  |  | $\geq 50$ | 2,364 (97.6\%) | 216 (9.1\%) | 2,139 (90.5\%) | 52 (2.2\%) | 365 (15.4\%) | 1,722 (72.8\%) | 9 (0.4\%) |
| Deaths | 20-Mar-22 | All ages | 2,084 (100\%) | 202 (9.7\%) | 1,873 (89.9\%) | 49 (2.4\%) | 333 (16.0\%) | 1,491 (71.5\%) | 9 (0.4\%) |
|  |  | $\geq 18$ | 2,083 (99.95\%) | 202 (9.7\%) | 1,872 (89.9\%) | 48 (2.3\%) | 333 (16.0\%) | 1,491 (71.6\%) | 9 (0.4\%) |
|  |  | $\geq 50$ | 2,030 (97.4\%) | 186 (9.2\%) | 1,836 (90.4\%) | 45 (2.2\%) | 315 (15.5\%) | 1,476 (72.7\%) | 8 (0.4\%) |


| Deaths | 27-Mar-22 | All ages | $2,144(100 \%)$ | $214(10.0 \%)$ | $1,773(82.7 \%)$ | $1(0.05 \%)$ | $215(10.0 \%)$ | $1,557(72.6 \%)$ | $10(0.5 \%)$ |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
|  |  | $\geq 18$ | $2,142(99.9 \%)$ | $213(9.9 \%)$ | $1,772(82.7 \%)$ | $1(0.05 \%)$ | $214(10.0 \%)$ | $1,557(72.7 \%)$ | $10(0.5 \%)$ |
|  |  | $\geq 50$ | $2,090(97.5 \%)$ | $199(9.5 \%)$ | $1,736(83.1 \%)$ | $1(0.05 \%)$ | $200(9.6 \%)$ | $1,535(73.4 \%)$ | $9(0.4 \%)$ |

Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death (reported weekly for prior 4 weeks period) in NIMSdatabase based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARS-CoV2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

Table S7a: Vaccine effectiveness of over 18 years of age NIMS population

| Rolling Four weeks period ending | SARS-CoV2 cases; $\mathbf{\geq 1 8}$ yrs of age (during four weeks period) |  |  |  | Incidence rate per 100,000 population |  |  |  | Vaccine effectiveness (95\% CI) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 dose | 2 dose | 3rd dose | Unvacinated | 1 dose | 2 doses | 3rd <br> dose | Unvaccinated | 1 dose* | Two doses ${ }^{\ddagger}$ | Third dose $\varnothing$ |
| 12-Sep-21 | 81332 | 288470 |  | 101867 | 2706.5 | 789.2 |  | 956.2 | $\begin{aligned} & -183.1 \%(-187 \% \text { to }- \\ & 178.9 \%) \end{aligned}$ | 17.5\% (16.5\% to 18.4\%) |  |
| 19-Sep-21 | 55159 | 276831 |  | 87377 | 2036.0 | 750.2 |  | 826.5 | $\begin{aligned} & -146.3 \%(-150.3 \% \text { to }- \\ & 142.2 \%) \end{aligned}$ | 9.2\% (8.1\% to 10.3\%) |  |
| 26-Sep-21 | 40434 | 272498 |  | 75925 | 1605.8 | 740.9 |  | 723.3 | $\begin{aligned} & -122 \%(-126 \% \text { to - } \\ & 117.8 \%) \end{aligned}$ | -2.4\% (-3.7\% to -1.2\%) |  |
| 3-Oct-21 | 28361 | 265485 |  | 64589 | 1188.1 | 736.6 |  | 619.0 | -91.9\% (-96\% to -87.7\%) | $\begin{aligned} & -19.0 \%(-20.6 \% \text { to }- \\ & 17.4 \%) \end{aligned}$ |  |
| 10-Oct-21 | 23218 | 287527 |  | 60497 | 1014.8 | 821.7 |  | 583.5 | -73.9\% (-78\% to -69.9\%) | $\begin{aligned} & -40.8 \%(-42.7 \% \text { to - } \\ & 39.0 \%) \end{aligned}$ |  |
| 17-Oct-21 | 23238 | 339317 |  | 63961 | 1053.2 | 1003.9 |  | 620.7 | $\begin{aligned} & -69.7 \%(-73.7 \% \text { to - } \\ & 65.7 \%) \end{aligned}$ | $\begin{aligned} & -61.7 \%(-63.8 \% \text { to - } \\ & 59.7 \%) \end{aligned}$ |  |
| 24-Oct-21 | 24038 | 390274 |  | 70006 | 1122.2 | 1205.2 |  | 683.7 | $\begin{aligned} & -64.1 \% ~(-67.9 \% \text { to - } \\ & 60.4 \%) \end{aligned}$ | $\begin{aligned} & -76.3 \%(-78.4 \% \text { to - } \\ & 74.2 \%) \end{aligned}$ |  |
| 31-Oct-21 | 25293 | 438972 |  | 76219 | 1211.9 | 1419.6 |  | 748.6 | $\begin{aligned} & -61.9 \%(-65.5 \% \text { to - } \\ & 58.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -89.6 \%(-91.8 \% \text { to }- \\ & 87.5 \%) \\ & \hline \end{aligned}$ |  |
| 7-Nov-21 | 25554 | 450186 |  | 79516 | 1256.0 | 1540.8 |  | 785.1 | $\begin{aligned} & \hline-60.0 \%(63.5 \% \text { to - } \\ & 56.5 \%) \end{aligned}$ | $\begin{aligned} & -96.3 \%(-98.5 \% \text { to - } \\ & 94.1 \%) \\ & \hline \end{aligned}$ |  |
| 14-Nov-21 | 25350 | 448916 |  | 81589 | 1282.2 | 1642.0 |  | 810.1 | $\begin{aligned} & -58.3 \%(-61.8 \% \text { to - } \\ & 54.9 \%) \end{aligned}$ | $\begin{aligned} & -102.7 \%(-105.0 \% \text { to - } \\ & 100.5 \%) \\ & \hline \end{aligned}$ |  |
| 21-Nov-21 | 24894 | 443166 |  | 83121 | 1291.3 | 1744.6 |  | 829.8 | $\begin{aligned} & \hline-55.6 \% ~(-59.0 \% \text { to - } \\ & 52.2 \%) \end{aligned}$ | $\begin{aligned} & -110.2 \%(-112.6 \% \text { to - } \\ & 107.9 \%) \end{aligned}$ |  |
| 28-Nov-21 | 24489 | 437450 |  | 85038 | 1305.0 | 1872.1 |  | 853.7 | $\begin{aligned} & -52.9 \%(-56.2 \% \text { to - } \\ & 49.6 \%) \end{aligned}$ | $\begin{aligned} & -119.3 \%(-121.7 \% \text { to }- \\ & 116.9 \%) \end{aligned}$ |  |
| 5-Dec-21 | 26242 | 469465 |  | 92746 | 1438.0 | 2208.1 |  | 937.1 | $\begin{aligned} & -53.4 \%(-56.7 \% \text { to - } \\ & 50.2 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -135.6 \%(-138.1 \% \text { to - } \\ & 133.2 \%) \end{aligned}$ |  |
| 12-Dec-21 | 29274 | 517061 |  | 104612 | 1649.3 | 2740.9 |  | 1064.4 | $\begin{aligned} & \hline-54.9 \%(-58.0 \% \text { to - } \\ & 51.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -157.5 \%(-160.1 \% \text { to - } \\ & 155.0 \%) \end{aligned}$ |  |
| 19-Dec-21 | 39618 | 736016 |  | 132809 | 2283.1 | 5153.1 |  | 1367.3 | $\begin{aligned} & \hline-67.0 \% ~(-69.9 \% \text { to - } \\ & 64.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -276.9 \%(-280.1 \% \text { to }- \\ & 273.6 \%) \\ & \hline \end{aligned}$ |  |


| 2-Jan-22 | 84102 | 1654525 |  | 240879 | 4927.5 | 16023.7 |  | 2520.4 | $\begin{aligned} & -95.5 \%(-97.9 \% \text { to - } \\ & 93.2 \%) \end{aligned}$ | $\begin{aligned} & -535.8 \%(-539.7 \% \text { to }- \\ & 531.9 \%) \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 9-Jan-22 | 103771 | 2073522 |  | 292438 | 6136.3 | 22404.2 |  | 3084.8 | $\begin{aligned} & \hline-98.9 \% \text { (-101.1\% to - } \\ & 96.8 \%) \end{aligned}$ | $\begin{aligned} & -626.3 \%(-630.3 \% \text { to - } \\ & 622.3 \%) \\ & \hline \end{aligned}$ |  |
| 16-Jan-22 | 100960 | 1095228 | 934915 | 285948 | 5993.8 | 12552.7 | 3075.2 | 3037.8 | $\begin{aligned} & -97.3 \% ~(-99.5 \% \text { to - } \\ & 95.2 \%) \end{aligned}$ | $\begin{aligned} & -313.2 \% ~(-315.8 \% \text { to - } \\ & 310.7 \%) \end{aligned}$ | $\begin{aligned} & -1.2 \%(-1.9 \% \\ & \text { to }-0.6 \%) \end{aligned}$ |
| 23-Jan-22 | 88213 | 825293 | 1013017 | 255701 | 5259.6 | 9761.1 | 3296.0 | 2732.5 | $\begin{aligned} & -92.5 \%(-94.7 \% \text { to - } \\ & 90.2 \%) \end{aligned}$ | $\begin{aligned} & -257.2 \%(-259.6 \% \text { to }- \\ & 254.8 \%) \end{aligned}$ | $\begin{aligned} & -20.6 \%(- \\ & 21.4 \% \text { to - } \\ & 19.8 \%) \\ & \hline \end{aligned}$ |
| 30-Jan-22 | 75802 | 583313 | 1018299 | 231750 | 4543.0 | 7076.5 | 3284.3 | 2489.9 | $\begin{aligned} & -82.5 \%(-84.8 \% \text { to }- \\ & 80.2 \%) \end{aligned}$ | $\begin{aligned} & -184.2 \%(-186.3 \% \text { to }- \\ & 182.1 \%) \end{aligned}$ | $\begin{aligned} & \hline-31.9 \% \text { (- } \\ & 32.8 \% \text { to - } \\ & 31.0 \%) \\ & \hline \end{aligned}$ |
| 6-Feb-22 | 51615 | 344772 | 884793 | 159596 | 3118.9 | 4251.0 | 2837.3 | 1720.9 | $\begin{aligned} & -81.2 \%(-84.0 \% \text { to }- \\ & 78.5 \%) \end{aligned}$ | $\begin{aligned} & -147.0 \%(-149.3 \% \text { to }- \\ & 144.7 \%) \end{aligned}$ | $\begin{aligned} & -64.9 \% \text { (- } \\ & 66.2 \% \text { to - } \\ & 63.6 \%) \\ & \hline \end{aligned}$ |
| 13-Feb-22 | 42017 | 264366 | 839411 | 128278 | 2570.7 | 3306.4 | 2677.9 | 1387.0 | $\begin{aligned} & -85.3 \%(-88.5 \% \text { to }- \\ & 82.2 \%) \end{aligned}$ | $\begin{aligned} & -138.4 \%(-140.9 \% \text { to }- \\ & 135.9 \%) \end{aligned}$ | $\begin{aligned} & \hline-93.1 \%(- \\ & 94.8 \% \text { to - } \\ & 91.4 \%) \end{aligned}$ |
| 20-Feb-22 | 33209 | 200489 | 750857 | 100923 | 2055.5 | 2537.0 | 2385.4 | 1093.5 | $\begin{aligned} & -88.0 \% ~(-91.6 \% \text { to - } \\ & 84.4 \%) \end{aligned}$ | $\begin{array}{\|l} \hline-132.0 \% ~(-134.8 \% \text { to - } \\ \text { 129.2\%) } \\ \hline \end{array}$ | $\begin{aligned} & -118.1 \% ~(- \\ & 120.2 \% \text { to }- \\ & 116.1 \%) \\ & \hline \end{aligned}$ |
| 27-Feb-22 | 24454 | 144037 | 614846 | 74831 | 1530.3 | 1840.8 | 1946.2 | 812.5 | $\begin{aligned} & -88.3 \% ~(-92.6 \% \text { to - } \\ & 84.2 \%) \end{aligned}$ | $\begin{aligned} & -126.6 \%(-129.8 \% \text { to }- \\ & 123.4 \%) \end{aligned}$ | $\begin{aligned} & -139.5 \% ~(- \\ & 142.2 \% \text { to - } \\ & 136.9 \%) \end{aligned}$ |
| 6-Mar-22 | 18878 | 109575 | 543808 | 59904 | 1194.5 | 1410.8 | 1716.4 | 651.6 | $\begin{aligned} & -83.3 \%(-88.0 \% \text { to - } \\ & 78.7 \%) \end{aligned}$ | $\begin{aligned} & -116.5 \%(-120.0 \% \text { to }- \\ & 113.1 \%) \end{aligned}$ | $\begin{aligned} & -163.4 \% ~(- \\ & 166.6 \% \text { to - } \\ & 160.2 \%) \\ & \hline \end{aligned}$ |
| 13-Mar-22 | 18039 | 104580 | 617982 | 60372 | 1155.3 | 1355.1 | 1945.4 | 657.7 | $\begin{aligned} & -75.6 \% ~(-80.2 \% \text { to - } \\ & 71.2 \%) \end{aligned}$ | $\begin{array}{\|l} \begin{array}{\|l} -106.0 \% ~(-109.3 \% ~ t o ~-~ \\ 102.8 \%) \end{array} \\ \hline \end{array}$ | $\begin{aligned} & -195.8 \% ~(- \\ & 199.3 \% \text { to - } \\ & \text { 192.3\%) } \\ & \hline \end{aligned}$ |
| 20-Mar-22 | 20229 | 117728 | 790490 | 70018 | 1311.9 | 1534.3 | 2482.4 | 764.0 | $\begin{aligned} & -71.7 \%(-75.9 \% \text { to - } \\ & 67.6 \%) \end{aligned}$ | $\begin{aligned} & -100.8 \%(-103.9 \% \text { to - } \\ & 97.9 \%) \end{aligned}$ | $\begin{aligned} & -224.9 \% ~(- \\ & 228.5 \% \text { to - } \\ & 221.4 \%) \\ & \hline \end{aligned}$ |
| 27-Mar-22 | 24334 | 142964 | 1008836 | 85614 | 1594.9 | 1873.8 | 3160.9 | 935.3 | $\begin{aligned} & -70.5 \% ~(-74.3 \% \text { to - } \\ & 66.8 \%) \\ & \hline \end{aligned}$ | $\begin{array}{\|l} -100.3 \% ~(-103.1 \% ~ t o ~-~ \\ 97.7 \%) \end{array}$ | $\begin{aligned} & -237.9 \% \text { (- } \\ & 241.3 \% \text { to - } \\ & 234.7 \%) \\ & \hline \end{aligned}$ |

Table S7a: Vaccine effectiveness of over 18 years of age NIMS population (rolling four weeks cases reported weekly) since August 16, 2021 to March 27, 2022 until UKHSA stopped reporting data of weekly cases among age groups based on vaccination status.
*SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

## Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health England

| Time period | Confirmed Delta variant COVID-19 cases ( $\geq 50 \mathrm{yrs}$ of age) |  |  | Incidence rate per 100,000 population |  |  | Vaccine effectiveness (95\% CI) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 dose | 2 doses | Unvaccinated | 1 dose | 2 doses | Unvaccinated | 1 dose | 2 doses |
| until June 20, 2021 | 4651 | 5234 | 1267 | 516.7 | 27.0 | 57.5 | $\begin{aligned} & \hline-797.9 \%(-889.6 \% \text { to } \\ & -717.1 \%) \end{aligned}$ | $\begin{aligned} & 53.1 \% ~(48.4 \% \\ & \text { to } 57.2 \%) \end{aligned}$ |
| June 21-July $\text { 18, } 2021$ | 795 | 8193 | 1070 | 138.1 | 41.4 | 50.5 | $\begin{aligned} & -173.7 \%(-217.1 \% \text { to } \\ & -135.8 \%) \end{aligned}$ | $\begin{aligned} & \text { 18.0\% (9.8\% to } \\ & 25.2 \%) \end{aligned}$ |
| $\begin{aligned} & \text { July 19-Aug 1, } \\ & 2021 \end{aligned}$ | 389 | 8045 | 1103 | 75.5 | 40.5 | 52.7 | $\begin{aligned} & -43.3 \% ~(-71.1 \% \text { to }- \\ & 19.0 \%) \end{aligned}$ | $\begin{aligned} & 23.2 \%(15.6 \% \\ & \text { to } 29.8 \%) \end{aligned}$ |
| Aug 2-Aug 15, 2021 | 468 | 11356 | 1451 | 98.5 | 56.9 | 70.0 | $\begin{aligned} & -40.7 \% ~(-65.0 \% \text { to - } \\ & \text { 19.1\%) } \end{aligned}$ | $\begin{aligned} & 18.6 \% ~(11.7 \% \\ & \text { to 24.8\%) } \\ & \hline \end{aligned}$ |
| Aug 16-Aug $29,2021$ | 596 | 18592 | 1833 | 134.1 | 93.0 | 89.1 | $\begin{aligned} & -50.4 \% ~(-73.3 \% \text { to - } \\ & 29.8 \%) \end{aligned}$ | $\begin{aligned} & -4.3 \%(-11.9 \% \\ & \text { to 2.5\%) } \end{aligned}$ |
| Aug 30-Sept $\text { 12, } 2021$ | 544 | 20571 | 1827 | 128.3 | 102.7 | 89.4 | $\begin{aligned} & -43.5 \% ~(-66.0 \% \text { to - } \\ & 23.3 \%) \end{aligned}$ | $\begin{aligned} & -14.9 \%(-23.1 \% \\ & \text { to }-7.5 \%) \end{aligned}$ |

Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health England until September 12, 2021. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses.

Table S7c: Vaccine effectiveness of over 50 years of age NIMS population

| Rolling <br> Four <br> weeks <br> period <br> ending | COVID-19 cases; $\geq 50 \mathrm{yrs}$ of age (during four weeks period) |  |  |  | Incidence rate per 100,000 population |  |  |  | Vaccine effectiveness (95\% CI) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & 1 \\ & \text { dose* } \end{aligned}$ | Two doses $^{\ddagger}$ | Third dose ${ }^{\varnothing}$ | Unvacainated | 1dose | 2doses | $\begin{aligned} & \text { 3rd } \\ & \text { dose } \end{aligned}$ | Unvacinated | 1dose | 2doses | 3rddose |
| 12-Sep-21 | 81332 | 288470 |  | 101867 | 843.4 | 711.7 |  | 551.3 | $\begin{aligned} & -183.1 \%(-187 \% \text { to - } \\ & 178.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { 17.5\% (16.5\% to } \\ & 18.4 \%) \end{aligned}$ |  |
| 19-Sep-21 | 55159 | 276831 |  | 87377 | 755.4 | 674.7 |  | 503.1 | $\begin{array}{\|l\|} \hline-146.3 \%(-150.3 \% \text { to } \\ -142.2 \%) \\ \hline \end{array}$ | 9.2\% (8.1\% to 10.3\%) |  |
| 26-Sep-21 | 40434 | 272498 |  | 75925 | 692.7 | 646.3 |  | 449.8 | $\begin{aligned} & \hline-122 \%(-126 \% \text { to - } \\ & 117.8 \%) \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline-2.4 \%(-3.7 \% \text { to - } \\ 1.2 \%) \\ \hline \end{array}$ |  |
| 3-Oct-21 | 28361 | 265485 |  | 64589 | 651.6 | 635.4 |  | 397.1 | $\begin{aligned} & \hline-91.9 \%(-96 \% \text { to - } \\ & 87.7 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline-19.0 \%(-20.6 \% \text { to - } \\ & 17.4 \%) \\ & \hline \end{aligned}$ |  |
| 10-Oct-21 | 23218 | 287527 |  | 60497 | 656.8 | 712.5 |  | 381.1 | $\begin{aligned} & -73.9 \%(-78 \% \text { to - } \\ & 69.9 \%) \end{aligned}$ | $\begin{aligned} & -40.8 \%(-42.7 \% \text { to - } \\ & 39.0 \%) \\ & \hline \end{aligned}$ |  |
| 17-Oct-21 | 23238 | 339317 |  | 63961 | 753.7 | 902.2 |  | 413.2 | $\begin{aligned} & -69.7 \%(-73.7 \% \text { to - } \\ & 65.7 \%) \end{aligned}$ | $\begin{aligned} & \hline-61.7 \%(-63.8 \% \text { to - } \\ & 59.7 \%) \\ & \hline \end{aligned}$ |  |
| 24-Oct-21 | 24038 | 390274 |  | 70006 | 841.2 | 1155.6 |  | 473.3 | $\begin{aligned} & -64.1 \%(-67.9 \% \text { to - } \\ & 60.4 \%) \end{aligned}$ | $\begin{aligned} & -76.3 \%(-78.4 \% \text { to - } \\ & 74.2 \%) \\ & \hline \end{aligned}$ |  |
| 31-Oct-21 | 25293 | 438972 |  | 76219 | 941.3 | 1444.1 |  | 529.4 | $\begin{aligned} & \hline-61.9 \%(-65.5 \% \text { to - } \\ & 58.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline-89.6 \%(-91.8 \% \text { to - } \\ & 87.5 \%) \\ & \hline \end{aligned}$ |  |
| 7-Nov-21 | 25554 | 450186 |  | 79516 | 974.0 | 1672.1 |  | 557.2 | $\begin{aligned} & -60.0 \% ~(63.5 \% \text { to - } \\ & 56.5 \%) \end{aligned}$ | $\begin{aligned} & -96.3 \%(-98.5 \% \text { to - } \\ & 94.1 \%) \\ & \hline \end{aligned}$ |  |
| $\begin{array}{r} \hline \text { 14-Nov- } \\ 21 \end{array}$ | 25350 | 448916 |  | 81589 | 986.9 | 1906.1 |  | 580.0 | $\begin{aligned} & \hline-58.3 \%(-61.8 \% \text { to - } \\ & 54.9 \%) \end{aligned}$ | $\begin{aligned} & \hline-102.7 \%(-105.0 \% \text { to - } \\ & 100.5 \%) \\ & \hline \end{aligned}$ |  |
| $\begin{array}{r} 21-\mathrm{Nov}- \\ 21 \end{array}$ | 24894 | 443166 |  | 83121 | 1001.2 | 2136.7 |  | 586.9 | $\begin{aligned} & -55.6 \%(-59.0 \% \text { to - } \\ & 52.2 \%) \end{aligned}$ | $\begin{aligned} & -110.2 \%(-112.6 \% \text { to - } \\ & 107.9 \%) \end{aligned}$ |  |
| $\begin{array}{r} \hline 28 \text {-Nov- } \\ 21 \\ \hline \end{array}$ | 24489 | 437450 |  | 85038 | 1008.7 | 2442.3 |  | 600.4 | $\begin{aligned} & -52.9 \%(-56.2 \% \text { to - } \\ & 49.6 \%) \end{aligned}$ | $\begin{aligned} & \hline-119.3 \%(-121.7 \% \text { to - } \\ & 116.9 \%) \\ & \hline \end{aligned}$ |  |
| 5-Dec-21 | 26242 | 469465 |  | 92746 | 1119.7 | 3083.5 |  | 651.9 | $\begin{aligned} & -53.4 \%(-56.7 \% \text { to - } \\ & 50.2 \%) \end{aligned}$ | $\begin{aligned} & \hline-135.6 \%(-138.1 \% \text { to - } \\ & 133.2 \%) \\ & \hline \end{aligned}$ |  |


| 12-Dec-21 | 29274 | 517061 |  | 104612 | 1209.8 | 4066.0 |  | 704.8 | $\begin{aligned} & -54.9 \%(-58.0 \% \text { to }- \\ & 51.9 \%) \end{aligned}$ | $\begin{aligned} & -157.5 \%(-160.1 \% \text { to }- \\ & 155.0 \%) \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 19-Dec-21 | 39618 | 736016 |  | 132809 | 1402.3 | 6920.1 |  | 818.3 | $\begin{aligned} & \hline-67.0 \% ~(-69.9 \% \text { to - } \\ & 64.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -276.9 \%(-280.1 \% \text { to - } \\ & 273.6 \%) \\ & \hline \end{aligned}$ |  |
| 2-Jan-22 | 84102 | 1654525 |  | 240879 | 2774.2 | 23991.2 |  | 1421.8 | $\begin{aligned} & -95.5 \% ~(-97.9 \% \text { to - } \\ & 93.2 \%) \end{aligned}$ | $\begin{aligned} & -535.8 \%(-539.7 \% \text { to - } \\ & 531.9 \%) \end{aligned}$ |  |
| 9-Jan-22 | 103771 | 2073522 |  | 292438 | 3462.9 | 35837.9 |  | 1746.3 | $\begin{aligned} & -98.9 \%(-101.1 \% \text { to - } \\ & 96.8 \%) \end{aligned}$ | $\begin{aligned} & -626.3 \%(-630.3 \% \text { to - } \\ & 622.3 \%) \end{aligned}$ |  |
| 16-Jan-22 | 100960 | 1095228 | 934915 | 285948 | 3518.0 | 8823.1 | 2910.4 | 1783.9 | $\begin{aligned} & -97.3 \% ~(-99.5 \% \text { to - } \\ & 95.2 \%) \end{aligned}$ | $\begin{aligned} & -313.2 \%(-315.8 \% \text { to - } \\ & 310.7 \%) \end{aligned}$ | $\begin{aligned} & -1.2 \%(-1.9 \% \\ & \text { to }-0.6 \%) \\ & \hline \end{aligned}$ |
| 23-Jan-22 | 88213 | 825293 | 1013017 | 255701 | 3132.7 | 6802.7 | 2876.2 | 1625.9 | $\begin{aligned} & -92.5 \%(-94.7 \% \text { to - } \\ & 90.2 \%) \end{aligned}$ | $\begin{aligned} & -257.2 \%(-259.6 \% \text { to }- \\ & 254.8 \%) \end{aligned}$ | $\begin{aligned} & \hline-20.6 \%(- \\ & 21.4 \% \text { to }- \\ & 19.8 \%) \\ & \hline \end{aligned}$ |
| 30-Jan-22 | 75802 | 583313 | 1018299 | 231750 | 2502.4 | 4536.1 | 2429.3 | 1378.3 | $\begin{aligned} & -82.5 \%(-84.8 \% \text { to - } \\ & 80.2 \%) \end{aligned}$ | $\begin{aligned} & -184.2 \% ~(-186.3 \% \text { to }- \\ & 182.1 \%) \end{aligned}$ | $\begin{aligned} & -31.9 \%(- \\ & 32.8 \% \text { to }- \\ & 31.0 \%) \\ & \hline \end{aligned}$ |
| 6-Feb-22 | 51615 | 344772 | 884793 | 159596 | 1786.6 | 2700.8 | 1890.4 | 985.7 | $\begin{aligned} & -81.2 \%(-84.0 \% \text { to - } \\ & 78.5 \%) \end{aligned}$ | $\begin{aligned} & -147.0 \%(-149.3 \% \text { to }- \\ & 144.7 \%) \end{aligned}$ | $\begin{aligned} & \hline-64.9 \% ~(- \\ & 66.2 \% \text { to }- \\ & 63.6 \%) \\ & \hline \end{aligned}$ |
| 13-Feb-22 | 42017 | 264366 | 839411 | 128278 | 1494.3 | 2044.6 | 1751.5 | 797.0 | $\begin{aligned} & -85.3 \%(-88.5 \% \text { to }- \\ & 82.2 \%) \end{aligned}$ | $\begin{aligned} & -138.4 \%(-140.9 \% \text { to }- \\ & 135.9 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -93.1 \%(- \\ & 94.8 \% \text { to - } \\ & 91.4 \%) \\ & \hline \end{aligned}$ |
| 20-Feb-22 | 33209 | 200489 | 750857 | 100923 | 1250.3 | 1628.2 | 1633.4 | 657.0 | $\begin{aligned} & -88.0 \% ~(-91.6 \% \text { to - } \\ & 84.4 \%) \end{aligned}$ | $\begin{aligned} & -132.0 \%(-134.8 \% \text { to - } \\ & 129.2 \%) \end{aligned}$ | $\begin{aligned} & \hline-118.1 \% ~(- \\ & 120.2 \% \text { to - } \\ & 116.1 \%) \\ & \hline \end{aligned}$ |
| 27-Feb-22 | 24454 | 144037 | 614846 | 74831 | 1002.5 | 1246.0 | 1418.7 | 524.8 | $\begin{aligned} & -88.3 \%(-92.6 \% \text { to - } \\ & \text { 84.2\%) } \end{aligned}$ | $\begin{aligned} & -126.6 \%(-129.8 \% \text { to }- \\ & 123.4 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -139.5 \% ~(- \\ & 142.2 \% \text { to - } \\ & 136.9 \%) \end{aligned}$ |
| 6-Mar-22 | 18878 | 109575 | 543808 | 59904 | 838.4 | 1037.5 | 1335.0 | 446.6 | $\begin{aligned} & -83.3 \%(-88.0 \% \text { to - } \\ & 78.7 \%) \end{aligned}$ | $\begin{aligned} & -116.5 \%(-120.0 \% \text { to }- \\ & 113.1 \%) \\ & \hline \end{aligned}$ | $\begin{aligned} & -163.4 \% \text { (- } \\ & 166.6 \% \text { to - } \\ & 160.2 \%) \\ & \hline \end{aligned}$ |
| 13-Mar22 | 18039 | 104580 | 617982 | 60372 | 863.1 | 1072.1 | 1585.9 | 466.3 | $\begin{aligned} & -75.6 \% ~(-80.2 \% \text { to - } \\ & 71.2 \%) \end{aligned}$ | $\begin{aligned} & -106.0 \%(-109.3 \% \text { to - } \\ & 102.8 \%) \end{aligned}$ | $\begin{aligned} & \hline-195.8 \% ~(- \\ & 199.3 \% \text { to - } \\ & \text { 192.3\%) } \\ & \hline \end{aligned}$ |
| 20-Mar22 | 20229 | 117728 | 790490 | 70018 | 1009.3 | 1279.1 | 2085.9 | 556.7 | $\begin{aligned} & -71.7 \% ~(-75.9 \% \text { to - } \\ & 67.6 \%) \end{aligned}$ | $\begin{aligned} & -100.8 \%(-103.9 \% \text { to - } \\ & 97.9 \%) \end{aligned}$ | $\begin{aligned} & \hline-224.9 \% \text { (- } \\ & 228.5 \% \text { to - } \\ & 221.4 \%) \\ & \hline \end{aligned}$ |
| 27-Mar22 | 24334 | 142964 | 1008836 | 85614 | 1262.0 | 1596.3 | 2714.8 | 689.7 | $\begin{aligned} & -70.5 \% ~(-74.3 \% \text { to }- \\ & 66.8 \%) \end{aligned}$ | $\begin{aligned} & -100.3 \%(-103.1 \% \text { to }- \\ & 97.7 \%) \end{aligned}$ | $\begin{aligned} & -237.9 \% \text { (- } \\ & 241.3 \% \text { to - } \\ & 234.7 \%) \\ & \hline \end{aligned}$ |

Table S7c: Vaccine effectiveness of over 50 years of age NIMS population (rolling four weeks cases reported weekly) since August 16, 2021 to March 27, 2022 until UKHSA stopped reporting data of weekly cases among age groups based on vaccination status. *SARSCoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

Table S8a-f: Proportion test of SARS-CoV2 cases, hospitalizations and deaths among NIMS vaccinated population of over 18 and over 50 years of age.

| Study period (rolling 4 weeks) | Proportion of population (cases/population) |  |  |  | Compared groups | Statistical analysis <br> Proportion test (X2=; df=; $p=v a l u e$ ) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All vaccinated | 2 doses $^{\ddagger}$ | Third dose $\varnothing$ | Unvaccinated |  |  |
| Aug 16-Sept 12, 2021 | 0.009345 | 0.007892 |  | 0.009562 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=42.277, d f=1, p-=1 \\ & X^{2}=2804.2, d f=1, p-=1 \end{aligned}$ |
| $\begin{aligned} & \text { Aug 23-Sept 19, } \\ & 2021 \end{aligned}$ | 0.008373 | 0.007502 |  | 0.008265 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=11.686, d f=1, p=0.0003149 \\ & X^{2}=627.65, d f=1, p=1 \end{aligned}$ |
| Aug 30-Sept 26, 2021 | 0.007877 | 0.007409 |  | 0.007233 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=448.21, d f=1, p<0.001 \\ & X^{2}=34.737, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Sept 13-Oct 10, } \\ & 2021 \end{aligned}$ | 0.007797 | 0.008217 |  | 0.005835 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=4317.8, d f=1, p<0.001 \\ & X^{2}=5961.9, d f=1, p<0.001 \end{aligned}$ |
| Oct 11-Nov 7, 2021 | 0.011865 | 0.015408 |  | 0.007851 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=11915, d f=1, p<0.001 \\ & X^{2}=32339, d f=1, p<0.001 \end{aligned}$ |
| Nov 8-Dec 5, 2021 | 0.012292 | 0.022081 |  | 0.009371 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=5855.7, d f=1, p<0.001 \\ & X^{2}=61570, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 6, 2021-Jan 2, } \\ & 2022 \end{aligned}$ | 0.042753 | 0.160237 |  | 0.025204 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=62948, d f=1, p<0.001 \\ & X^{2}=1049374, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 20, 2021-Jan } \\ & \text { 16, } 2022 \end{aligned}$ | 0.052219 | 0.125527 | 0.030752 | 0.030378 | All vaccinated vs. Unvaccinated Third dose vs. Unvaccinated Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=79651, d f=1, p<0.001 \\ & X^{2}=33.892, d f=1, p<0.001 \\ & X^{2}=582725, d f=1, p<0.001 \\ & X^{2}=1237850, d f=1, p=1 \end{aligned}$ |
|  | 0.062683 | 0.097611 | 0.032960 | 0.027325 | All vaccinated vs. Unvaccinated | $\mathrm{X}^{2}=174246, \mathrm{df}=1, \mathrm{p}<0.001$ |


| $\begin{aligned} & \text { Dec 27, 2021-Jan } \\ & 23,2022 \end{aligned}$ |  |  |  |  | Third dose vs. Unvaccinated Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=7433.2, d f=1, p<0.001 \\ & X^{2}=384927, d f=1, p<0.001 \\ & X^{2}=619910, d f=1, p=1 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Jan 3-Jan 30, 2022 | 0.054101 | 0.070765 | 0.032843 | 0.024899 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=135316, d f=1, p<0.001 \\ & X^{2}=15037, d f=1, p<0.001 \\ & X^{2}=207668, d f=1, p<0.001 \\ & X^{2}=239234, d f=1, p=1 \end{aligned}$ |
| Jan 17-Feb 13, 2022 | 0.027963 | 0.033064 | 0.026779 | 0.013870 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=60619, d f=1, p<0.001 \\ & x^{2}=51150, d f=1, p<0.001 \\ & X^{2}=71007, d f=1, p<0.001 \\ & x^{2}=9227.7, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022 | 0.019099 | 0.018408 | 0.019462 | 0.008125 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=53922, d f=1, p<0.001 \\ & X^{2}=55147, d f=1, p<0.001 \\ & X^{2}=35266, d f=1, p<0.001 \\ & X^{2}=368.53, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Feb 14-Mar 13, } \\ & 2022 \end{aligned}$ | 0.018043 | 0.013551 | 0.019454 | 0.006577 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=62838, d f=1, p<0.001 \\ & x^{2}=72465, d f=1, p<0.001 \\ & x^{2}=21090, d f=1, p<0.001 \\ & x^{2}=12041, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Feb 28-Mar 27, } \\ & 2022 \end{aligned}$ | 0.028637 | 0.018738 | 0.031609 | 0.009353 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=113642, d f=1, p<0.001 \\ & x^{2}=135833, d f=1, p<0.001 \\ & x^{2}=27278, d f=1, p<0.001 \\ & x^{2}=36077, d f=1, p<0.001 \end{aligned}$ |

Table S8a: Proportion test of SARS-CoV2 cases among NIMS vaccinated population of over 18 years of age since August 16, 2021 to March 27, 2022. $\ddagger$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

| Study period (rolling 4 weeks) | Proportion of population (hospitalizations/population) |  |  |  | Groups compared | Statistical analysis <br> Proportion test (X2=; df=;pValue) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All vaccinated | 2 doses $^{\ddagger}$ | Third dose $\varnothing$ | Unvaccinated |  |  |
| Aug 16-Sept 12, 2021 | 0.000121 | 0.000120 |  | 0.000275 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1292.9, d f=1, p=1 \\ & X^{2}=1286.1, d f=1, p=1 \end{aligned}$ |
| Aug 23-Sept 19, 2021 | 0.000124 | 0.000123 |  | 0.000259 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=998.05, d f=1, p=1 \\ & X^{2}=985.86, d f=1, p=1 \end{aligned}$ |
| Aug 30-Sept 26, 2021 | 0.000119 | 0.000119 |  | 0.000232 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=750.01, d f=1, p=1 \\ & X^{2}=721.94, d f=1, p=1 \end{aligned}$ |
| Sept 13-Oct 10, 2021 | 0.000081 | 0.000087 |  | 0.000140 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=304.78, d f=1, p=1 \\ & X \text {-squared }=232.96, d f=1, p=1 \end{aligned}$ |
| Oct 11-Nov 7, 2021 | 0.000169 | 0.000221 |  | 0.000269 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=429.48, d f=1, p-=1 \\ & X^{2}=73.123, d f=1, p=1 \end{aligned}$ |
| Nov 8-Dec 5, 2021 | 0.000120 | 0.000213 |  | 0.000270 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1205.4, d f=1, p=1 \\ & X^{2}=96.403, d f=1, p=1 \end{aligned}$ |
| Nov 22-Dec 19, 2021 | 0.000107 | 0.000281 |  | 0.000321 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=2407.3, d f=1, p=1 \\ & X^{2}=29.835, d f=1, p=1 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 6, 2021-Jan 2, } \\ & 2022 \end{aligned}$ | 0.000141 | 0.000511 |  | 0.000341 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\mathrm{X}^{2}=1728.9, \mathrm{df}=1, \mathrm{p}=1$ $\mathrm{X}^{2}=332.3, \mathrm{df}=1, \mathrm{p}<0.001$ |
| $\begin{aligned} & \text { Dec 20, 2021-Jan 16, } \\ & 2022 \end{aligned}$ | 0.000243 | 0.000472 | 0.000169 | 0.000366 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=432.84, d f=1, p=1 \\ & X^{2}=1292.4, d f=1, p=1 \\ & X^{2}=121.31, d f=1, p<0.001 \\ & X^{2}=2625.6, d f=1, p=1 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 27, 2021-Jan 23, } \\ & 2022 \end{aligned}$ | 0.000272 | 0.000470 | 0.000210 | 0.000343 | All vaccinated vs. Unvaccinated Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=133.64, d f=1, p=1 \\ & X^{2}=529.15, d f=1, p=1 \\ & X^{2}=178.58, d f=1, p<0.001 \end{aligned}$ |


|  |  |  |  |  | Third dose vs. Two doses | $\mathrm{X}^{2}=1695.2, \mathrm{df}=1, \mathrm{p}=1$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Jan 10-Feb 6, 2022 | 0.000187 | 0.000258 | 0.000163 | 0.000187 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=0.016292, d f=1, p=0.5508 \\ & X^{2}=25.596, d f=1, p=1 \\ & X^{2}=97.746, d f=1, p<0.001 \\ & X^{2}=319.9, d f=1, p=1 \end{aligned}$ |
| Jan 17-Feb 13, 2022 | 0.000174 | 0.000221 | 0.000158 | 0.000156 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=14.103, d f=1, p<0.001 \\ & x^{2}=0.12568, d f=1, p-=0.3615 \\ & x^{2}=98.344, d f=1, p<0.001 \\ & x^{2}=151.35, d f=1, p=1 \end{aligned}$ |
| Jan 24-Feb 20, 2022 | 0.000164 | 0.000183 | 0.000157 | 0.000131 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=52.732, d f=1, p<0.001 \\ & X^{2}=33.446, d f=1, p<0.001 \\ & X^{2}=75.858, d f=1, p<0.001 \\ & X^{2}=25.972, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022 | 0.000146 | 0.000147 | 0.000144 | 0.000111 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=65.454, d f=1, p<0.001 \\ & X^{2}=58.17, d f=1, p<0.001 \\ & X^{2}=42.996, d f=1, p<0.001 \\ & x^{2}=0.28271, d f=1, p=0.7025 \end{aligned}$ |
| Feb 14-Mar 13, 2022 | 0.000125 | 0.000107 | 0.000129 | 0.000084 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=104.5, d f=1, p<0.001 \\ & X^{2}=121.11, d f=1, p<0.001 \\ & X^{2}=21.615, d f=1, p p<0.001 \\ & X^{2}=25.946, d f=1, p<0.001 \end{aligned}$ |
| Feb 28-Mar 27, 2022 | 0.000199 | 0.000150 | 0.000211 | 0.000120 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=249.43, d f=1, p<0.001 \\ & X^{2}=309.05, d f=1, p<0.001 \\ & X^{2}=26.895, d f=1, p<0.001 \\ & X^{2}=117.1, d f=1, p<0.001 \end{aligned}$ |

Table S8b: Proportion test of SARS-CoV2 hospitalizations among NIMS vaccinated population of over 18 years of age since August 16,2021 to March 27, 2022. $\ddagger$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

| Study period (rolling 4 weeks) | Proportion of population (deaths/population) |  |  |  | Groups compared | Statistical analysis <br> Proportion test (X2=; df=; $p=$ Value) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All vaccinated | 2 doses $^{\ddagger}$ | Third dose $\varnothing$ | Unvaccinated |  |  |
| Aug 16-Sept 12, 2021 | 0.000056 | 0.000057 |  | 0.000068 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=20.926, d f=1, p=1 \\ & X^{2}=15.286, d f=1, p=1 \end{aligned}$ |
| Aug 23-Sept 19, 2021 | 0.000060 | 0.000062 |  | 0.000069 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=9.0561, d f=1, p=0.9987 \\ & X^{2}=5.8408, d f=1, p=0.9922 \end{aligned}$ |
| Aug 30-Sept 26, 2021 | 0.000062 | 0.000064 |  | 0.000065 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1.5266, d f=1, p=0.8917 \\ & X^{2}=0.26222, d f=1, p=0.6957 \end{aligned}$ |
| Sept 13-Oct 10, 2021 | 0.000056 | 0.000061 |  | 0.000053 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=0.84631, d f=1, p=0.1788 \\ & X^{2}=7.6872, d f=1, p= \\ & 0.002781 \end{aligned}$ |
| Oct 11-Nov 7, 2021 | 0.000070 | 0.000094 |  | 0.000057 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=20.339, d f=1, p<0.001 \\ & X^{2}=116.92, d f=1, p<0.001 \end{aligned}$ |
| Nov 8-Dec 5, 2021 | 0.000064 | 0.000117 |  | 0.000071 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=6.4766, d f=1, p=0.9945 \\ & X^{2}=136.46, d f=1, p<0.001 \end{aligned}$ |
| Nov 22-Dec 19, 2021 | 0.000053 | 0.000143 |  | 0.000080 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=100.78, d f=1, p=1 \\ & X^{2}=195.77, d f=1, p<0.001 \end{aligned}$ |
| Dec 6, 2021-Jan 2, 2022 | 0.000051 | 0.000189 |  | 0.000084 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=154.01, d f=1, p=1 \\ & X^{2}=390.22, d f=1, p<0.001 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 20, 2021-Jan 16, } \\ & 2022 \end{aligned}$ | 0.000070 | 0.000163 | 0.000041 | 0.000107 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=137.28, d f=1, p<0.001 \\ & X^{2}=542.63, d f=1, p=1 \\ & X^{2}=104.52, d f=1, p<0.001 \\ & X^{2}=1455.7, d f=1, p=1 \end{aligned}$ |
| $\begin{aligned} & \text { Dec 27, 2021-Jan 23, } \\ & 2022 \end{aligned}$ | 0.000088 | 0.000185 | 0.000060 | 0.000107 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=30.094, d f=1, p=1 \\ & X^{2}=223.02, d f=1, p=1 \\ & X^{2}=185.8, d f=1, p<0.001 \\ & X^{2}=1186, d f=1, p=1 \end{aligned}$ |


| Jan 10-Feb 6, 2022 | 0.000123 | 0.000201 | 0.000102 | 0.000097 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=41.017, d f=1, p<0.001 \\ & X^{2}=1.7226, d f=1, p=0.09468 \\ & X^{2}=316.69, d f=1, p<0.001 \\ & X^{2}=506.48, d f=1, p=1 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Jan 17-Feb 13, 2022 | 0.000118 | 0.000169 | 0.000106 | 0.000078 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=107.58, d f=1, p<0.001 \\ & X^{2}=53.465, d f=1, p<0.001 \\ & X^{2}=291.24, d f=1, p<0.001 \\ & X^{2}=213.81, d f=1, p=1 \end{aligned}$ |
| Jan 24-Feb 20, 2022 | 0.000105 | 0.000131 | 0.000100 | 0.000060 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=156.88, d f=1, p<0.001 \\ & X^{2}=122.84, d f=1, p<0.001 \\ & X^{2}=229.37, d f=1, p<0.001 \\ & X^{2}=57.692, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022 | 0.000086 | 0.000093 | 0.000086 | 0.000043 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=181.54, d f=1, p<0.001 \\ & X^{2}=171.55, d f=1, p<0.001 \\ & x^{2}=159.44, d f=1, p<0.001 \\ & x^{2}=3.5199, d f=1, p=0.9697 \end{aligned}$ |
| Feb 14-Mar 13, 2022 | 0.000053 | 0.000049 | 0.000055 | 0.000026 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=115.23, d f=1, p<0.001 \\ & X^{2}=122.59, d f=1, p<0.001 \\ & X^{2}=64.207, d f=1, p<0.001 \\ & V=2.8687, d f=1, p=0.04516 \end{aligned}$ |
| Feb 28-Mar 27, 2022 | 0.000043 | 0.000028 | 0.000049 | 0.000023 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=74.306, d f=1, p<0.001 \\ & x^{2}=106.86, d f=1, p<0.001 \\ & x^{2}=3.5483, d f=1, p=0.0298 \\ & x^{2}=58.664, d f=1, p<0.001 \end{aligned}$ |

Table S8c: Proportion test of SARS-CoV2 deaths among NIMS vaccinated population of over 18 years of age from August 16, 2021 to March 27, 2022. ${ }^{\ddagger}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\Phi}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

| Study period (rolling 4 weeks*) | Proportion of population (cases/population) |  |  |  | Compared groups | Statistical analysis <br> Proportion test (X2=; df=; pValue) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All vaccinated | 2 doses $^{\ddagger}$ | Third dose ${ }^{\varnothing}$ | Unvaccinated |  |  |
| until June 20, 2021 (Delta Variant) | 0.000486989 | 0.000269881 |  | 0.000575473 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=31.212, d f=1, p=1 \\ & X^{2}=612.53, d f=1, p=1 \end{aligned}$ |
| June 21-July 18, 2021 (Delta Variant) | 0.000441024 | 0.000413819 |  | 0.000504709 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=17.288, d f=1, p=1 \\ & X^{2}=37.234, d f=1, p=1 \end{aligned}$ |
| July 19-Aug 1, 2021 <br> (Delta Variant) | 0.000413326 | 0.000404604 |  | 0.000526581 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=57.242, d f=1, p=1 \\ & X^{2}=67.473, d f=1, p=1 \end{aligned}$ |
| Aug 2-Aug 15, 2021 <br> (Delta Variant) | 0.000578857 | 0.000569373 |  | 0.000699815 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=46.5, d f=1, p=1 \\ & X^{2}=54.749, d f=1, p=1 \end{aligned}$ |
| Aug 30-Sept 12, 2021 (Delta Variant) | 0.000938593 | 0.00092997 |  | 0.000891319 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=4.4235, d f=1, p=0.018 \\ & X^{2}=2.9683, d f=1, p=0.042 \end{aligned}$ |
| Aug 16-Sept 12, 2021* | 0.00714124 | 0.00711672 |  | 0.00551307 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=708.94, d f=1, p<0.001 \\ & X^{2}=688.86, d f=1, p<0.001 \end{aligned}$ |
| Aug 23-Sept 19, 2021* | 0.00675283 | 0.00674656 |  | 0.00503149 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=837.18, d f=1, p<0.001 \\ & X^{2}=830.53, d f=1, p<0.001 \end{aligned}$ |
| Aug 30-Sept 26, 2021* | 0.00635938 | 0.00646325 |  | 0.00449816 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & \mathrm{X}^{2}=1039.4, \mathrm{df}=1, \mathrm{p}<0.001 \\ & \mathrm{X}^{2}=1138.5, \mathrm{df}=1, \mathrm{p}<0.001 \end{aligned}$ |
| Sept 13-Oct 10, 2021* | 0.00635639 | 0.00712503 |  | 0.00381063 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1954.1, d f=p<0.001 \\ & v=2953.9, d f=1, p<0.001 \end{aligned}$ |
| Oct 11-Nov 7, 2021* | 0.01033954 | 0.01672072 |  | 0.00557227 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=4197.6, d f=1, p<0.001 \\ & X^{2}=14260, d f=1, p<0.001 \end{aligned}$ |
| Nov 8-Dec 5, 2021* | 0.00883519 | 0.03083521 |  | 0.00651932 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=1119, d f=1, p<0.001 \\ & x^{2}=35890, d f=1, p<0.001 \end{aligned}$ |
| Dec 6, 2021-Jan 2, 2022* | 0.02429517 | 0.23991204 |  | 0.01421828 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=7742.2, d f=1, p<0.001 \\ & x^{2}=441724, d f=1, p<0.001 \end{aligned}$ |
| Dec 20, 2021-Jan 16, 2022* | 0.03417810 | 0.08823135 | 0.02910401 | 0.01783886 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=14577, d f=1, p<0.001 \\ & X^{2}=7987, d f=1, p<0.001 \\ & X^{2}=91810, d f=1, p<0.001 \end{aligned}$ |


|  |  |  |  |  | Third dose vs. Two doses | $\mathrm{X}^{2}=168485, \mathrm{df}=1, \mathrm{p}=1$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Dec 27, 2021-Jan 23, 2022* | 0.03200767 | 0.06802698 | 0.02876190 | 0.01625914 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=14404, d f=1, p<0.001 \\ & X^{2}=9969.2, d f=1, p<0.001 \\ & X^{2}=61097, d f=1, p<0.001 \\ & X^{2}=76888, d f=1, p=1 \end{aligned}$ |
| Jan 3-Jan 30, 2022* | 0.02597837 | 0.04536145 | 0.02429350 | 0.01378302 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=10531, d f=1, p<0.001 \\ & X^{2}=8281.8, d f=1, p<0.001 \\ & X^{2}=31550, d f=1, p<0.001 \\ & X^{2}=26421, d f=1, p=1 \end{aligned}$ |
| Jan 17-Feb 13, 2022* | 0.01770613 | 0.02044630 | 0.01751527 | 0.00797034 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=9808.3, d f=1, p<0.001 \\ & X^{2}=9486.1, d f=1, p<0.001 \\ & X^{2}=9912.7, d f=1, p<0.001 \\ & X^{2}=722.09, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022* | 0.01292623 | 0.01245956 | 0.01418682 | 0.00524788 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=8334.2, d f=1, p<0.001 \\ & X^{2}=10303, d f=1, p<0.001 \\ & X^{2}=5228.9, d f=1, p<0.001 \\ & X^{2}=309.3, d f=1, p<0.001 \end{aligned}$ |
| Feb 14-Mar 13, 2022* | 0.01538218 | 0.01072085 | 0.01585947 | 0.00466257 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=13786, d f=1, p<0.001 \\ & X^{2}=14569, d f=1, p<0.001 \\ & X^{2}=4210.6, d f=1, p<0.001 \\ & X^{2}=2455.8, d f=1, p<0.001 \end{aligned}$ |
| Feb 28-Mar 27, 2022* | 0.02480554 | 0.01596269 | 0.02718747 | 0.00689690 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=24098, d f=1, p<0.001 \\ & X^{2}=28284, d f=1, p<0.001 \\ & X^{2}=6334.1, d f=1, p<0.001 \\ & X^{2}=6868.5, d f=1, p<0.001 \end{aligned}$ |

Table S8d: Proportion test of SARS-CoV2 cases among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. $\ddagger$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

| Study period (rolling 4 weeks*) | Proportion of population (hospitalizations/population) |  |  |  | Compared groups | Statistical analysis <br> Proportion test (X2=; df=; pValue) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All <br> vaccinated | 2 doses $^{\ddagger}$ | Third dose $\varnothing$ | Unvaccinated |  |  |
| until June 20, 2021 (Delta Variant) | 0.00002049 | 0.00001366 |  | 0.00008857 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=336.46, d f=1, p=1 \\ & X^{2}=517.31, d f=1, p=1 \end{aligned}$ |
| June 21-July 18, 2021 <br> (Delta Variant) | 0.00002434 | 0.00002212 |  | 0.00011556 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=482.5, d f=1, p=1 \\ & X^{2}=533.6, d f=1, p=1 \end{aligned}$ |
| July 19-Aug 1, 2021 <br> (Delta Variant) | 0.00002313 | 0.00002153 |  | 0.00010980 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=454.62, d f=1, p=1 \\ & X^{2}=490.35, d f=1, p=1 \end{aligned}$ |
| Aug 2-Aug 15, 2021 <br> (Delta Variant) | 0.00003779 | 0.00003545 |  | 0.00015385 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=520.52, d f=1, p=1 \\ & X^{2}=562.56, d f=1, p=1 \end{aligned}$ |
| Aug 16-Aug 29, 2021* | 0.00004241 | 0.00004067 |  | 0.00016193 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=498.22, d f=1, p=1 \\ & X^{2}=525.21, d f=1, p=1 \end{aligned}$ |
| Aug 16-Sept 12, 2021* | 0.00019764 | 0.00019316 |  | 0.00066460 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1686, d f=1, p=1 \\ & X^{2}=1738.6, d f=1, p=1 \end{aligned}$ |
| Aug 23-Sept 19, 2021* | 0.00020657 | 0.00020296 |  | 0.00065748 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1520.9, d f=1, p=1 \\ & X^{2}=1557.6, d f=1, p=1 \end{aligned}$ |
| Aug 30-Sept 26, 2021* | 0.00019658 | 0.00019615 |  | 0.00058376 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1194.4, d f=1, p=1 \\ & X^{2}=1188.7, d f=1, p=1 \end{aligned}$ |
| Sept 13-Oct 10, 2021* | 0.00013129 | 0.00014412 |  | 0.00032709 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=471.89, d f=1, p=1 \\ & X^{2}=372.25, d f=1, p=1 \end{aligned}$ |
| Oct 11-Nov 7, 2021* | 0.00028050 | 0.00044881 |  | 0.00069854 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=997.52, d f=1, p=1 \\ & X^{2}=221.12, d f=1, p=1 \end{aligned}$ |
| Nov 8-Dec 5, 2021* | 0.00018716 | 0.00063849 |  | 0.00074169 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & x^{2}=2331.7, d f=1, p=1 \\ & x^{2}=23.277, d f=1, p=1 \end{aligned}$ |
| Dec 6, 2021-Jan 2, 2022* | 0.00020196 | 0.00191293 |  | 0.00092076 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=3428.6, d f=1, p=1 \\ & X^{2}=678.34, d f=1, p<0.001 \end{aligned}$ |
| Dec 20, 2021-Jan 16, 2022* | 0.00035854 | 0.00140191 | 0.00024814 | 0.00099393 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1697, d f=1, p=1 \\ & X^{2}=3010.4, d f=1, p=1 \\ & X^{2}=126.61, d f=1, p<0.001 \end{aligned}$ |


|  |  |  |  |  | Third dose vs. Two doses | $\mathrm{X}^{2}=6101.6, \mathrm{df}=1, \mathrm{p}=1$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Dec 27, 2021-Jan 23, 2022* | 0.00041049 | 0.00142582 | 0.00030687 | 0.00092962 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=1024.9, d f=1, p=1 \\ & X^{2}=1823.1, d f=1, p=1 \\ & X^{2}=188.07, d f=1, p<0.001 \\ & X^{2}=4841.4, d f=1, p=1 \end{aligned}$ |
| Jan 17-Feb 13, 2022* | 0.00025935 | 0.00062660 | 0.00022149 | 0.00042185 | All vaccinated vs. Unvaccinated Third dose vs. Unvaccinated Two doses vs. Unvaccinated Third dose vs. Two doses | $\begin{aligned} & X^{2}=165.77, d f=1, p=1 \\ & X^{2}=284.7, d f=1, p=1 \\ & X^{2}=69.562, d f=1, p<0.001 \\ & X^{2}=948.59, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022* | 0.00022910 | 0.00044469 | 0.00020744 | 0.00029924 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=35.636, d f=1, p=1 \\ & X^{2}=66.058, d f=1, p=1 \\ & X^{2}=48.828, d f=1, p<0.001 \\ & X^{2}=357.61, d f=1, p=1 \end{aligned}$ |
| Feb 14-Mar 13, 2022* | 0.00020319 | 0.00033807 | 0.00019016 | 0.00021887 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=1.9844, \mathrm{df}=1, \mathrm{p} \text {-value }= \\ & 0.92 \\ & X^{2}=7.1195, \mathrm{df}=1, \mathrm{p} \text {-value }= \\ & 0.996 \\ & X^{2}=43.462, \mathrm{df}=1, \mathrm{p}<0.001 \\ & \mathrm{X}^{2}=153.28, \mathrm{df}=1, \mathrm{p}=1 \end{aligned}$ |
| Feb 28-Mar 27, 2022* | 0.00032888 | 0.00045991 | 0.00031621 | 0.00028400 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=10.468, d f=1, p<0.001 \\ & x^{2}=5.523, d f=1, p=0.0093 \\ & x^{2}=70.784, d f=1, p<0.001 \\ & x^{2}=87.958, d f=1, p=1 \end{aligned}$ |

Table S8e: Proportion test of SARS-CoV2 hospitalizations among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. \#SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

| Study period (rolling 4 weeks*) | Proportion of population (deaths/population) |  |  |  | Compared groups | Statistical analysis <br> Proportion test (X2=; df=; pValue) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | All <br> vaccinated | 2 doses $^{\ddagger}$ | Third dose ${ }^{\varnothing}$ | Unvaccinated |  |  |
| until June 20, 2021 (Delta Variant) | 0.00000778 | 0.00000598 |  | 0.00003225 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=114.41, d f=1, p=1 \\ & X^{2}=154.52, d f=1, p=1 \end{aligned}$ |
| June 21-July 18, 2021 (Delta Variant) | 0.00000594 | 0.00000525 |  | 0.00002830 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=116.63, d f=1, p=1 \\ & X^{2}=132.9, d f=1, p=1 \end{aligned}$ |
| July 19-Aug 1, 2021 <br> (Delta Variant) | 0.00000887 | 0.00000850 |  | 0.00003533 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=115.01, d f=1, p=1 \\ & X^{2}=120.95, d f=1, p=1 \end{aligned}$ |
| Aug 2-Aug 15, 2021 <br> (Delta Variant) | 0.00001395 | 0.00001319 |  | 0.00005450 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=172.67, d f=1, p=1 \\ & X^{2}=185.31, d f=1, p=1 \end{aligned}$ |
| Aug 30-Sept 12, 2021 <br> (Delta Variant) | 0.00002138 | 0.00002011 |  | 0.00005787 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=99.209, d f=1, p=1 \\ & X^{2}=110.91, d f=1, p=1 \end{aligned}$ |
| Aug 16-Sept 12, 2021* | 0.000105248 | 0.00010247 |  | 0.00029315 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=534.8, d f=1, p=1 \\ & X^{2}=559.64, d f=1, p=1 \end{aligned}$ |
| Aug 23-Sept 19, 2021* | 0.00011445 | 0.00011185 |  | 0.00030198 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=494.27, d f=1, p=1 \\ & X^{2}=515, d f=1, p \text {-value }=1 \end{aligned}$ |
| Aug 30-Sept 26, 2021* | 0.00011705 | 0.00011634 |  | 0.00028868 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=409.22, d f=1, p=1 \\ & X^{2}=411.49, d f=1, p=1 \end{aligned}$ |
| Sept 13-Oct 10, 2021* | 0.00010668 | 0.00011701 |  | 0.00024135 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=279.44, d f=1, p=1 \\ & X^{2}=215.47, d f=1, p=1 \end{aligned}$ |
| Oct 11-Nov 7, 2021* | 0.00013501 | 0.00021503 |  | 0.00025680 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & \mathrm{X}^{2}=183.77, \mathrm{df}=1, \mathrm{p}=1 \\ & \mathrm{X}^{2}=13.381, \mathrm{df}=1, \mathrm{p}=0.9999 \end{aligned}$ |
| Nov 8-Dec 5, 2021* | 0.00012198 | 0.00041925 |  | 0.00031641 | All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=484.81, d f=1, p=1 \\ & X^{2}=39.061, d f=1, p<0.001 \end{aligned}$ |
| Dec 6, 2021-Jan 2, 2022* | 0.00009639 | 0.00091918 |  | 0.00036390 | All vaccinated vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1046.9, d f=1, p=1 \\ & X^{2}=467.11, d f=1, p<0.001 \end{aligned}$ |
| Dec 20, 2021-Jan 16, 2022* | 0.00013310 | 0.00077283 | 0.00006678 | 0.00047476 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated | $\begin{aligned} & X^{2}=1247.8, d f=1, p=1 \\ & X^{2}=2731.4, d f=1, p=1 \\ & X^{2}=129.96, d f=1, p<0.001 \end{aligned}$ |


|  |  |  |  |  | Third dose vs. Two doses | $\mathrm{X}^{2}=6227.2, \mathrm{df}=1, \mathrm{p}=1$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Dec 27, 2021-Jan 23, 2022* | 0.00016911 | 0.00088350 | 0.00009779 | 0.00047887 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=848.38, d f=1, p=1 \\ & X^{2}=1870.2, d f=1, p=1 \\ & X^{2}=217.07, d f=1, p<0.001 \\ & X^{2}=5852.6, d f=1, p=1 \end{aligned}$ |
| Jan 3-Jan 30, 2022* | 0.00021155 | 0.00099077 | 0.00013624 | 0.00048501 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & x^{2}=548.74, d f=1, p=1 \\ & X^{2}=1234.4, d f=1, p=1 \\ & X^{2}=310.4, d f=1, p<0.001 \\ & X^{2}=5361.9, d f=1, p=1 \end{aligned}$ |
| Jan 17-Feb 13, 2022* | 0.00022885 | 0.00081722 | 0.00017383 | 0.00035145 | All vaccinated vs. Unvaccinated Third dose vs. Unvaccinated Two doses vs. Unvaccinated Third dose vs. Two doses | $\begin{aligned} & X^{2}=107.58, d f=1, p=1 \\ & X^{2}=282.23, d f=1, p=1 \\ & X^{2}=329.59, d f=1, p<0.001 \\ & X^{2}=2704.6, d f=1, p=1 \end{aligned}$ |
| Jan 31-Feb 27, 2022* | 0.00016817 | 0.00044276 | 0.00014243 | 0.00019183 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=5.5114, d f=1, p \text {-value }= \\ & 0.9906 \\ & X^{2}=27.948, d f=1, p=1 \\ & X^{2}=174.2, d f=1, p<0.001 \\ & X^{2}=782.09, d f=1, p=1 \end{aligned}$ |
| Feb 14-Mar 13, 2022* | 0.00010368 | 0.00023821 | 0.00009147 | 0.00011559 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=2.2098, d f=1, p \text {-value }= \\ & 0.9314 \\ & X^{2}=10.304, d f=1, p \text {-value }= \\ & 0.9993 \\ & X^{2}=73.402, d f=1, p<0.001 \\ & X^{2}=296.23, d f=1, p=1 \end{aligned}$ |
| Feb 28-Mar 27, 2022* | 0.00008413 | 0.00013235 | 0.00008154 | 0.00010663 | All vaccinated vs. Unvaccinated <br> Third dose vs. Unvaccinated <br> Two doses vs. Unvaccinated <br> Third dose vs. Two doses | $\begin{aligned} & X^{2}=9.8147, \text { df }=1, p \text {-value }= \\ & 0.9991 \\ & X^{2}=12.465, \text { df }=1, p \text {-value }= \\ & 0.9998 \\ & X^{2}=4.4595, d f=1, p \text {-value }= \\ & 0.0173 \\ & X^{2}=41.747, \text { df }=1, p=1 \end{aligned}$ |

Table S8f: Proportion test of SARS-CoV2 deaths among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. \#SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days
post second dose are considered vaccinated with two doses. ${ }^{\varnothing}$ SARS-CoV2 cases tested positive with the specimen date $\geq 14$ days post third dose are considered vaccinated with the third dose.

## REFERENCES:

1. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
2. National Health Service (NHS) England. COVID-19 Hospital Activity. Accessed October 22, 2021. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
3. NHS England and NHS Improvement. COVID-19 Daily Deaths. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/
4. UK Prime Minister's Office. Schools and colleges to reopen from tomorrow as part of Step One of the roadmap. Published online 2021. Accessed March 6, 2021. https://www.gov.uk/government/news/schools-and-colleges-to-reopen-from-tomorrow-as-part-of-step-one-of-the-roadmap
5. UK Prime Minister's Office. Further easing of Covid restrictions confirmed for 12 April -Outdoor pubs, shops, gyms and hairdressers to reopen. Published online 2021. Accessed April 4, 2021. https://www.gov.uk/government/news/further-easing-of-covid-restrictions-confirmed-for-12april
6. UK Prime Minister's Office. Further easing of COVID restrictions confirmed for 17 May -Planned Step 3 easements will go ahead on 17 May. Published online 2021. Accessed May 9, 2021. https://www.gov.uk/government/news/further-easing-of-covid-restrictions-confirmed-for-17may
7. UK Prime Minister's Office. Prime Minister to set out plans ahead of step 4. Published online 2021. Accessed July 4, 2021. https://www.gov.uk/government/news/prime-minister-to-set-out-plans-ahead-of-step-4
